THE ROLES OF PI3K AND MAPK PATHWAY MUTATIONS IN GLIOMAGENESIS AND RESPONSE TO TARGETED INHIBITION by McNeill, Robert
 THE ROLES OF PI3K AND MAPK PATHWAY MUTATIONS IN GLIOMAGENESIS 
AND RESPONSE TO TARGETED INHIBITION 
 
 
Robert Shawn McNeill 
 
 
A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Pathology and Laboratory Medicine in the School of Medicine. 
 
 
Chapel Hill 
2017 
 
 
Approved by: 
C. Ryan Miller 
William B. Coleman 
Cyrus Vaziri 
Albert S. Baldwin 
William Y. Kim
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 
Robert Shawn McNeill 
ALL RIGHTS RESERVED   
iii 
 
ABSTRACT 
Robert Shawn McNeill: The Roles of PI3K and MAPK Pathway Mutations in 
Gliomagenesis and Response to Targeted Inhibition 
(Under the direction of C. Ryan Miller) 
 
Glioblastoma (GBM) is the most common malignant primary brain tumor in 
adults, and even with treatment, its median survival is only 12-15 months.  Molecular 
analyses by The Cancer Genome Atlas and others have identified the genetics 
underlying GBM pathogenesis, but this knowledge has yet to influence therapy.  The 
receptor tyrosine kinase (RTK) pathway is frequently mutated in GBM, including its 
phosphoinositide-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) effector 
arms.  Because of their mutational frequency and established role in GBM 
pathogenesis, these pathways are important therapeutic targets.  However, results from 
clinical investigations of inhibitors targeting RTK/PI3K/MAPK signaling in GBM have 
been disappointing. 
The primary aim of this dissertation was to determine how PI3K and MAPK 
pathway mutations influence response to targeted inhibition.  We previously developed 
a series of non-germline genetically engineered mouse (nGEM) models in which PI3K 
and/or MAPK signaling were activated in immortalized astrocytes (T) by deletion of Pten 
(P) and expression of a constitutively active Kras mutant (R), respectively.  We used 
these models to define how PI3K/MAPK mutations and drug potency influence signaling 
dynamics, efficacy, and synergism of PI3K and MEK inhibitors.  We found that 
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PI3K/MAPK signaling are alternate bypass pathways that promote resistance to 
inhibition of either pathway alone.  Pten/Kras mutation status and drug potency 
interacted to influence single agent efficacy and PI3K/MEK inhibitor synergism.  
Subcutaneous TRP allografts were most sensitive to dual PI3K/MEK inhibitor treatment, 
but target inhibition and efficacy were limited in orthotopic allografts. 
PIK3CA missense mutations frequently occur in GBM, but their role in disease 
pathogenesis had not been experimentally validated.  We therefore transduced 
immortalized, normal human astrocytes with lentiviral vectors encoding wild-type or 
mutant PIK3CA.  We showed that mutations in the helical or kinase domains of PIK3CA 
activate PI3K signaling and cooperate with mutant RAS to potentiate gliomagenesis in 
orthotopic xenografts.  PIK3CA mutations did not affect PI3K inhibitor efficacy, but they 
influenced synergism with MEK inhibition.  Taken together, the work described here 
explored how PI3K and MAPK mutations altered response to targeted inhibition, and will 
inform future research into predictive biomarkers and rationale combination therapies. 
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CHAPTER I: INTRODUCTION 
 
The promise of precision medicine 
Systematic genomic analyses of cancers, such as the NCI’s precision medicine 
initiative, seek to individualize patient care by screening for “actionable” alterations in 
oncogenic pathways in order to direct treatment with targeted inhibitors.1,2  Successful 
implementation of precision medicine relies upon identifying mutations which drive 
tumorigenesis and are predictive of drug efficacy.3  A straightforward approach to 
precision medicine makes important simplifications and assumes that within a signaling 
pathway, activating mutations in oncogenes and loss-of-function mutations in tumor 
suppressor genes are equivalent for tumorigenesis and drug response.  It also assumes 
that mutations within the same gene have equivalent effects.  However, this approach 
does not account for potential biologic differences between loss of tumor suppressors 
and activation of oncogenes.  It also does not reflect the potential for divergent effects of 
multiple mutations within the same gene. 
A more nuanced and realistic approach to precision medicine accounts for the 
gene mutated and the specific mutation within a gene.  Whether a straightforward or 
nuanced approach to precision medicine is required remains unclear, and may be 
disease and pathway specific.3  Preclinical studies can aid in answering these questions 
by defining how multiple mutations within the same gene and pathway impact 
tumorigenesis and drug response.  Furthermore, results of these studies may help 
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guide clinical investigations of targeted inhibitors and accelerate the clinical 
implementation of precision medicine. 
Glioblastoma histology and molecular pathology 
Diffuse gliomas are a histologically and molecularly diverse group of malignant 
primary brain tumors.4,5  Glioblastoma (GBM) is the most common and aggressive 
glioma in adults.6,7  Traditional diagnosis has relied purely on histology, but now 
histological and molecular criteria have been included in the updated WHO 2016 
classification.4,6  However, this updated classification does not reflect an improvement in 
GBM standard-of-care.  GBM is currently treated empirically and uniformly with radiation 
and concurrent and adjuvant temozolomide chemotherapy, yielding a median survival of 
only 12-15 months and 10% 5-year survival.8,9  Recurrence is inevitable, and alternative 
treatments are limited.  Thus, therapies that improve GBM patient outcomes are 
desperately needed.  Despite uniform treatment, and the absence of approved targeted 
inhibitors, the molecular characteristics of GBM have been well defined.10-12  GBM is 
genetically heterogeneous with frequent mutations occurring in three “core” pathways: 
RB mediated G1/S cell cycle checkpoint, TP53, and receptor tyrosine kinase (RTK)/ 
mitogen activated protein kinase (MAPK)/ phosphoinositide-3-kinase (PI3K).10,12  Large 
scale transcriptome analyses have shown that GBM is composed of four molecular 
subtypes with distinct clinical outcomes: proneural, classical, mesenchymal, and 
neural.12  Moreover, alterations in specific genes are enriched in each molecular 
subtype of GBM, particularly NF1 deletions in mesenchymal, PDGFRA amplifications in 
proneural, and EGFR amplifications/truncations in classical.10,12 
RTK and MAPK signaling are prime therapeutic targets in GBM, due to their 
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frequent activation and the myriad of drugs designed to inhibit them.13,14  Mutations in 
the RTK/MAPK pathways have an established role in cancer biology, including GBM.  
RTK are mutated in ~67% of GBM, and their activation promotes many downstream 
pathways, including MAPK and PI3K.10,15-17  MAPK signaling is frequently activated in 
GBM via upstream RTK mutations or by mutations in canonical MAPK genes, 
particularly the proto-oncogenes KRAS and BRAF and the tumor suppressor NF1.  
Moreover, activation of RTK or mutations in canonical MAPK genes cooperate with RB 
and/or TP53 pathway mutations to promote tumorigenesis in preclinical glioma 
models.18-30 
The role of PI3K signaling in GBM pathogenesis 
PI3K are a diverse group of kinases that are divided into three classes based on 
their structural features and lipid substrates.31,32  Class IA PI3K (hereafter just PI3K), 
regulate many of the hallmarks of cancer, including proliferation and migration, and has 
a well-established role in cancer biology.31-34  In contrast, the role of class II and III PI3K 
in cancer are less clear.  PI3K are heterodimeric proteins composed of a catalytic 
subunit encoded by PIK3CA, PIK3CB, or PIK3CD, and a regulatory subunit encoded by 
PIK3R1, PIK3R2, or PIK3R3.31,32  Regulatory subunits stabilize and constitutively inhibit 
the catalytic subunit in the absence of upstream activating signals.  Upon activation, 
catalytic subunits produce the phosphatidylinositol (3,4,5)-trisphosphate (PIP3) 
secondary messenger from membrane bound phosphatidylinositol (4,5)-bisphosphate 
(PIP2).  Furthermore, the lipid phosphatase PTEN antagonizes PI3K signaling via the 
conversion of PIP3 to PIP2.  The PI3K pathway is activated by numerous upstream 
proteins that specifically interact with either the catalytic or regulatory subunit.31,32,35  For 
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example, RTK interact with the regulatory subunit to activate signaling, while RAS 
stimulates activity by directly binding to the catalytic subunit.  Moreover, catalytic 
isoforms differentially respond to upstream proteins.32  Current evidence suggests that 
RTK preferentially activate PI3K signaling via p110α compared to p110β, the proteins 
encoded by PIK3CA and PIK3CB respectively.  Moreover, GPCR have been shown to 
activate p110β, but inhibit p110α. 
The canonical PI3K pathway genes PIK3CA, PIK3R1, and PTEN are mutated in 
46% of GBM, with individual frequencies of 10%, 11%, and 31% respectively.10,15,16  
Mutations in these genes tend to be mutually exclusive, suggesting that they have 
similar roles in GBM pathogenesis.  The role of PTEN in GBM tumorigenesis has been 
well-established using multiple preclinical models.19,36-38  For instance, we found that 
Pten deletion alone is not sufficient for gliomagenesis, but it cooperates with oncogenic 
RAS in immortalized astrocytes to activate PI3K signaling and potentiate malignant 
progression.19,37  This is consistent with the observation that somatic PTEN mutations 
often occur later in the course of GBM pathogenesis in patients, suggesting that they 
function in disease progression, but not initiation.39,40  Similarly, loss-of-function PIK3R1 
mutations were recently shown to activate signaling and promote tumorigenesis in 
preclinical GBM models.41  Based on the mutational frequency of PIK3CA and its 
established role in other cancers, PIK3CA mutations are presumed to active PI3K 
signaling and drive gliomagenesis.10,32,42  However, these assumptions have not been 
validated in GBM models until now. 
Recurrent PIK3CA missense mutations in GBM are restricted to three of its 
protein domains: helical, kinase, and adaptor binding (ABD).15,16  Structural analyses 
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predict that PIK3CA missense mutations activate signaling via distinct mechanisms 
based upon the location within the mutated protein.35,43-47  Helical domain mutations 
disrupt the inhibitory interactions between p110α and the nSH2 domain of p85α, a 
regulatory subunit encoded by PIK3R1.  Kinase domain mutations alter the 
conformation of p110α activation loop, resulting in increased binding to the cellular 
membrane and catalytic efficiency.  ABD mutations, specifically R88Q, alter the 
conformation of the kinase domain increasing its enzymatic activity.  These predicted 
structural changes translate into distinct biologic effects in experimental models of non-
brain tissues.  For instance, helical domain mutations require RAS for activation of PI3K 
signaling, but not the p85α regulatory subunit.48  Furthermore, the converse was true for 
kinase domain mutations.  Helical and kinase domain PIK3CA mutations also initiate 
tumorigenesis and promote malignant progression in non-brain tissues, such as the 
breast.42,49,50  Not as much is known about the role of the less frequent ABD domain 
mutations in cancer pathogenesis.15,16  The R88Q ABD mutation has been shown to 
induce PI3K signaling in vitro, but its requirement for RAS or p85α and its role in 
tumorigenesis remains unclear.51 
Targeting the RTK/MAPK/PI3K pathways in GBM 
The RTK/MAPK/PI3K pathways are prime therapeutic targets in GBM because 
they are frequently mutated and promote gliomagenesis in preclinical models.  Kinase 
inhibitors targeting these pathways have been clinically investigated as single agents in 
GBM, but results have been disappointing.14,52,53  One reason for this is the poor brain 
penetrance of many targeted kinase inhibitors.  For example, EGFR is the most 
frequently mutated RTK in GBM, and the success of the EGFR inhibitors gefitinib and 
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erlotinib in EGFR-mutant non-small cell lung cancer fueled clinical investigations of 
these inhibitors in GBM.3,10,54  However, they do not effectively cross the blood brain 
barrier (BBB), limiting their therapeutic benefit in GBM.55,56 
Drug resistance mediated by adaptive kinome reprogramming is another potential 
reason for the lack of efficacy of the kinase inhibitors tested in GBM.  Kinase inhibitors 
can induce widespread kinome changes that promote drug resistance via re-activation 
of the targeted pathway or activation of alternate pro-tumorigenic pathways.14,57,58  For 
instance, preclinical studies suggested that sensitivity to mTOR inhibitors was increased 
by PTEN loss in multiple cancer types.59-61  The mTOR inhibitor rapamycin was 
therefore investigated in PTEN-deficient GBM patients.62  Interestingly, rapamycin led to 
increased activation of the upstream kinase AKT in several patients.  Moreover, AKT 
activation correlated with a decreased time to disease progression, suggesting that 
rapamycin-induced AKT activity may promote malignancy in these patients.  Taken 
together, these clinical results highlight some of the challenges in effectively targeting 
the RTK/MAPK/PI3K pathways in GBM and suggest that a nuanced approach to 
precision medicine will be required.  Furthermore, they exemplify the necessity for 
preclinical research that evaluates drug efficacy, determines mechanisms of drug 
resistance, and validates putative predictive biomarkers in a specific disease context. 
 Genetically engineered models enable determination of direct genotype to 
phenotype relationships in preclinical studies.3,63  In contrast, tumor-derived models 
have more complex genomic profiles that may obscure the phenotypic consequences of 
individual mutations.  We leveraged this advantage of genetically engineered models to 
characterize how PI3K and MAPK activation via Pten loss and a constitutively active 
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Kras mutant in immortalized mouse astrocytes influenced response to single agent and 
combination treatments with PI3K and MAPK inhibitors.19,64  Additionally, we used 
genetically engineered human astrocytes to characterize the role of PIK3CA missense 
mutations in gliomagenesis and sensitivity to PI3K and MAPK inhibitors.18  Taken 
together, the results described in the following chapters may aid in the design of future 
preclinical and clinical studies investigating predictive biomarkers and resistance 
mechanisms for single agent and combination treatments with targeted kinase 
inhibitors. 
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CHAPTER II: CONTEMPORARY MURINE MODELS IN PRECLINICAL 
ASTROCYTOMA DRUG DEVELOPMENT1 
 
Introduction 
Oncology drug development is an inherently long and expensive process.  The 
average time required from the initial filing of an investigational new drug application to 
marketing approval by the US Food and Drug Administration (FDA) is ~9 years.1  Most 
oncology drugs fail late in the clinical trials process from lack of efficacy.  Only 5% 
ultimately receive FDA approval, after a typical cost of $400 million.2  In addition to 
length and cost, this inefficiency significantly limits the number of drugs with proven 
clinical benefit.  Since nitrogen mustard (mechlorethamine) became the first cytotoxic 
anti-cancer agent in 1949, only 138 oncology drugs have received FDA approval – an 
average of 1.4 per year.  The approval rate was even lower (~1 drug per year) during 
the era of empirical therapy with cytotoxic drugs (1949-1996).  However, the rate of new 
drug approvals has increased dramatically (~4 per year) since the dawn of the precision 
medicine era of oncology,3 marked by the 1996 approval of rituximab, the first targeted 
anti-cancer agent. 
 
1A version of this work appeared as an article in Neuro-Oncology.  The original citation is as 
follows: McNeill RS, Vitucci M, Wu J, Miller CR. Contemporary murine models in preclinical 
astrocytoma drug development. Neuro Oncol. 2015;17(1):12-28. 
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Targeted agents now constitute 36% of all FDA-approved oncology drugs.  Twenty-
three were approved in the last four year alone (Fig 2.1).  Dozens more are currently in 
clinical trials and hundreds are in preclinical development at pharmaceutical companies 
and academic centers worldwide.  
However, only three drugs have been approved specifically for the treatment of 
astrocytomas, the most common malignant primary brain tumors.4  These include two 
cytotoxic agents, carmustine wafers and temozolomide (TMZ), and one targeted agent, 
bevacizumab.  Carmustine wafers were approved for recurrent and newly diagnosed 
glioblastoma (GBM), a WHO grade IV astrocytoma, in 1997 and 2003.  TMZ was 
approved for recurrent anaplastic astrocytomas (WHO grade III) and newly diagnosed 
GBM in 1999 and 2005.  The targeted agent bevacizumab, a humanized monoclonal 
antibody directed against VEGF, was approved for recurrent GBM in 2009.  Thus, 
despite the accelerated pace of oncology drug development over the past two decades, 
the therapeutic armamentarium for astrocytomas remains severely limited. 
Histopathological classification has served as the foundation for diagnosis and 
management of astrocytomas for nearly a century.5  Periodic refinement of the initial 
1926 classification culminated in the current scheme, published in 2007 by the World 
Health Organization.6,7  This system utilizes cytological evidence of astrocytic 
differentiation and the presence of morphological features, including mitotic activity, 
angiogenesis, and necrosis, to stratify patients into prognostically distinct diagnostic 
entities with increasingly poor survival.  Low grade (WHO grade II) astrocytomas have a 
10-year median overall survival.  High-grade astrocytomas, including anaplastic 
astrocytomas and GBM, feature elevated mitotic activity and angiogenesis and/or 
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necrosis.  These tumors have dismal prognoses of ~3 years and 15 months, 
respectively.7  Despite their classification into distinct diagnostic entities, comprehensive 
genomic analyses have shown that astrocytomas of all grades are molecularly 
diverse.8,9  Recognition of this fact has fueled efforts to develop a molecular 
classification scheme to further accelerate the shift from empirical, cytotoxic therapies to 
precision medicine with targeted agents in molecularly-defined tumor subsets (Fig 
2.2).3,8 
Although astrocytomas significantly contribute to cancer-related death and 
disability, they are relatively rare.  GBM accounts for 86% of all astrocytomas, but only 
affects 3.2 in 100,000 individuals in the United States.  Its incidence is age-dependent, 
ranging from 0.14 in children to a peak of 14.9 in 100,000 75-84 year olds.4  Moreover, 
less than 20% of adult astrocytoma patients enroll in clinical trials.10  The low 
prevalence and limited clinical trial participation represent significant challenges for 
astrocytoma drug development. 
As the diagnostic and treatment landscape evolves from empirical to precision 
medicine, now is an opportune time to reassess the way drugs are developed for adult 
patients with astrocytomas (Fig 2.2).  The reality that, relative to other cancer types, 
astrocytomas are rare and that trial participation is limited makes this issue even more 
acute.  A number of innovative approaches to clinical trial design, including adaptive, 
biomarker-based trials, are currently under investigation and will not be the focus of this 
chapter.11,12  Rather, we focus on the role of murine models in preclinical drug 
development for adult astrocytoma patients and will argue that fundamental changes in 
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their use are required to expand the therapeutic armamentarium and improve outcomes 
for these devastating malignancies. 
Given the number of promising targeted agents that deserve clinical testing, 
preclinical astrocytoma modeling will be critical in validating drug targets and prioritizing 
candidates for clinical studies.  These models will also be critical in discovery and 
development of novel predictive biomarkers that can be used to stratify patients into 
biologically meaningful disease subtypes and identify likely responders.  Finally, these 
models will be critical in defining the molecular mechanisms of drug sensitivity and 
resistance so that rational combination therapies, and molecular diagnostic tests to 
guide their use, can be developed. 
The last twenty years have witnessed major improvements in the preclinical 
modeling of astrocytomas.  A number of recent reviews have described these in 
detail.13-24  Here we examine the role of conventional mouse models in the development 
of cytotoxic drugs commonly used to treat adult astrocytoma patients.  We then 
examine their use in the development of select targeted agents that have recently failed 
in late stage clinical trials.  We will then describe contemporary mouse models and how 
they may be best utilized to improve clinical drug development in the future. 
Development of DNA alkylating agents for GBM 
Three cytotoxic, DNA alkylating agents, carmustine (bis-chloroethylnitrosourea, 
BCNU), lomustine (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, CCNU), and TMZ have 
been the cornerstones of astrocytoma chemotherapy for the past five decades.  The 
nitrosoureas, BCNU and CCNU, entered clinical practice in the 1960s and were studied 
in a number of clinical trials through the 1990s.  TMZ was developed in the late 1980s 
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and entered clinical practice in the mid-1990s.  Here we describe the clinical 
development of these drugs and how animal model studies were utilized to inform their 
development. 
Randomized phase III clinical trials of nitrosoureas in adult astrocytoma patients 
were published in the late 1970s.25,26  BCNU and CCNU were initially chosen for clinical 
development based on their excellent ability to cross the blood-brain barrier (BBB) and 
their efficacy in multiple preclinical models.  However, individual trial results from 1976 
to 2001 were inconclusive and a meta-analysis of over 3,000 patients from twelve trials 
was required to definitively demonstrate their efficacy, specifically a ~2 month increase 
in median survival and a 5% increase in 2-year survival.27  Although this study 
established chemotherapy as a valuable adjuvant to surgical resection and radiation 
therapy, the clinical benefits of nitrosoureas were marginal and systemic toxicity was 
common. 
The successful culture of spontaneous tumors from chemically mutagenized 
rodents as established cell lines (ECL) transformed the cancer research landscape in 
the 1940s (Fig 2.3A).  Development of the P388 and L1210 models of leukemia in 
particular were critical in development of dozens of cytotoxic drugs by the 
Developmental Therapeutics Program at the National Cancer Institute from the 1950s 
through the 1980s.28,29  Their rapid, reproducible growth, high penetrance, and short 
latency when injected into syngeneic hosts made these models particularly attractive for 
preclinical drug studies.  It is therefore not surprising, in retrospect, that the nitrosoureas 
were first tested and found to have efficacy in intracranial leukemia models.30  While 
chemical mutagenesis had been shown to produce gliomas in rodents during the 
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1940s,31 ECL and allograft models of murine gliomas, including GL26, GL261, 9L, and 
C6, became widespread during the late 1960s and early 1970s.13,19,31-34  ECL cultures 
from human astrocytomas and xenotransplantation in immunodeficient mice were 
developed contemporaneously.19,35-39  Thus, preclinical testing of nitrosoureas in glioma 
models occurred much later during their clinical development, with the first results 
published in 1973.33  A meta-analysis of preclinical studies employing either murine 
allograft or human xenograft ECL models showed highly variable efficacy significantly 
influenced by experimental design.  Overall effect sizes were small (0.19-fold and 0.43-
fold increases in median survival for BCNU and CCNU, respectively) and no statistically 
significant beneficial effect was found.40 
TMZ, a mono-alkylating agent developed in the 1980s, was clinically investigated 
due to its broad anti-tumor activity and favorable toxicity profile in preclinical models, 
particularly L1210 leukemias (Fig 2.4).41  It was found to have excellent oral 
bioavailability in a phase I study.  Fortunately, this trial included several high-grade 
astrocytoma patients who experienced partial sustained responses.42  Subsequent 
clinical experience in recurrent and newly diagnosed high-grade astrocytoma patients 
was similarly favorable.43  Phase II trials in recurrent high-grade astrocytomas and in 
combination with radiation in newly diagnosed GBM patients showed 58% radiographic 
response rates and 16 month median survival, respectively.44,45  The definitive phase III 
trial published in 2005 established adjuvant TMZ in combination with fractionated 
radiation as standard-of-care for newly diagnosed GBM based on a 21% increase in 
median survival and a 5-fold increase in 5-year survival compared to radiation alone, 
which produced only 12.1 month median and 1.9% 5-year survivals.46,47 
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The first preclinical study of TMZ efficacy in GBM ECL models was published in 
1994, seven years after its first description and two years after entering clinical trials.48  
A 2013 meta-analysis of TMZ in murine allograft and human xenograft ECL models of 
GBM showed that it was consistently efficacious in both, producing 50% decreases in 
tumor volume and ~2-fold increases in median survival on average.49  This contrasts 
with the meta-analysis of nitrosoureas in similar preclinical models that showed far 
smaller and inconsistent effect sizes.40 
The biological effects of TMZ are largely mediated by its ability to methylate the 
O6 position of guanine.50  Repair of this lesion is carried out by a single enzyme, 
encoded by the methylguanine-DNA methyltransferase (MGMT) gene.  MGMT 
expression is regulated through promoter methylation and ~50% of GBM have 
methylated MGMT.51  Based upon this knowledge, a retrospective companion study to 
the definitive phase III trial that established TMZ as standard-of-care for GBM showed 
that MGMT promoter methylation was a favorable prognostic and likely predictive 
marker for TMZ benefit in GBM patients.52  Subsequent studies using more 
contemporary human GBM models whereby patient-derived tumors are directly 
xenografted into immunodeficient mice without prior serum-based culture showed that 
MGMT promoter methylation was an important predictor of TMZ efficacy.53,54  TMZ 
given concurrently with radiation produced a survival benefit only in a subset of GBM 
patient-derived xenografts (PDX) models with methylated MGMT.55  Moreover, TMZ 
showed a wider response range in PDX (0.2 to 5.9-fold increases in median survival) 
than in human ECL models (0.3 to 2.5-fold) of GBM, suggesting that these newer 
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models may more accurately reflect its clinical efficacy, particularly in molecularly 
defined subsets of tumors.49,54,55 
Based on the role of MGMT in TMZ resistance and the fact that protracted, dose-
dense TMZ depleted MGMT activity in peripheral blood mononuclear cells, the 
hypothesis that dose-dense TMZ would enhance its therapeutic benefits, particularly in 
GBM with unmethylated MGMT, was explored in a randomized, phase III clinical trial.56-
58  Although this recently published trial prospectively confirmed the prognostic 
significance of MGMT promoter methylation, dose-dense TMZ failed to improve survival 
in either MGMT unmethylated or methylated GBM.  These results are consistent with a 
preclinical study in GBM PDX models that showed that TMZ induced MGMT 
expression, even in MGMT unmethylated GBM.59  A similar lack of efficacy and 
correlation with MGMT methylation status was found in a preclinical study of dose-
dense TMZ with seven GBM PDX models published during trial accrual.60 
Development of targeted agents for GBM 
The promise of small molecule inhibitors that target the dysregulated signaling 
pathways driving gliomagenesis has fueled neuro-oncology drug development since the 
late 1990s.  The epidermal growth factor receptor (EGFR) had long been known to be a 
mutated target in GBM, where amplifications and activating truncation mutations are 
among the most common genetic abnormalities.61-64  Based upon this knowledge, their 
anti-tumor activity in preclinical models,65-69 and their efficacy in EGFR-mutant non-
small-cell lung cancers (NSCLC),70 the first generation EGFR tyrosine kinase inhibitors 
(TKI) gefitinib and erlotinib entered clinical trials in the 2000s (Fig 2.5A).  However, no 
significant activity was found in a number of phase II GBM studies and no reliable 
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biomarkers to predict their efficacy could be identified in retrospective molecular 
analyses.71-81  Reasons for their failure remain poorly understood, but signaling pathway 
redundancy and molecular heterogeneity likely contributed.82  Subsequent 
pharmacokinetic (PK) studies in patients with NSCLC brain metastases showed limited 
CSF penetration of both gefitinib and erlotinib.83  Moreover, expression of ABC 
transporters, including P-glycoprotein and breast cancer resistance protein (BRCP), 
were shown to significantly limit brain penetration of erlotinib.84 
Newer EGFR TKI showed broader activity spectra and targeted multiple EGFR 
family receptors.  Whereas first generation EGFR TKI bound only the active 
conformation of the EGFR TK domain, second generation TKI such as lapatinib bound 
the inactive conformation.  It was subsequently shown using GBM ECL and 
neurosphere culture models that, unlike EGFR TK domain mutations characteristic of 
NSCLC, GBM-specific extracellular domain mutations were poorly inhibited by first-
generation TKI, but effectively inhibited by lapatinib.82  However, lapatinib showed 
minimal activity in recurrent GBM clinical trials.85  Subsequent retrospective PK studies 
using NABTC 04-01 trial material showed intratumoral lapatinib concentrations well 
below its predicted therapeutic threshold.82 
In contrast to EGFR TKI, data from preclinical glioma models significantly 
influenced the design of clinical trials with cilengitide, an alpha v-integrin antagonist and 
putative anti-angiogenic agent (Fig 2.5B). Cilengitide showed efficacy in subcutaneous 
GBM ECL xenografts in a 2001 study.86  A subsequent phase I trial in recurrent GBM 
patients reported promising biological activity and demonstrated a correlation between 
PK parameters and radiographic response.87  Moderate antitumor activity in the 
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recurrent setting was confirmed in a single-agent phase II trial, supporting its continued 
investigation in combination regimens.88  Prior to those trials, preclinical studies in GBM 
ECL xenograft models demonstrated the radiosensitization effects of cilengitide and 
revealed an unanticipated dependence on schedule.89  These preclinical data informed 
the design of subsequent phase I-III trials of cilengitide in combination with 
chemoradiation in newly diagnosed GBM.90-92  Retrospective molecular analysis of 
phase II specimens suggested that MGMT methylation was associated with cilengitide 
benefit in this clinical setting.90  However, cilengitide failed to prolong survival in newly 
diagnosed GBM patients with methylated MGMT in a randomized phase III trial.92 
Lessons from the development of cytotoxic and targeted agents for GBM 
What lessons can be gleaned from the development of alkylating and targeted 
agents for GBM that might improve future drug development efforts?  Clinical trials of 
nitrosoureas and TMZ were initiated based on preclinical data from murine leukemia 
models.  Data from glioma models came later.  With the benefit of hindsight and 
decades of research that have conclusively demonstrated that neoplasms from different 
tissues are molecularly and biologically distinct, it is now clear that the decision to 
initiate clinical studies should be based on preclinical data in the tumor type of interest.  
Preclinical data from models that do not accurately reflect the tumor histology or its 
native organ-based microenvironmental interactions are likely to produce misleading 
results.28,93 
However, comparison of alkylating agent efficacy in preclinical glioma models 
and clinical studies demonstrates striking similarities.  Nitrosoureas produced small, but 
significant benefits in some murine models and astrocytoma patients.  In contrast, TMZ 
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was consistently effective in both ECL model studies and clinical trials, with relatively 
large effect sizes.  These data suggest that large effect sizes in multiple preclinical 
models may be required to accurately predict efficacy in clinical trials, particularly those 
that enroll molecularly heterogeneous, unselected patient populations.  We therefore 
recommend that the bar for future preclinical drug studies be set well beyond small, but 
statistically significant prolongations of survival in single model systems, particularly 
ECL models.  Rather, consistent demonstration of large effect sizes in newer model 
systems that more accurately recapitulate the genomic and biological properties of 
human astrocytomas may have increased ability to predict clinical efficacy in unselected 
patient populations. 
How do newer model systems, such as PDX, fare in predicting clinical success 
relative to conventional ECL models?  Preclinical studies with nitrosoureas and 
cilengitide were only conducted in ECL models (Table 2.1).  Many of the same ECL 
models were also used in the initial preclinical development of TMZ (Fig 2.4), as well as 
the EGFR TKI gefitinib and erlotinib (Fig 2.5).  However, the more recent preclinical 
TMZ and EGFR TKI studies utilized PDX models to characterize genetic mechanisms of 
response and resistance, and discover predictive biomarkers.53-55,59,60,68,69,94-96  Thus, 
the fact that TMZ succeeded clinically, while EGFR TKI and cilengitide failed, cannot be 
attributed simply to use of newer model systems in preclinical development.  
Comprehensive comparison of drug efficacy in newer PDX versus conventional ECL 
models is limited to TMZ.  Such data suggest that PDX models may more accurately 
reflect the heterogeneity of response seen in GBM patients.  Therefore, systematic drug 
efficacy screening in multiple genomically characterized PDX models might be useful for 
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prospective identification of molecularly-defined subsets of tumors that are likely to 
respond.18,97  In order to evaluate the predictive accuracy of these models and 
maximize their utility for biomarker discovery and development, preclinical studies in 
PDX models should be performed earlier in the drug development process, ideally prior 
to initiating clinical trials or concurrently as “co-clinical trials.”98 
Rather than relying on data from preclinical models, predictive biomarker 
discovery for TMZ and EGFR TKI was largely conducted by retrospective molecular 
analyses of clinical trial specimens.  Of the above examples, only the phase III 
cilengitide trial utilized prospective molecular stratification of MGMT-methylated GBM to 
increase molecular homogeneity and enrich for likely responders.  While this approach 
is critical for clinical biomarker validation and required for their eventual incorporation as 
an inclusion criterion in prospective trials, retrospective analyses are inefficient because 
they require completion of the trial.  Given the limited incidence and trial participation of 
astrocytoma patients, we would argue that a more efficient approach for the discovery 
of predictive biomarkers would be an increased reliance on preclinical drug studies in 
genomically and biologically faithful murine models.  Such markers could then be 
validated in retrospective molecular studies of clinical trial specimens.  Indeed, this 
approach has been applied to investigate the ability of a prognostic gene expression 
signature to predict bevacizumab efficacy in mesenchymal GBM.99-102  Increased use of 
this approach for future drug development is likely to reduce time and costs and 
improve the efficiency of clinical trials. 
Nitrosoureas and TMZ were attractive clinical candidates due to their lipophilic 
chemical structures and favorable brain PK profiles.  Indeed, their ability to penetrate 
26 
the BBB and reach diffusely infiltrative tumor cells is likely one reason for their clinical 
efficacy.103  In contrast, the failure of first and second generation TKI to fulfill the 
promise of EGFR targeted therapy was likely due in part to their poor brain PK and the 
activity of BBB drug efflux pumps.  Unfortunately, CNS neoplasms are a frequent 
exclusion criterion in phase I studies and brain PK is not routinely analyzed during early 
development of many targeted agents.  The unfortunate failure of EGFR TKI clearly 
demonstrates the importance of such data.  Preclinical PK studies in both glioma 
models and mice with genetically engineered defects in BBB efflux pumps have the 
potential to predict clinical failure on the basis of poor PK if used prior to, or concurrent 
with, the initiation of advanced clinical trials. 
In addition to poor brain PK, receptor tyrosine kinase (RTK) signaling pathway 
redundancy and inter-tumoral molecular heterogeneity likely contributed to the clinical 
failures of first-generation EGFR TKI.  Although they share EGFR mutations in 
common, the divergent efficacy of these drugs in NSCLC and GBM demonstrates that 
mutation status of a biologically attractive target gene alone is insufficient to predict 
efficacy of inhibitors that specifically target its activity.  Rather, preclinical and clinical 
data with these drugs in NSCLC and GBM demonstrate that mutation location, within 
specific functional domains, and its impact on protein structure and catalytic activity is 
equally important in determining efficacy.  Moreover, these data suggest that current 
precision medicine initiatives that utilize next generation sequencing to identify 
“actionable” somatic mutations in oncogenic kinases may require more nuance to fulfill 
their potential of targeted therapy.  Indeed, success of such efforts rests on three critical 
assumptions: 1) that the identified mutation activates downstream signaling and 
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promotes tumorigenesis in the specific tumor type in which it is found; 2) that the 
mutated kinase is sensitive to drug inhibition in the appropriate anatomical context (e.g. 
lung versus brain); and 3) that inhibition results in clinical benefit in the specific tumor 
type of interest.  Because the biological function and druggability of mutational targets 
are likely tissue specific, it stands to reason that experimental evidence, such as that 
provided by contemporary preclinical model studies, is necessary to prove the 
“actionability” of drug-targetable gene mutations in the specific clinical context to be 
investigated. 
Astrocytoma genomic heterogeneity and its impact on drug development 
Over the last 15 years, advances in genomics and DNA sequencing technologies 
have revolutionized cancer research.  Studies have conclusively demonstrated that 
significant inter-tumoral heterogeneity exists on multiple molecular levels, both within 
and among the three diagnostic categories of astrocytomas.9,104,105  The transcriptome 
profiles of lower grade astrocytomas (WHO grades II and III) and GBM are distinct102,103 
and each consists of three or four transcriptomal subtypes.61,64,106,107  Particular patterns 
of somatic mutations, chromosomal alterations, and DNA methylation are evident not 
only within each grade, but also within grade-specific subtypes.61,64,108  For example, the 
IDH1 and IDH2 genes are mutated in ~60-80% of lower grade astrocytomas and ~50-
80% of the secondary GBM into which they inevitably progress, but only ~3-7% of 
primary GBM that arise de novo without a clinically detectable, lower grade 
antecedent.109  Lower grade astrocytomas that lack IDH mutations have transcriptome 
and copy number profiles similar to GBM.  A molecular classification system that 
supplements histological classifiers with layers of molecular information promises to 
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provide a diagnostic framework that not only reflects the inter-tumoral heterogeneity 
present in these neoplasms, but facilitates more accurate prognostic stratification and 
prediction of therapeutic response to targeted therapies.8,9 
Many of the putative oncogenic driver mutations in astrocytomas occur in genes 
that comprise three core signaling pathways – the G1/S cell cycle checkpoint controlled 
by the Rb family of pocket proteins, RTK and their downstream RAS-mitogen activated 
protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) effector pathways, and the 
TP53 pathway.63  Dozens of drugs are currently in development to inhibit kinases in 
these pathways and many are actively being investigated in astrocytoma clinical trials.  
However, given limited trial participation, low disease prevalence, and the number of 
promising targeted agents that deserve clinical testing, a more rational approach to 
preclinical drug development for astrocytomas is required. 
In addition to inter-tumoral heterogeneity, genomics studies have shown 
significant molecular heterogeneity within individual astrocytomas as well.110-113  
Sequencing data from multiple samples of individual tumors has demonstrated 
coexistence of spatially distinct clones with divergent mutational and transcriptomal 
profiles.  Phylogenetic reconstruction showed patient-specific patterns of evolution 
within each tumor.111,112  Moreover, treatment of lower grade astrocytomas with DNA 
damaging agents such as TMZ may modify the evolutionary path to high-grade disease 
by inducing alternative mutational spectra.112  Similarly, comprehensive fluorescence in 
situ hybridization studies have shown that multiple RTK genes, including EGFR, MET, 
and PDGFRA, can be simultaneously amplified not only within spatially distinct 
subpopulations of tumor cells, but within individual tumor cells as well.114  This mosaic 
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gene amplification can lead to coactivation of multiple redundant RTK signaling 
pathways, limiting the effectiveness of inhibitors targeting individual kinases and 
suggesting the need to develop rational combination therapies.115 
In addition to molecular heterogeneity, murine modeling studies of human GBM 
have suggested that individual cells within the tumor may be functionally 
heterogeneous.116  The cancer stem hypothesis posits that a small subpopulation of 
tumor cells, termed cancer stem cells (CSC), are uniquely capable of tumor 
maintenance and hierarchical differentiation into multiple tumor cell lineages.117-119 CSC 
have been proposed as a cause of therapeutic resistance and tumor recurrence.120  
Their implications in astrocytoma biology and drug development have been previously 
reviewed in detail.121-125 
GBM subtypes may have distinct treatment responses.64  Although transcriptome 
profiling was recently evaluated in the trial of bevacizumab in combination with 
standard-of-care therapy for newly diagnosed GBM,99,102 it is remains unclear how this 
measure of inter-tumoral genomic heterogeneity should be incorporated in future clinical 
trials.  It is likely that novel drug efficacy will be restricted to specific molecular subtypes 
with unique mutational, epigenetic, or CSC profiles.  However, the ideal molecular 
diagnostic approach to prospectively identify likely responders has yet to be developed.  
How should molecular profiles be incorporated into clinical trial design to account for the 
heterogeneity present in astrocytomas?  In the absence of definitive data on their 
prognostic and predictive significance, a prudent approach would be to retrospectively 
characterize genomic heterogeneity in clinical trial specimens on as many molecular 
levels as is economically feasible.  An even more cost-effective approach may be to 
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conduct preclinical drug studies, either before or in parallel with clinical trials, using 
biologically diverse panels of contemporary murine models that have also been 
comprehensively profiled. 
Conventional and contemporary murine models of astrocytomas 
Like diagnosis and therapy, the last two decades have witnessed major 
improvements in preclinical modeling of astrocytomas (Figs 2.2, 2.3).  A number of 
recent reviews have described these improvements in detail.13-24  Here, we compare 
contemporary with conventional ECL models and discuss how they may be utilized to 
improve preclinical astrocytoma drug development. 
Established cell line (ECL) models 
ECL cultured from rodent astrocytomas induced by chemical mutagenesis 
transformed the preclinical drug development landscape in the late 1960s (Fig 
2.3A).13,19,31-38  These technically straightforward, highly penetrant models were widely 
disseminated and developed tumors with rapid, uniform growth kinetics, and short 
latency when transplanted subcutaneously or orthotopically in the brains of murine 
hosts (Table 2.2).  Many recapitulated the histopathological features of human high-
grade astrocytomas, including their diffuse invasion of normal brain.  Orthotopic murine 
allograft models were particularly attractive for the development of drugs targeting 
tumor-stroma interactions or immune-modulatory therapies because tumorigenesis 
could be induced in the native brain microenvironment in immunocompetent, syngeneic 
mice.13,19 
Developed in the late 1960s through the 1980s, xenograft models using ECL 
cultured from human astrocytomas shared many of the attractive features of murine 
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allograft models.  Because ECL originated from human tumors, extrapolation of 
experimental results were uncomplicated by molecular and physiological differences 
between mice and humans.  However, many failed to recapitulate the brain invasive 
histopathology of human astrocytomas.20,126,127  The requirement for immunodeficient 
hosts also rendered examination of microenvironmental and immune influences on drug 
response impossible. 
Comprehensive genomics analyses of both murine and human ECL models 
identified a number of additional limitations.  Phenotypic and genotypic drift due to 
clonal selection upon serial culture of adherent cells in serum-containing media 
rendered ECL markedly different from their original tumor.19  ECL cultured under these 
non-physiological conditions adapted to the presence of abundant nutrients by 
increasing metabolic and proliferation programs and to their artificial micro-environment 
by decreasing cell adhesion.  Thus, ECL frequently developed uncharacteristic and 
complex chromosomal abnormalities and their molecular profiles differed significantly 
from acutely-isolated GBM samples.128-131  Although genomic analyses have defined the 
mutational landscapes of many astrocytoma ECL, their abundance of mutations and 
complex chromosomal alterations render genotype-phenotype comparisons difficult. 
Subcutaneous ECL models remain a popular method of assessing both in vivo 
tumorigenesis and drug efficacy due to the technical ease of monitoring growth kinetics 
in this anatomic compartment.  Nevertheless, these models fail to account for native 
microenvironmental influences on tumor pathogenesis and drug response and do not 
accurately model PK effects of the BBB.  Targeted agents, such as palbociclib, that 
show efficacy in subcutaneous xenografts have failed when tested in orthotopic models 
32 
due to drug efflux pumps at the BBB.132  The molecular profiles of ECL xenografted 
subcutaneously markedly differ from corresponding orthotopic xenografts.133  Tumor 
location can also significantly impact molecular and biological responses to cytotoxic 
therapies, such as radiation.134  Because subcutaneous ECL models can over-estimate 
the therapeutic potential of novel agents, their use should be restricted to validation of 
therapeutic targets in biological proof-of-principle experiments and their role in 
prioritizing drugs for clinical investigation should be minimized. 
Patient-derived xenograft (PDX) models 
Many of the shortcomings of ECL models can be directly attributed to their serial 
culture as adherent cells in serum-containing media.  Some of these have subsequently 
been overcome through development of PDX (Fig 2.3B), whereby fresh tumor tissue 
fragments are directly injected into the brain or serially passaged subcutaneously in 
immunodeficient mice.  Alternatively, PDX can be cultured as non-adherent spheroids in 
growth factor-defined, serum-free medium prior to orthotopic transplantation.15,19,135  
Development of these techniques have been critical in defining the functional 
heterogeneity present in human astrocytoma cells and exploring the biological and 
therapeutic implications of the CSC hypothesis in these tumors.121-125 
PDX share many of the advantages of ECL models for preclinical drug 
development, including high penetrance, short latency, and rapid, uniform growth 
kinetics in vivo.  However, unlike ECL, PDX maintain the genomic features of the 
tumors from which they were derived and faithfully recapitulate the molecular profiles 
and histopathological features of GBM, including diffuse brain invasion.19,136-141  
Although their cellular origin is undefined and their genomic complexity renders 
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elucidating the phenotypic consequences of individual oncogenic mutations difficult, 
when studied in multi-model panels, PDX more broadly recapitulate the inter-tumoral 
genomic heterogeneity evident in GBM.137  As such, systematic drug screening in these 
models has the potential to more accurately reflect clinical activity of novel drugs and to 
more readily identify predictive molecular characteristics.  The multi-institutional Ivy 
Genomics-based Medicine Project is currently utilizing this approach to investigate both 
novel and conventional cytotoxic agents and develop predictive biomarkers in a 
genomically diverse panel of PDX models.18,97 
Genetically engineered human cell (geHC) models 
Models using genetically engineered normal human brain cells (geHC) have 
been recently developed to overcome some of the limitations of human astrocytoma 
ECL and PDX models (Fig 2.3C).  These models were generated by purifying specific 
cell types, such as astrocytes or neural stem cells, from normal human brains and using 
standard molecular biology techniques to engineer their expression of specific 
oncogenic mutations.142-145  By virtue of their design, these genetically-defined models 
permit direct determination of the phenotypic consequences of astrocytoma associated 
mutations in specific neural cell types.  Their serial culture in vitro is generally 
unaccompanied by additional genomic abnormalities.144  While penetrance, growth 
kinetics, and latency vary based on mutations and cellular origin, many geHC models 
give rise to diffusely infiltrative astrocytomas when orthotopically injected into the brains 
of immunodeficient mice. 
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Genetically engineered mouse (GEM) models 
Genetically engineered mouse (GEM) models revolutionized basic cancer 
research in the 1990s.  Over the past two decades, dozens of astrocytoma GEM 
models have been developed to dissect the genetics of de novo tumorigenesis in the 
native brain microenvironment (Fig 2.3D).19,20  Because knockout and transgenic GEM 
harbored engineered mutations in all cell types, embryonic lethality precluded study of 
genes critical for development.20  GEM that utilized conditional alleles were 
subsequently developed to overcome this limitation and to spatially restrict oncogenic 
mutations to defined cell types within the brain.  Conditional, inducible and somatic gene 
transfer GEM, including the RCAS-tva system, were designed to facilitate temporal as 
well as spatial control of mutations.  The value of these models in basic astrocytoma 
research has been reviewed extensively elsewhere.16-24  Here we focus on their use in 
astrocytoma drug development. 
A number of factors inherent in the design of astrocytoma GEM models has 
limited their use in preclinical drug development, particularly for studies evaluating drug 
efficacy by conventional clinical endpoints – radiographic response and overall 
survival.146-149  Whereas single oncogenic alleles are sufficient to induce tumorigenesis 
in medulloblastoma models, multiple mutations are typically required to induce 
astrocytoma tumorigenesis in GEM.20,150,151  Conditional GEM models require complex 
and often inefficient breeding schemes to generate sufficiently large cohorts for 
preclinical drug studies.  RCAS/tva GEM are much more amenable because multiple 
pre-defined, oncogenic alleles can be simultaneously introduced into specific neural cell 
types using a single transgenic mouse line engineered to express tva receptors.20,152  
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However, because RCAS retroviral vectors are required, these models are limited to the 
transformation of endogenously proliferative cell types.152  High-grade astrocytoma 
tumorigenesis typically occurs with variable penetrance after relatively long periods of 
latency in these model systems.  Moreover, GBM develop in a temporally 
heterogeneous, stochastic manner.  Therefore, the presence and location of tumors in 
individual mice must be confirmed by radiographic imaging prior to treatment initiation 
and intermittently thereafter in order to monitor drug response in vivo.20,152-154  Taken 
together, these features make preclinical drug studies in astrocytoma GEM long, 
cumbersome, and expensive. 
Non-germline genetically engineered mouse (nGEM) models 
Non-germline GEM (nGEM) models overcome many of the limitations of GEM 
and may be more amenable to preclinical drug studies.  Like geHC, nGEM models 
utilize cultures of specific cell types harvested from GEM brains, including astrocytes 
and neural stem cells (Fig 2.3D).127,155-159  They harbor defined genetic mutations and 
their serial culture is generally unaccompanied by additional genomic abnormalities 
(unpublished observations).  While penetrance and latency vary with mutations and 
cellular origin, nGEM astrocytomas developed with uniform growth kinetics in vivo when 
injected into syngeneic, immunocompetent hosts, precluding the need for radiographic 
screening.127  Like ECL, PDX, and geHC, these cells can be readily modified genetically 
to express luminescence proteins to facilitate monitoring of disease burden and drug 
response with bioluminescence imaging.53,160  Both geHC and nGEM models enable 
direct determination of genotype-phenotype relationships.  Unlike ECL and PDX, these 
models can be used to define the oncogenic roles of single mutations and the 
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cooperative roles of multiple mutations during tumorigenesis.  They are thus uniquely 
suited for the systematic validation of putative oncogenic “driver” mutations identified in 
large-scale genome characterization projects.161  Because geHC and nGEM grow in 
vitro and in vivo and feature defined genomic landscapes, these models can also be 
used to unambiguously define the genetics of drug response and resistance. 
Moreover, nGEM may be useful in dissecting the role of individual mutations and 
their cellular origin in generating genomic diversity of human astrocytomas.  As such, 
subtype-specific nGEM models of GBM may be developed for drug development.  We 
have recently published an nGEM model derived from G1/S-defective astrocytes with 
activated MAPK and PI3K signaling that molecularly mimics proneural human 
GBM.64,127  However, in contrast to ECL, PDX, and geHC models, nGEM models utilize 
syngeneic, immunocompetent hosts and may be useful in development of drugs 
targeting tumor-stroma interactions or immune-modulatory therapies. 
Modeling low grade astrocytomas 
Despite advances in modelling techniques, murine models that mimic the natural 
history of low grade astrocytomas (WHO grade II) in humans have been difficult to 
develop.  These tumors generally fail to become established when cultured in vitro or 
grow when transplanted into immunodeficient mice.  In fact, in vivo tumorigenesis has 
long been known to correlate with histological grade and poor prognosis.162  Thus, 
human ECL and PDX models of low grade astrocytomas are virtually non-existent.  
Their absence has significantly impeded study of the genetics of malignant progression 
and the development of effective drugs for these tumors.  However, several GEM 
models have recently been described that develop clinically silent, but 
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histopathologically detectable low grade astrocytomas.154,163  These tumors 
progressively expand over time, spontaneously acquire additional mutations, and 
undergo malignant progression to lethal, high-grade disease.164  Despite their initiation 
by a limited number of oncogenic mutations, malignant progression in these GEM 
results in GBM with transcriptomes that recapitulate the full spectrum of human 
subtypes.153,154  Moreover, we have genomically characterized multiple, spatially distinct 
GBM that developed in different brain regions of individual mice and found that their 
genomic landscapes differ, suggesting that divergent genetic evolution occurs in these 
models (Vitucci et al, submitted).164  These GEM models therefore may be uniquely 
suited to define the genetics of malignant progression, the prognostic impact of TMZ-
induced hypermutation in low grade astrocytomas,112,165 and the development of novel 
treatments to prevent or delay their progression. 
IDH1 and IDH2 mutations are subtype-defining genetic features of lower grade 
astrocytomas (The Cancer Genome Atlas Research Network, manuscript 
submitted).107,109  However, effective preclinical models for the development of IDH-
mutant astrocytoma therapies are scarce.  Most studies published to date have used 
stably transfected ECL or geHC to investigate the biological effects of IDH mutations in 
vitro.166-174  Adherent, serum cultures of IDH-mutant astrocytomas have been shown to 
lose the mutant allele upon serial passage and mutant-containing clones fail to become 
ECL.175  In contrast, four IDH1R132H-mutant anaplastic gliomas (WHO grade III) have 
been successfully cultured as neurospheres in vitro.176-179  However, only two of these, 
both from anaplastic oligodendroglial neoplasms, formed serially transplantable gliomas 
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in the immunodeficient mouse brain.  Thus, only two potential PDX models are currently 
available for preclinical IDH-mutant glioma drug development.178,179 
The initial attempt to develop a GEM model of IDH-mutant gliomas was also 
disappointing.180  Conditional activation of a heterozygous, floxed IDH1R132H mutant 
allele using Nestin-cre or Gfap-cre drivers failed to elicit tumorigenesis in the developing 
mouse brain, despite production of the oncometabolite D-2-hydroxyglutarate (D2HG).  
Rather, D2HG blocked collagen maturation and altered vascular basement membranes, 
leading to brain hemorrhage and embryonic lethality.  These results suggest that IDH1 
mutations alone are not sufficient to induce tumorigenesis, at least in the developing 
mouse brain.  However, the effects of IDH1R132H have not been examined in the adult 
brain.  It therefore remains possible that temporal control of IDH1R132H induction in the 
adult mouse brain using drug-inducible Cre drivers may be more successful in modeling 
IDH-mutant gliomas. 
Alternatively, successful culture and xenografting of IDH-mutant human gliomas, 
as well as GEM modeling, may require the presence of cooperative oncogenic 
mutations.  geHC and nGEM represent attractive model systems to explore this 
hypothesis.  In this regard, the IDH1R132H mutation has been shown to impair histone 
demethylation in immortalized normal human astrocytes (NHA).173  IDH1R132H also 
remodeled the DNA methylome of these cells and was sufficient to induce the glioma 
CpG island methylator (G-CIMP) phenotype.174  Moreover, IDH1R132H blocked astrocytic 
differentiation in neurosphere cultures of neural stem cells harvested from neonatal 
Ink4a/Arf null GEM.173  When engineered to express mutations in the RAS-MAPK and 
PI3K pathways, immortalized human and murine astrocytes have been shown to induce 
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tumorigenesis upon transplantation into mouse brains.127,143,144,181  Thus, IDH-mutant 
geHC or nGEM brain cells with additional engineered mutations may represent 
promising preclinical systems for development of IDH targeted therapies. 
Contemporary murine models in preclinical astrocytoma drug development 
Murine models can address a number of issues important in the clinical drug 
development for astrocytomas.  These include validation of molecular targets, defining 
the role of cellular origin in drug response, prioritizing drugs for clinical development, 
and developing predictive markers to identify potential responders (Table 2.3).  The 
ideal model(s) to address these issues differs based on the inherent strengths and 
weaknesses of their design. 
GEM have established roles in the validation of molecular targets, particularly in 
defining the role of putative oncogenic drivers in the initiation and progression of 
tumorigenesis.  Because of their genetic tractability, nGEM and geHC models are 
poised to supplement GEM in future target validation efforts.  Indeed, we utilized nGEM 
models to establish that cooperativity between MAPK and PI3K signaling is required for 
GBM pathogenesis in vivo, suggesting that simultaneous inhibition of both pathways 
may be required for effective therapeutic design.127  Moreover, geHC models with 
human astrocytes proved critical in defining the effects of IDH mutations on the 
epigenetic control of tumor cell differentiation.173 
In addition to target validation, GEM, nGEM, and geHC models may be useful in 
defining the impact of cellular origin on astrocytoma tumorigenesis and drug 
sensitivity.20  Like high-grade astrocytomas, multiple genomic subtypes of 
medulloblastoma with distinct mutations exist.182  GEM models have shown that 
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different oncogenic mutations in specific cells of origin in the developing mouse 
cerebellum lead to distinct genomic subtypes of medulloblastoma that mimic their 
human counterparts.  GEM models of sonic hedgehog-associated medulloblastoma in 
particular are currently being utilized for the preclinical evaluation of subtype-specific 
targeted therapies.150 
PDX and GEM models with defective ABC transporters have established roles in 
characterizing CNS PK.132,183  The advantages of PDX, nGEM, and geHC over ECL 
models promise to replace their use in defining dose and schedule dependencies of 
combination therapies for GBM.89  Due to the redundancies of RTK signaling, mosaic 
amplification of multiple RTK in GBM, and significant inter- and intratumoral molecular 
heterogeneity, mono-therapy with single targeted agents will likely prove ineffective for 
GBM.105  Increasing use of contemporary PDX, nGEM, and geHC models in preclinical 
development of these agents is likely to aid in defining and further characterizing these 
mechanisms of drug resistance.  Because these cells can be cultured in vitro, synthetic 
lethality screens or kinome profiling promises to aid definition of rational combination 
therapies to combat drug resistance.184  Moreover, more systematic use of multiple 
genomically diverse models in preclinical drug efficacy screens promises to aid 
development of predictive genomic biomarkers.18,97 
Conclusion 
Despite decades of research, the therapeutic armamentarium of approved drugs 
for astrocytomas remains limited.  The field of neuro-oncology has yet to benefit from 
the accelerated pace of oncology drug development due to issues of prevalence, trial 
participation, and biological complexity of the disease.  However, comprehensive 
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genomic characterization and changes in clinical trial design promise to improve 
disease classification and increase the number of targeted agents that can be clinically 
evaluated.  Improvements in preclinical murine models and their systematic integration 
by the neuro-oncology community during early drug development promises to further 
accelerate therapeutic advances for these devastating malignancies. 
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Table 2.1.  GBM models used in preclinical development of alkylating and targeted agents 
Chemotherapeutic agent Conventional ECL models 
 Contemporary models 
Murine allografts Human xenografts  PDX nGEM 
Alkylating agents 
Carmustine 
(BCNU) 
9L 40 
GL26, GL261 
VMDk 497-P(1)
D54MG 40 
U251MG   
 
Lomustine 
(CCNU) 
G XII 40 
G XIII 
GL26, GL261 
VMDk 497-P(1)
U251MG 40   
 
Temozolomide
(TMZ) 
9L 49 
C6 
F98 
T98 
A172 49 
D54MG, Hs683 
SNB-75, SF295 
U251MG, U373MG 
U87MG 
 
GBM6 49,53-55,59,60,94-96 
GBM8, GBM10, GBM12 
GBM14, GBM22, GBM 26
GBM34, GBM36, GBM39 
GBM43, GBM44 
TRP 127,185,186
Targeted agents 
Gefitinib  U87MG 67  
ODA-4-GEN 69 
GBM-1-HAM, GBM-17-
ROM 
GBM-14-RAV, TG-17-GIR
GBM-9-THI 
 
Erlotinib  U87MG 66  
GBM6, GBM8 68 
GBM12, GBM14, GBM15 
GBM22, GBM 28 
GBM34, GBM36, GBM39 
GBM44 
 
Lapatinib    GS676, GS600 82  
Celingitide  U87MG 
86 
U251MG 89   
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Table 2.2.  Comparison of conventional and contemporary murine astrocytoma models 
Characteristic 
Conventional ECL models Contemporary models 
Mouse 
allografts 
Human 
xenografts 
Human xenografts Engineered mice
PDX geHC GEM nGEM 
Host 
Intact immune system Y a Y Y 
Faithful microenvironment Y Y Y 
Intact DNA repair Y Y b Y b Y b Y Y 
Host and tumor genomes differ Y Y Y 
Tumor 
In vitro culture possible Y Y  Y Y   Y 
Subcutaneous growth Y Y  Y Y   Y 
Orthotopic growth Y Y Y Y Y Y 
Histologically faithful Y c Y Y Y Y 
Rapid growth kinetics Y Y Y Y d d 
High penetrance Y Y Y Y d d 
Short latency Y Y Y Y d d 
Defined oncogenic mutations e e  e Y  Y Y 
Straightforward genotype-phenotype 
comparisons 
    Y  Y Y 
Complex genome landscapes Y f Y  Y   Y f  
Defined cellular origin Y Y g Y 
Low grade astrocytomas develop    h   Y Y 
Stochastic malignant progression Y 
NOTES 
a. Some murine ECL are immunogenic and xenografting requires immunodeficient hosts.19 
b. Immunodeficient scid, but not nude mice have genetic DNA repair defects.187 
c. Some murine ECL fail to invade normal brain.19 
d. Growth kinetics, penetrance, and latency in GEM and nGEM models vary greatly depending on oncogenic mutations 
and targeted cell type. 
e. Mutational profiles can be defined by genomic analyses, but genomic complexity renders direct genotype-phenotype 
correlations difficult. 
f. Complex gene rearrangements occur less frequently in murine compared to human tumors. 
g. Conventional knockout GEM models do not have a defined cellular origin. 
h. IDH mutant PDX models of anaplastic oligodendrogliomas, not astrocytomas, have recently been described.177,179 
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Table 2.3.  The role of contemporary murine models in preclinical astrocytoma drug development 
Clinical issue Role of preclinical models Ideal model(s) References 
Target validation Define role in tumorigenesis GEM, nGEM, geHC 127,143,144,154,188 
Cellular origin Define role in tumorigenesis GEM, nGEM, geHC 
127,143,145,153,154,189,
190 
Drug prioritization 
Characterize CNS penetration PDX, GEM 132,183 
Define effective dose and schedule PDX, nGEM, geHC 53,60,89 
Define resistance mechanisms PDX, nGEM, geHC 82,191,192 
Test combination therapies PDX, nGEM, geHC 95,156,193-195 
Patient selection Developing predictive biomarkers PDX, nGEM 53-55,59,60,68,69,94-96
 
 
45 
 
Figure 2.1.  FDA approved oncology drugs. The cumulative number of cytotoxic (C), 
biological (B), and targeted (T) drugs approved by the FDA is shown.  Dates correspond 
to the first indication approved.  Approvals for subsequent indications are not shown.  
Drugs used for astrocytomas are indicated.  Data were compiled from 
http://www.drugs.com and http://www.medilexicon.com/drugs-list/cancer.php. 
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Figure 2.2.  Evolution of astrocytoma treatment, classification, and murine 
models. Shading in black depicts increased emphasis over time. Major developments 
in each category are noted.5,7,25,31,35,46,64,117,118,143,144,158,196-204 Abbreviations: BCNU, bis-
chloroethylnitrosourea; Bev, bevacizumab; DI, direct injection; ECL, established cell 
line; GE, genetically engineered; geHC, genetically engineered human cells; GEM, 
genetically engineered mice; GEP, gene expression profiling; GSC, glioma stem cell; 
nGEM, non-germline genetically engineered mice; PDX, patient derived xenografts; 
TCGA, The Cancer Genome Atlas; Thal, thalidomide; TMZ, temozolomide; VB, 
vinblastine; WHO, World Health Organization. 
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Figure 2.3.  Conventional and contemporary murine astrocytoma models.  
Conventional murine and human astrocytoma models utilized established cell lines (ECL) 
(A).  Murine ECL models were generated by serum culture of cells harvested from 
spontaneous rodent astrocytomas induced by chemical carcinogens and transplantation 
into immunocompetent rodents.  Human ECL were similarly generated from human 
astrocytomas and xenografted into immunodeficient mice.  Contemporary human models 
(B) consist of patient-derived xenografts (PDX) whereby tumor cells harvested from 
human astrocytomas are directly injected or culture as non-adherent spheroids in defined, 
serum-free media prior to engraftment in immunodeficient mice.  Genetically engineered 
models include genetically-engineered human cells (geHC), whereby astrocytes or neural 
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stem cells (NSC) are harvested from normal human brains, genetically modified with 
oncogenic mutations, and xenografted into immunodeficient mice (C); GEM, whereby 
induction of oncogenic mutations produces tumorigenesis in situ (D); and non-germline 
genetically-engineered mouse (nGEM) models, whereby astrocytes or NSC are 
harvested from GEM, cultured in vitro, and allografted into immunocompetent or 
immunodeficient mice (D). 
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Figure 2.4.  Developmental timeline for temozolomide (TMZ).  Clinical studies outlined 
in black were conducted with newly diagnosed GBM patients, unless otherwise noted.41-
49,53-55,58-60  Preclinical studies are highlighted in gray.  Abbreviations:  DD, dose-dense; 
ECL, established cell line models; HGG, high-grade gliomas; PDX, patient-derived 
xenograft models. 
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Figure 2.5.  Developmental timelines for EGFR tyrosine kinase inhibitors (A) and 
cilengitide (B).  Clinical studies outlined in black were conducted with newly diagnosed 
GBM patients, unless otherwise noted.  Preclinical studies are highlighted in gray and 
were performed with established GBM xenograft models, unless otherwise noted.65-69,71-
74,76-78,80,82,85-92 
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CHAPTER III: COMBINATION THERAPY WITH POTENT PI3K AND MAPK 
INHIBITORS OVERCOMES ADAPTIVE KINOME RESISTANCE TO SINGLE 
AGENTS IN PRECLINICAL MODELS OF GLIOBLASTOMA2 
 
Introduction 
Glioblastoma (GBM) is the most common and aggressive adult primary brain 
tumor.  Despite advances in diagnosis, specifically incorporation of both histological and 
molecular criteria in the 2016 classification, GBM is uniformly treated with surgery, 
radiation, and temozolomide chemotherapy.1  Recurrence is inevitable and leads to ~15 
month survival.2  Molecular heterogeneity of GBM has been extensively characterized 
using genomics.  Primary GBM that arise de novo without a lower grade antecedent 
have been stratified into four molecular subtypes characterized by mutations in three 
core signaling pathways: RB, TP53, and RTK/phosphoinositide 3-kinase (PI3K)/mitogen 
activated protein kinase (MAPK).3,4 
 
2A version of this work was recently accepted in Neuro-Oncology.  The original citation is as 
follows: McNeill RS, Canoutas DA, Stuhlmiller TJ, Dhruv HD, Irvin DM, Bash RE, Angus SP, 
Herring LE, Simon JM, Skinner KR, Limas JC, Chen X, Schmid RS, Siegel MB, Van 
Swearingen AED, Hadler MJ, Sulman EP, Sarkaria JN, Anders CK, Graves LM, Berens ME, 
Johnson GL, and Miller CR. Combination therapy with potent PI3K and MAPK inhibitors 
overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. 
Neuro Oncol. 2017;doi:10.1093/neuonc/nox044. 
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The RTK/PI3K/MAPK pathways are mutated in 90% of GBM.3  The PI3K and 
MAPK pathways promote many cancer hallmarks, including survival, proliferation, and 
migration.5-7  PI3K is most frequently activated in GBM via mutations in its negative 
regulator, PTEN.3,5,6  Activation of MAPK signaling is due either to activating mutations 
in RTK or KRAS, or inactivating mutations in its negative regulator NF1.3,8,9  
RTK/PI3K/MAPK pathways are attractive therapeutic targets because of their mutation 
frequency and role in tumorigenesis. 
Kinase inhibitors targeting the PI3K or MAPK pathways are currently approved 
for non-glioma tumors or in clinical development.10,11  However, single agent kinase 
inhibitors have had disappointing clinical results in gliomas due to limited brain 
penetrance and drug resistance.12-14  Many kinase inhibitors, including the EGFR 
inhibitors gefitinib and erlotinib, have low brain penetrance, restricting their ability to 
reach and suppress their biologic target.13  Additionally, intrinsic and acquired drug 
resistance has significantly limited the impact of kinase inhibitors in gliomas.13,15 
Preclinical studies that define drug efficacy, elucidate resistance mechanisms, 
and confirm target modulation will aid in clinical drug development.  Genetically 
engineered mouse (GEM) and patient-derived xenograft (PDX) models are valuable 
tools for these efforts because they enable direct genotype to phenotype comparisons 
and faithfully recapitulate the molecular heterogeneity of human tumors, respectively.13  
We and others have shown that activating PI3K and MAPK mutations cooperate to 
promote gliomagenesis in preclinical models.16-20  We developed a series of nGEM 
models using cultured astrocytes immortalized via an N-terminal SV40 large T (T121, T) 
mutant that ablates the Rb family of pocket proteins.  MAPK and PI3K were activated 
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alone and in combination via oncogenic Kras (KrasG12D, R) and Pten deletion (P), 
respectively.20  We used these models to show that activated PI3K and MAPK 
cooperate to promote astrocyte proliferation, migration, and de-differentiation in vitro 
and malignant progression to rapidly fatal GBM in vivo.  TRP astrocytes also displayed 
the phenotypic hallmarks of GBM stem cells (GSC) and molecularly recapitulated 
proneural GBM.16,20  Here we utilized the TRP nGEM culture and allograft model system 
and GBM PDX to define the influence of drug potency on signaling dynamics, efficacy, 
and synergism of PI3K (PI3Ki) and MEK1/2 (MEKi) inhibitors.16,20  
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Materials and Methods 
Murine astrocyte cultures.  Cortical, genetically engineered mouse (GEM)-derived 
astrocytes were cultured as previously described.16,20,21  Briefly, mice harboring 
conditional TgGZT121 (T), KrasG12D knock-in (R), and Pten knock-out (P) alleles were 
crossed to generate compound TRP mice.20,22-24  Astrocytes harboring the floxed alleles 
(T/R, heterozygous; P, homozygous) were harvested from neonatal mice.  
Recombination was induced in vitro with a recombinant adenoviral vector encoding 
cytomegalovirus promoter-driven Cre recombinase (Ad5CMVCre, University of Iowa 
Gene Transfer Vector Core).  TRP astrocytes expressing luciferase were generated as 
previously described.16  Astrocytes were maintained as adherent cells at 37 °C and 5% 
CO2 in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin.  The UNC Institutional Animal Care and 
Use Committee approved all animal studies (Protocol # 16-112). 
Human ECL and PDX cultures.  D32, D65, D54, U251, and U87 ECL were a kind gift 
from G. Yancey Gillespie at the University of Alabama at Birmingham.  U373, LN229, 
and LN18 ECL were obtained from ATCC (Manassas, VA).  ECL were maintained as 
adherent cells in DMEM supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin at 37 °C and 5% CO2 as previously described.25,26  GSC20, 
GSC23, GSC6-27, GBM6, GBM12, GBM46, and GBM59 PDX were maintained at 37 
°C and 5% CO2 as non-adherent spheroids in DMEM/F12 supplemented with 1x B27 
(ThermoFisher, Waltham, MA), 20 ng/ml epidermal growth factor (EGF), and basic 
fibroblast growth factor (bFGF) (Sigma-Aldrich, St. Louis, MO or ThermoFisher), with or 
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without N-2 supplement (ThermoFisher) and 1% penicillin/streptomycin, as previously 
described.27,28  Subcutaneous PDX were maintained as previously described.29 
Drugs.  See Table S3.1 for details on drugs used in this study.30-37  For in vitro 
experiments, working stocks of buparlisib, LY, temsirolimus, everolimus, selumetinib, 
PD01, and trametinib were dissolved in dimethyl sulfoxide (DMSO), while dactolisib was 
dissolved in N,N-Dimethylformamide (DMF). 
Dose response.  To examine relative growth in response to drugs, TRP astrocytes 
were plated in technical replicates (N=3-6) in 96-well tissue culture plates and allowed 
to adhere overnight.  Cells were treated the following day with increasing concentrations 
of drug or an equal concentration of solvent (control).  Cell growth was assessed 5 days 
after treatment with the CellTiter 96 Aqueous One Solution Cell Proliferation Assay 
(MTS, Promega, Madison, WI) according to manufacturer’s instructions.  Absorbance 
was measured on an Emax plate reader (Molecular Devices, Chicago, IL) equipped with 
SoftMax Pro 5 software.  Baseline absorbance (MTS reagent plus media) was 
subtracted from the absorbance in each well and relative growth was calculated as 
absorbance of treated relative to control cells. 
Drug response of cultured PDX (GBM6, GBM12, GBM46, and GBM59) was 
performed as previously described with minor modifications.38  Briefly, PDX were 
seeded (3000 cells/well) in technical replicates (N=7) in 96-well plates and cultured for 
72 hours to form neurospheres.  Increasing drug concentrations were added and 
treated cells were incubated for 96 hours. Vehicle only and staurosporine (a drug toxic 
to most cell lines at 5 µM) were included as negative and positive controls, respectively.  
CellTiterGlo® (Promega, San Luis Obispo, CA) was used to assess cell viability.  
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Luminescence was measured using a Perkin Elmer Envision 2104 Multilabel Reader.  
Raw values were normalized on a plate-by-plate basis such that 100% cell viability was 
equivalent to the mean of vehicle wells and 0% cell viability was equivalent to the mean 
of the staurosporine treated control. 
Data from independent TRP (N=2-5) and PDX (N=1) drug treatment experiments 
were pooled and fit to a non-linear, log [inhibitor] versus response curves with variable 
slope.  IC50, GI50, Imax and Hill slopes were calculated as previously described.16,39,40  
Genotype and drug potency effects on IC50 were calculated by two-way ANOVA.  The 
pairwise effects of PDX model and drugs on IC50 were compared using the extra-sum-
of-squares F test. 
Cell cycle analysis.  TRP astrocytes were plated in 12-well tissue culture plates, 
allowed to adhere overnight, and then treated with drugs or vehicle control.  Cell cycle 
analysis was performed 2 days post-treatment using Guava Cell Cycle Reagent 
according to the manufacturer’s instructions (EMD Millipore, Billerica, MA).  Briefly, cells 
were harvested by trypsinization, fixed for >1 h in 70% ethanol on ice, and relative DNA 
content was determined on a Guava EasyCyte Plus.  Percent cells in each cell cycle 
phase were analyzed using ModFit LT v3.2 (Verity, Topsham, ME).  Mean percent cells 
in G0/G1, S, and G2/M were calculated from 1-2 technical replicates from two 
independent experiments.  Drug effects on cell cycle distribution were analyzed by two-
way ANOVA. 
Kinome profiling.  For dynamic kinome profiling of TRP astrocytes, cells were treated 
with either 1 µM of buparlisib for 4, 24, and 48 h or DMSO (control) for ~20 min (0 h).  
Multiplexed inhibitor bead chromatography was performed as previously described for 
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astrocytes and untreated, snap-frozen GBM PDX samples.41,42  Briefly, cells or frozen 
PDX samples were lysed in a HEPES/NaCl/Triton X-100 buffer and lysates gravity-
flowed through columns containing inhibitor-conjugated beads (CTx-0294885, VI-16832, 
PP58, Purvalanol B, and two custom-synthesized compounds UNC-2147A and UNC-
8088A).  Beads were then washed and kinases eluted.  Kinases were purified by 
chloroform/methanol extraction, suspended in 50 mM HEPES (pH 8), digested with 
trypsin, labeled with iTRAQ (AB SCIEX, Framingham, MA) or TMT (Thermo Scientific) 
according to manufacturer’s instructions, and cleaned with PepClean C18 Spin 
Columns (Thermo Scientific).  Peptide samples were analyzed by LC/MS/MS using an 
Easy nLC1000 coupled to a QExactive or QExactive HF mass spectrometer (Thermo 
Scientific).  Peptides were injected onto an Easy Spray PepMap C18 column (75 µm x 
25 cm, 2 µm particle size) (Thermo Scientific) and separated over a 300 min 
(QExactive) or 165 min (QExactive HF) gradient.  The gradient for separation consisted 
of 5–40% mobile phase B at a 250 nl/min flow rate, where mobile phase A was 0.1% 
formic acid in water and mobile phase B consisted of 0.1% formic acid in acetonitrile. 
Mass spectrometer parameters were as follows: 3e6 AGC MS1, 80ms MS1 max inject 
time, 1e5 AGC MS2, 100ms MS2 max inject time, 20 loop count, 1.8 m/z isolation 
window, 45s dynamic exclusion.  Spectra were searched against the Uniprot/Swiss-Prot 
database with Sequest HT on Proteome Discoverer software with 5% false discovery 
rate (FDR).  Peptides with greater than 25%-coisolation interference were omitted.  
Multiplexed inhibitor beads (MIB)-binding of treated samples was set relative to controls 
and pooled from two independent experiments.  For baseline PDX comparison, scaled 
abundance values in biological triplicate from Proteome Discoverer were used for 
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principal components analysis using Perseus software (Max Planck Institute of 
Biochemistry) and hierarchical clustering (one minus Pearson correlation) using GENE-
E software (Broad Institute). 
Baseline kinome profiling of ECL and human samples were performed as 
described above.  Baseline spectra were searched with MaxQuant software using 
default parameters and Label Free Quantification (LFQ) intensity was used as the 
normalized level for each kinase. D54, U373, LN18, and LN229 were selected and 
pooled as a standard reference for MIB and mass spectrometry (MIB-MS) analysis of 
the human GBM samples based on their differentially enriched kinases.  All kinome tree 
illustrations reproduced courtesy of Cell Signaling Technology, Inc. 
(www.cellsignal.com).  One minus Pearson hierarchical clustering was performed on 
LFQ intensities using GENE-E software.  Principal components analysis (PCA) was 
performed using Cluster 3.0.  Human GBM samples were obtained from the UNC 
Tissue Procurement Facility in compliance with institutional guidelines under a protocol 
approved by the UNC Office of Human Research Ethics (Institutional Review Board 
[IRB], 15-0923). 
Immunoblots.  TRP astrocytes were treated with drug(s) or solvent (control).  Cells 
were mechanically harvested 4 or 24 h after treatment, and proteins were extracted.  
Briefly, proteins (20 µg for immunoblots to detect PI3K and MAPK signaling and 50 µg 
for immunoblots to detect cleaved caspase-3) were resolved by gradient (8-16%) gel 
electrophoresis (SDS-PAGE, Bio-Rad, Hercules, CA) then transferred to PVDF 
membranes (EMD Millipore).  Immunoblots were probed at 4 °C overnight using primary 
antibodies against Gapdh (#AB2302, EMD Millipore) and Akt (#2967), p-Akt (Ser473, 
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#9271), p-S6 (Ser240/244, #2215), p-Erk1/2 (Thr202/Tyr204, #9101), Erk1/2 (#4696), 
and cleaved caspase-3 (#9664) all from Cell Signaling Technology (Danvers, MA).  
Blots were incubated with species specific Alexa 488, 568, or 633 conjugated 
secondary antibodies at room temperature for 30 min, imaged on a GE Typhoon Trio 
(GE Healthcare), and band intensities were quantified using ImageJ (NIH, Bethesda, 
MD).  Signaling levels were assessed by normalization of phosphoproteins to the 
corresponding total protein or Gapdh and then set relative to control-treated cells.  
Alternatively, normalized proteins from tumor samples were set relative to a TRP protein 
standard contained on all blots, and then were normalized to untreated tumors. 
Whole Exome Sequencing.  DNA from PDX tumors was isolated from subcutaneous 
tumor pieces using Qiagen’s AllPrep Kit.  Isolated DNA was used to generate whole 
exome sequencing libraries.  Genomic tumor and normal DNAs (1.1 µg) for each 
sample were fragmented to a target size of 150–200 bp; 100 ng of fragmented product 
was run on TAE gel to verify fragmentation.  The remaining 1 µg of fragmented DNA 
was prepared using Agilent's SureSelectXT Human All Exon 50 Mb kit (catalog# 
G7544C).  Exome libraries were prepared with Agilent's SureSelectXT Human All Exon 
V4 library preparation kit (catalog# 5190-4632) and SureSelectXT Human All Exon 
V4+UTRs (catalog# 5190-4637) following the manufacturer's protocols.  Libraries were 
paired-end sequenced on the Illumina HiSeq 2000 and analyzed after Fastq generation 
and alignment using the Burrows-Wheeler Alignment against the human reference 
genome and matched patient germline DNA sequence for identification of somatic 
events.43 
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Drug synergism.  Relative growth of TRP astrocytes was determined for single agent 
and combination treatments at a constant molar ratio as described above and 
synergism was determined using the Chou-Talalay method.44  Briefly, fraction affected 
(1 – relative growth, FA) was determined and the combination index was calculated 
using CompuSyn (ComboSyn, Inc., Paramus, NJ).  Data were pooled from 2–4 
independent experiments.  Combination index (CI) values >1, 1–0.86, and <0.86 were 
considered antagonistic, additive, and synergistic, respectively. 
EdU incorporation.  EdU incorporation assays were performed as previously described 
with the following modifications.45  TRP astrocytes were seeded on poly-D lysine 
(Sigma-Aldrich) coated Nunc Lab-Tek II chamber slides (ThermoFisher).  Cells were 
allowed to adhere and at ~60% confluence were treated with vehicle control (DMSO), 
selumetinib (2.5 μM), buparlisib (1.5 μM) or both selumetinib (2.5 μM) + buparlisib (1.5 
μM).  At 24 h post-treatment, 10 µM 5-ethynyl-2′-deoxyuridine (EdU, Invitrogen, Grand 
Island, NJ) was supplemented to the culture + drug containing media and cells were 
incubated in the presence of EdU for 6 hr.  Cells were then fixed with 4% para-
formaldehyde for 5 min, blocked with 0.1% Triton X-100, 1% BSA, 5% horse serum, and 
0.01 M glycine in PBS at 4 °C for 30 min.  EdU was detected by labeling with Alexa 555 
or 647 using the Click-iT EdU Imaging Kit (ThermoFisher) according to manufacturer’s 
instructions.  Cells were washed, counter-stained with DAPI, and coverslipped with 
PermaFluor (ThermoFisher).  Three images per well were taken with a LSM 780 
confocal microscope (Zeiss, Oberkochen, Germany) equipped with 20X objective and 
ZEN 2012 software.  Percentage of EdU positive cells per image was quantified using 
ImageJ (NIH) and the mean (±SEM) percent EdU+ cells was calculated from the three 
78 
images per two technical replicates from two independent experiments.  Drug effects on 
EdU incorporation were analyzed by Students’s t tests. 
Apoptosis.  TRP astrocytes were plated in 12-well tissue culture plates, allowed to 
adhere overnight, and then treated with vehicle control (DMSO), selumetinib (2.5 μM), 
buparlisib (1.5 μM) or both selumetinib (2.5 μM) + buparlisib (1.5 μM).  Apoptosis was 
measured 24 h post-treatment by flow cytometry using the Guava Viacount Assay 
according to the manufacturer’s instructions (EMD Millipore).  Briefly, cells were 
harvested by trypsinization, stained with the Guava Viacount reagent and dye exclusion 
was determined on a Guava EasyCyte Plus.  Gates for viable, apoptotic and dead cells 
were set according to the manufacture’s instructions and percent apoptotic cells (mean 
± SEM) was calculated from one technical replicate from four independent experiments.  
Drug effects on apoptosis were analyzed by Student’s t tests. 
Orthotopic TRP allografts.  TRP astrocytes expressing luciferase were injected 
orthotopically into syngeneic C57Bl/6 mice as previously described.20,21  Briefly, 
astrocytes were harvested by trypsinization, counted, and suspended in serum free 
DMEM with 5% methyl cellulose.  Adult mice (mean ~6 months) were anesthetized with 
Avertin (250 mg/kg) and 105 astrocytes were injected into the right basal ganglia using 
the coordinates 1, -2, and -4 mm (A, L, D) from bregma.  Beginning on day 3 post 
injection, isoflurane anesthetized mice were imaged bi-weekly by bioluminescence 
imaging (BLI) on an Ivis Kinetic (PerkinElmer, Waltham, MA) as previously 
described.16,21  Briefly, mice were injected peritoneally with D-luciferin (PerkinElmer), 
images were acquired after 10-15 min, and bioluminescence flux (photons/sec/cm2) 
was quantified using PerkinElmer Living Image software.  Mice were randomized 7 days 
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after cell injection into 4 groups (control, buparlisib, selumetinib, and 
buparlisib/selumetinib; 13-18 mice per group), and treatment on a 5 days on, 2 days off 
schedule (Table S3.2) was initiated via chow on day 10 and continued until signs of 
neurologic morbidity.  BLI flux was expressed relative to initial flux (day 3).  Relative flux 
from treatment initiation (day 10) through day 21 was fit to an exponential growth 
equation and the rate constant k and doubling time [ln(2)/k] were calculated.  Animals 
were monitored for neurological symptoms and upon onset, mice were sacrificed, brains 
were harvested, and cut sagittally through the needle track.  A portion of grossly visible 
tumor was harvested and snap frozen while the remaining brain was immersion fixed in 
10% neutral buffered formalin overnight and stored in 70% ethanol prior to paraffin 
embedding.  Immunoblots on frozen tumor lysates (N=3 per group) were performed as 
described above. 
Orthotopic PDX.  PDX were established in athymic mice (Taconic) as described 
previously.29 Briefly, 3 x 105 glioma cells (GBM6, GBM12, and GBM46) were implanted 
in the right striatum and tumors established for 15 days. Mice were then randomized to 
receive vehicle control (n = 10) or 45 mg/kg dactolisib (n = 10) on a 5 days on/2 days off 
schedule every 28-day cycle.  Mice were observed daily and euthanized upon 
neurological morbidity.  Studies were approved by the Translational Drug Development 
Management Animal Care and Use Committee (Scottsdale, AZ). 
Histopathology.  Histopathological evaluation was conducted as previously 
described.16  Briefly, formalin-fixed, paraffin-embedded brains were cut in serial 4-5 µm 
sections on a rotary microtome, placed on glass slides, and stained with hematoxylin 
and eosin (H&E) on a Leica Microsystems Autostainer XL (Buffalo Grove, IL).  Stained 
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slides were scanned on an Aperio ScanScope XT (Vista, CA) using a 20X objective and 
svs files were imported into an Aperio eSlideManager web database.  Histopathological 
analyses and tumor grading was conducted according to the WHO 2007 criteria for 
human astrocytomas for each mouse within the control (n=15) or selumetinib (n=13) 
cohorts.46  Tumor area (mm2) on scanned H&E-stained slides (2 sections per brain) was 
measured using the annotation tools in Aperio ImageScope v12.2.1.5005.  
Photomicrographs were taken on an Olympus BX41 microscope and DP70 digital 
camera (Center Valley, PA).  Effects of treatment on diagnosis were compared by two-
way ANOVA with Bonferroni multiple comparisons post-tests.  Effects of treatment on 
tumor size were compared using unpaired t-tests. 
Subcutaneous TRP allografts.  TRP astrocytes expressing luciferase were harvested 
by trypsinization, counted, and suspended in serum free DMEM with 5% methyl 
cellulose.  Adult syngeneic C57Bl/6 mice (mean ~9.5 months) were anesthetized with 
Avertin (250 mg/kg) and 5 x 106 astrocytes were injected into the right flank.  Tumors 
were established for 14 days, volume (mm3) was determined with calipers using the 
formula (L*W2)/2, mice were randomized into treatment groups (Table S3.2) containing 
4-6 mice each with statistically insignificant differences in tumor volume, and treatment 
via oral gavage was initiated and continued for five days (14–19) with the following 
exception.  Dactolisib- and dactolisib/selumetinib-treated mice showed signs of drug-
induced toxicity and were thus not treated on day 19.  Tumor volume was measured 5 
days per week from days 14–25 and expressed relative to treatment initiation (day 14).  
Tumor volume data were then fit to an exponential growth equation and the rate 
constant k and doubling time [ln(2)/k] were calculated.  For pharmacokinetic 
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experiments, subcutaneous allografts and treatment were performed as described 
above, except that mice (n=2-3 per group) were treated for two days and then sacrificed 
4 h following the second treatment.  Subcutaneous tumors were harvested, snap frozen, 
and then lysed for immunoblots.  Buparlisib, dactolisib, and selumetinib were dissolved 
in 10/90 V/V of N-methyl-2-pyrrolidone (NMP)/poly(ethylene glycol) 300 (PEG300) at 15 
mg/ml, 15 mg/ml, and 10.8 mg/ml respectively.  Trametinib was dissolved in 0.5% 
methylcellulose and 0.2% Tween-80 in deionized water at 0.3 mg/ml. 
Statistics.  Statistical analyses were conducted in GraphPad Prism 5 (La Jolla, CA).  
P≤0.05 were considered statistically significant unless otherwise stated.  Error bars are 
SEM.  Log10 (Log) IC50 was graphed unless otherwise stated.  Effects of treatment on 
survival of allograft or xenograft mice were determined by Kaplan-Meier analyses and 
were compared by log-rank tests.  The effects of treatment on orthotopic or 
subcutaneous allograft growth (k value) was compared using the extra sum of squares 
F test.  
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Results 
PI3K and MAPK mutations are frequent in GBM and drive tumorigenesis in 
preclinical models.3,4,8,9,47  We previously showed that activated PI3K and MAPK 
cooperated to promote gliomagenesis in TRP nGEM culture and allograft models.16,20  
However, it remained unclear if these models were sensitive to PI3Ki and MEKi.  We 
addressed this issue by examining how drug potency influences target inhibition, 
adaptive kinome response, efficacy, and synergism of single agent and combination 
therapies in vitro and in vivo. 
PI3Ki and MEKi block TRP astrocyte and PDX growth in vitro 
A dose-dependent, sigmoidal growth reduction was evident for multiple PI3Ki in 
cultured TRP and PDX models (Fig S3.1AB), with the PI3Ki buparlisib inducing a G2/M 
cell cycle arrest in TRP astrocytes (Fig S3.2A).  Moreover, a direct association between 
potency (dactolisib > buparlisib > LY) and efficacy was evident, both for TRP astrocytes 
(Figs 3.1A, S3.2B) and PDX (Figs 3.1B, S3.3).  The PI3Ki/mTORi dactolisib was the 
most potent, but its efficacy may be due, in part, to direct mTOR inhibition.  Two mTORi 
reduced TRP astrocyte growth with IC50 in the low micro- to high nanomolar range (Fig 
S3.2B).  However, both caused more gradual decreases in growth (Hill slope, P≤0.03) 
and were less potent than dactolisib (P≤0.003). 
Next we assessed how MEKi potency (trametinib > PD01 > selumetinib) 
influences growth.  Although PD01 and trametinib have similar IC50 for purified MEK, 
their mechanism of inhibition differ and trametinib is the more potent inhibitor of 
signaling and cell growth.35  MEKi caused gradual, dose-dependent decreases in 
growth of cultured TRP and PDX (Fig S3.1C).  Moreover, a direct association between 
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potency and efficacy was evident, both for TRP astrocytes (Figs 3.1C, S3.2B) and PDX 
(Figs 3.1D, S3.3).  Selumetinib also induced a G1/S cell cycle arrest in TRP astrocytes 
(Fig S3.2C).  Taken together, these data showed that cultured TRP astrocytes and PDX 
were sensitive to PI3Ki and MEKi. 
PI3Ki induces adaptive kinome reprogramming, including alternate MAPK 
activation 
Among PI3Ki, mTORi, and MEKi, PI3Ki were generally the most effective at 
inhibiting TRP astrocyte growth (Figs 3.1AC, S3.1, S3.2).  However, many targeted 
kinase inhibitors that were effective in preclinical settings have had disappointing results 
when used as single agents in GBM patients.12,13  One reason for this may be 
compensatory signaling changes that manifest as drug resistance, suggesting that 
combination therapies will be necessary to improve outcomes. 
We have previously used MIB-MS to show that adaptive kinome reprogramming 
promotes resistance to single agent kinase inhibitors.41,42  We thus used this technique 
to examine the adaptive kinome response of TRP astrocytes to the PI3Ki buparlisib.  
Buparlisib induced widespread kinome changes, with alterations in multiple kinase 
families (Fig S3.4A).  Kinome response was dynamic and the patterns of activity 
differed among kinases (Figs 3.2A, S3.4B, Table S3.3).  Three major temporal patterns 
were discernible, as we have previously described (Fig 3.2B).41,42  Buparlisib induced 
sustained inhibition of proximal PI3K signaling (e.g. Akt1, pattern 1) and transient 
inhibition of distal PI3K (e.g. mTor), followed by re-activation (pattern 2).  Activation of 
alternative pathways such as MAPK (e.g. Erk1/2) was also apparent (pattern 3). 
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Immunoblots of TRP astrocytes treated with buparlisib for 4 h (data not shown) 
and 24 h (Fig 3.2C-E) showed that proximal (p-Akt) and distal (p-S6) PI3K signaling 
was inhibited at 4 h and sustained for 24 h, while MAPK signaling progressively 
increased over 24 h.  Next we assessed how potency influenced PI3K inhibition and 
alternate MAPK activation.  All PI3Ki caused dose-dependent inhibition of proximal and 
distal PI3K signaling, and inhibition was directly associated with drug potency (Fig 
3.2CD).  Moreover, both of the more potent PI3Ki, buparlisib and dactolisib, induced 
alternate MAPK activation (Fig 3.2CE).  Taken together, these results suggested that 
alternate MAPK activation contributes to PI3Ki resistance. 
MEKi induces MAPK inhibition and alternate PI3K activation in vitro 
We found that PI3Ki induced MAPK activation (Fig 3.2B-E) and that multiple 
MEKi reduced TRP astrocyte growth (Figs 3.1C, S3.1C, S3.2B).  MEKi have been 
shown to induce alternate PI3K activation in multiple cancer types.48-50  We therefore 
performed immunoblots on TRP astrocytes 24 h after treatment with increasingly potent 
MEKi to determine their effects on MAPK and PI3K signaling (Fig 3.2F).  All three MEKi 
caused dose-dependent decreases in MAPK signaling and dose/potency was directly 
associated with degree of inhibition (Fig 3.2FG).  Activation of proximal, but not distal, 
PI3K signaling was evident at 24 h with all three MEKi, and activation was associated 
directly with dose/potency (Fig 3.2FH). 
A subset of GBM and PDX models have hyperactive kinomes featuring MAPK 
activation 
GBM has extensive genome and transcriptome heterogeneity.3,4  However, 
details on the basal activation state of its kinome are limited.  We therefore analyzed 
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baseline kinome profiles of human GBM-derived ECL (Fig 3.3A) and patient samples 
(Fig 3.3B) via MIB-MS.  Hierarchical clustering showed kinome heterogeneity, with 
relative hyper-activation of unique kinases in each model and patient sample.  Principal 
component analysis stratified patient tumors into two kinome subtypes (K1 and K2) (Fig 
3.3C).  Heatmaps (Fig 3.3B) and kinome tree views (Figs 3.3DE, S3.5AB) showed that 
K1 tumors had a relatively hyperactive kinome compared to K2.  Among the hyper-
activated K1 kinases were MAP2K1 (MEK1), RPS6KA2 (RSK3), MAPK3 (ERK2), and 
MAPK1 (ERK1) (Fig 3.3F), suggesting that MAPK hyper-activation may be an attractive 
therapeutic target in these tumors.  Baseline kinome profiles of subcutaneous (Figs 
3.3GH, S3.5C) and cultured (Fig S3.6A) PDX were also variable.  GSC23 and GSC6-
27 harbored acitvation of numerous kinases within the tyrosine kinase (TK) and CMGC 
families, similar to the K1 subtype of patient samples (Figs S3.5A, S3.6B).  Moreover, 
the PDX GBM59, GBM46, and GBM12 had heterogenous genomes (Fig S3.7), but all 
harbored activation of numerous TK (Fig S3.5C, Table S3.4). 
PI3Ki and MEKi are synergistic in vitro 
Data from Fig 3.2 suggested that PI3K and MAPK are reciprocal bypass 
pathways that promote cell survival when either pathway alone is inhibited.  We 
therefore assessed whether dual PI3Ki/MEKi caused inhibition of both pathways.  
Immunoblots of TRP astrocytes 24 h after buparlisib plus selumetinib (Fig 3.4A) or 
trametinib (Fig 3.4B) showed a dose-dependent inhibition of both PI3K/MAPK signaling.  
The concentration of buparlisib required for PI3K inhibition was similar regardless of the 
MEKi used, but MEKi potency was directly associated with MAPK inhibition. 
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Next, we assessed whether PI3Ki/MEKi functioned synergistically.  
Buparlisib/selumetinib inhibited growth and was synergistic in TRP astrocytes (Fig 
3.4C), likely due to the combinatorial effects of selumetinib-induced decreases in 
proliferation (Fig S3.8AB) and buparlisib-induced increases in apoptosis (Fig S3.8C).  
Buparlisib plus the more potent MEKi trametinib also inhibited growth and was 
synergistic (Fig 3.4D).  However, the PI3Ki/MEKi concentrations required for synergism 
were dramatically reduced with buparlisib/trametinib, compared to 
buparlisib/selumetinib. 
PI3Ki and MEKi are effective in subcutaneous TRP allografts 
The blood-brain barrier can hinder drug penetrance and thus limit efficacy.13  We 
therefore first tested PI3Ki/MEKi efficacy in subcutaneous TRP allografts to eliminate 
the variable of blood-brain barrier penetrance.  Single agents were used at doses 
described in the literature (Table S3.2).31,51,52  Both PI3Ki effectively reduced tumor 
growth (Fig S3.9AB) and inhibited PI3K (pAkt) signaling by ~50% (Fig S3.10AB), but 
neither extended survival (Fig S3.9C).  Both MEKi also delayed tumor growth (Fig 
S3.9DE) and decreased MAPK (pErk) signaling >60% (Fig S3.10AC).  However, 
trametinib, but not selumetinib, extended survival (Fig S3.9F). 
Because PI3Ki/MEKi were synergistic in vitro (Fig 3.4), we hypothesized that 
combinations would be more effective than single agents in vivo.  However, drug-
induced toxicity can be amplified when combinations are used, necessitating dose 
reduction.  We found that maximum tolerated dose (MTD) of buparlisib/selumetinib was 
achieved at 1.2-2.1-fold lower doses in non-tumor bearing mice (Table S3.2, data not 
shown).  This combination was well-tolerated and effective in an intracranial xenograft 
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model of triple-negative breast cancer (TNBC) when used on a 5 days on/2 days off 
schedule.53  Dactolisib/selumetinib doses were based on published literature.51  For in 
vivo experiments with the PI3Ki buparlisib or dactolisib in combination with MEKi 
trametinib, we empirically kept the PI3Ki doses constant and empirically halved the 
trametinib dose, as we did with selumetinib (Table S3.2).  Combination treatments, as 
well as most single agents, caused an increase in cleaved caspase-3, an indicator of 
apoptosis (Fig S3.10DE).  Buparlisib/selumetinib caused tumor regression (Fig 3.5AB) 
and increased survival (Fig 3.5C).  Buparlisib plus the more potent MEKi trametinib also 
significantly reduced growth (Fig 3.5DE) and extended survival (Fig 3.5F).  Both 
combinations were more effective than either drug alone. 
Similar results were obtained with the more potent PI3Ki dactolisib combined with 
MEKi.  Dactolisib/selumetinib significantly reduced tumor growth (Fig 3.5GH), but did 
not extend survival (Fig 3.5I).  However, mice treated with dactolisib ± selumetinib, but 
not the more potent dactolisib/trametinib combination, exhibited drug-induced toxicity as 
evidenced by a rapid onset of lethargy.  Dactolisib/trametinib induced tumor regression 
(Fig 3.5JK) and increased survival (Fig 3.5L).  Moreover, dactolisib/trametinib was 
more effective at growth inhibition than either drug alone.  These results indicate that 
combination therapy with PI3Ki/MEKi are effective in subcutaneous TRP allografts, with 
the more potent inhibitors being particularly effective. 
Selumetinib delays orthotopic TRP allograft growth 
We found that TRP astrocytes were sensitive to single agent PI3Ki/MEKi (Figs 
3.1, S3.2) and that dual treatment was synergistic (Fig 3.4CD) in vitro.  Moreover, single 
agents delayed subcutaneous tumor growth, but dual treatment was more effective (Fig 
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3.5).  We therefore hypothesized that these treatments might be effective in orthotopic 
TRP allografts.  We thus tested the brain penetrant PI3Ki buparlisib and/or MEKi 
selumetinib in this model and found that selumetinib ± buparlisib transiently delayed 
tumor growth, but buparlisib alone did not (Fig 3.6AB).  Selumetinib modestly, but 
significantly prolonged survival, but all mice eventually succumbed to recurrent disease.  
Buparlisib ± selumetinib failed to extend survival (Fig 3.6C). 
Next, we defined the pharmacodynamic effects of treatment on PI3K/MAPK 
signaling in vivo by performing immunoblots on tumors harvested from terminal mice 
(Fig 3.6D).  Buparlisib did not affect PI3K signaling (Fig 3.6E), either alone or in 
combination with selumetinib.  In contrast, selumetinib caused a modest MAPK 
decrease (Fig 3.6F) when used alone, but not in combination with buparlisib, likely due 
to the ~2-fold increased dose.  Because selumetinib was the most effective treatment, 
we next compared the histopathology of terminal control and selumetinib-treated mice 
(Fig S3.11AB).  Tumor area was similar between groups (Fig S3.11C), but progression 
to GBM was more frequent in untreated tumors (Fig S3.11D).  Taken together, these 
data suggest that selumetinib was effective due to inhibition of MAPK (~50%, Fig 3.6F) 
with minimal PI3K reactivation when used alone at ~2-fold higher dose.  Moreover, they 
suggest that buparlisib alone was ineffective due to minimal PI3K inhibition despite 
favorable CNS pharmacokinetics.  Finally, these data suggest that the reduced doses of 
both drugs required for combination therapy limited target inhibition as well as efficacy 
in orthotopic GBM models. 
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GBM PDX response to dactolisib is heterogeneous 
 Human GBM PDX are valuable models for preclinical drug development because 
they faithfully recapitulate the genotypic and phenotypic characteristics of their parent 
tumors.54  Although dactolisib was the most effective PI3Ki in cultured TRP astrocytes 
and PDX models (Fig 3.1AB), its effectiveness an intracranial GBM model was 
limited.52  To confirm this finding, we examined efficacy of the most potent PI3Ki/mTORi 
dactolisib in a panel of orthotopic xenograft models.  Survival of mice harboring GBM46, 
but not GBM12 or GBM6, was extended by dactolisib, but its effects were modest in this 
model (17% increased survival, Fig 3.6G).  This heterogeneous response of PDX to 
dactolisib highlights the importance of identifying predictive biomarkers for the 
development of kinase inhibitors.  
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Discussion 
PI3K/MAPK mutations influence targeted inhibitor efficacy 
GBM are molecularly heterogeneous, but the vast majority harbor activated 
MAPK and PI3K.3,8  Core pathway mutations influence single agent kinase inhibitor 
efficacy in GBM ECL models.4,48,55  However, preclinical drug studies with ECL correlate 
poorly with clinical outcomes.13  PDX and nGEM are more genetically faithful and thus 
may be more predictive.56  We found that cultured PDX and TRP nGEM were sensitive 
to PI3Ki or MEKi treatment, with increased potency directly associated with efficacy 
(Figs 3.1, S3.1-3). 
Dual PI3Ki/MEKi therapies have shown efficacy in some preclinical GBM models 
and have demonstrated the importance of PI3K/MAPK crosstalk in GSC 
maintenance.48,50,52  We have shown that both of these pathways are critical for 
astrocyte de-differentiation into GSC in TRP nGEM models.16,20  We expanded these 
results here by determining that the PI3Ki/MEKi concentrations required for synergism 
in TRP astrocytes was dramatically reduced when a more potent MEKi was used (Fig 
3.4CD). 
Bypass pathways promote resistance to single agent kinase inhibitors 
We and others have shown that PI3K/MAPK crosstalk is essential for GSC 
genesis, maintenance, and tumorigenicity, suggesting that dual inhibition of these 
pathways may be effective.16,20,50  Additional evidence for the necessity of combination 
treatments comes from our own preclinical work in breast cancer, showing that dynamic 
kinome reprogramming promotes single agent kinase inhibitor resistance.41,42  We 
extended this work to GBM here and found that buparlisib induces extensive kinome 
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reprogramming in TRP astrocytes (Fig 3.2). Although we focused primarily on alternate 
MAPK activation, dynamic kinome profiling showed that multiple pathways were altered 
in response to PI3Ki and may thus promote resistance.  Future work will be required to 
investigate these pathways. 
We and others have found that PI3K and MAPK are reciprocal, bypass pathways 
that promote resistance to drugs targeting either pathway alone (Figs 3.2, 3.4).48,50,52  
However, these dynamic responses may be influenced by mutational activation of 
PI3K/MAPK signaling as well as by different mutations or tumor cells of origin.  Here we 
found that sensitivity of PDX to MEKi or PI3Ki was variable (Figs 3.1, 3.6, S3.1), but the 
reason for these differences were not readily apparent based on their genomic or 
baseline kinome profiles (Figs 3.3, S3.7, Table S3.4).  Thus, systematic profiling of 
chemovulnerability in a large, integrated panel of PDX and nGEM with diverse 
mutations and cells of origin will be necessary to further elucidate the contours of GBM 
kinome dynamics and aid in the development of combination treatments tailored to 
specific tumor subsets. 
We previously showed that genomic heterogeneity in breast cancer extends to its 
kinome.41,57  Here we extend these findings by demonstrating that MIB-MS analysis can 
stratify human GBM samples and PDX/ECL models based on their kinome profiles (Fig 
3.3).  Based on our experience with an ongoing “window” trial of neoadjuvant kinase 
inhibitor therapy in breast cancer, we anticipate that MIB-MS-based kinome profiling of 
pre- and post-treated GBM patient samples will ultimately result in identification of novel 
resistance mechanisms and facilitate design of rational combination treatments.57 
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Drug potency influences single and dual agent efficacy 
Increased potency facilitates target modulation at lower drug concentrations and 
dose reduction in vivo.  We found that increased PI3Ki/MEKi potency enhanced growth 
inhibition and synergism in vitro (Figs 3.1, 3.4, S3.1-3).  Single agent PI3Ki buparlisib 
and dactolisib were equally effective in subcutaneous TRP allografts, while trametinib 
was more effective than the less potent MEKi selumetinib (Fig S3.9).  Three of four dual 
treatments were more effective than their corresponding single agents, particularly the 
most potent combination, buparlisib/trametinib (Fig 3.5).  However, dactolisib ± 
selumetinib induced systemic toxicity, likely limiting their effectiveness. 
We investigated efficacy of the CNS penetrant PI3Ki/MEKi combination, 
buparlisib and selumetinib, in orthotopic TRP allografts.  Selumetinib alone caused 
signaling inhibition and was most effective.  Lack of buparlisib/selumetinib efficacy was 
likely due to dose reduction (~2-fold for selumetinib) required to prevent toxicity (Fig 3.6, 
Table S3.2), consistent with dose limiting toxicity for kinase inhibitor combinations found 
in clinical settings.14  We have also tested selumetinib and/or buparlisib in intracranial 
TNBC xenografts and found that target inhibition occurred in sensitive, but not resistant 
models.58  This suggests that drug levels within orthotopic TRP allografts were 
insufficient to cause signaling inhibition and affect outcomes; this limitation may be 
overcome using alternative delivery approaches (e.g. nanoparticles) that improve brain 
penetrance and reduce systemic toxicity.59 
Conclusion 
MIB-MS-based monitoring of the dynamic kinome en masse represents a 
valuable tool to identify bypass pathways and design rational drug combinations.  Its 
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use in directing preclinical trials in genetically faithful models, such as the nGEM model 
used here, can aid development of these therapies as well as predictive biomarkers to 
guide their use.  Our results suggest that highly-potent, brain-penetrant kinase inhibitor 
combinations designed to target resistance pathways will likely be required to design 
effective clinical trials in molecularly-defined GBM patients. 
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Figures and Tables 
 
Figure 3.1.  Single agent PI3Ki or MEKi potency is directly associated with 
efficacy in vitro.  PI3Ki (A,B) and MEKi (C,D) potency was inversely associated with 
IC50 in cultured TRP astrocytes (A,C) and PDX (B,D) (*, P<0.0001).  **, ambiguous IC50. 
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Figure 3.2.  Single agent PI3Ki/MEKi induces dynamic kinome changes in TRP 
astrocytes.  A heatmap demonstrated temporal changes from 4-48 h after buparlisib (A).  
Dynamics of select kinases illustrated three response types: sustained inhibition 
(Pattern 1, blue), re-activation (Pattern 2, green), and alternate pathway activation 
(Pattern 3, red) (B). Graphs show the first kinase listed.  Representative immunoblots 
(C) of PI3Ki-treated TRP astrocytes at 24 h showed that potency was directly 
associated with dose-dependent decreases of proximal (p-Akt) and distal (p-S6) PI3K 
(D), while the more potent PI3Ki, buparlisib and dactolisib, induced alternate MAPK (p-
Erk1/2) activation (E).  Immunoblots (F) performed on TRP astrocytes 24 h after 
selumetinib, PD01, or trametinib showed that MEKi potency directly associates with 
MAPK inhibition (G) and alternate activation of proximal, but not distal PI3K signaling 
(H).  A representative immunoblot quantification is shown (N=1-5 biologic replicates, 
Mean=2.5). 
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Figure 3.3.  GBM have heterogeneous kinomes.  Heterogeneous kinome activity was 
evident in ECL (A) and tumor samples from human GBM patients (B).  PCA showed 
two kinome subtypes of human tumors (K1, K2) (C).  K1 (D) had hyper-activation 
relative to K2 (E) tumors (Fig S3.5AB).  Kinases with ≥2x (red) or ≤0.4x (blue) relative 
MIB-binding are indicated; other detected kinases (black).  A waterfall plot shows the 
most differentially activated kinases (F).  Kinases significantly (P<0.05) enriched in K1 
(black) and K2 (red) are indicated (*).  Heterogeneous kinome activity was also evident 
in subcutaneous GBM PDX (G, Fig S3.5C).  PCA demonstrated that although variable, 
biologic replicates of subcutaneous GBM PDX were more similar to each other than to 
different PDX models (H).
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Figure 3.4.  PI3Ki/MEKi are synergistic and dual therapy inhibits alternate 
pathway activation.  Immunoblots of TRP astrocytes treated with buparlisib and either 
selumetinib (A) or trametinib (B) for 24 h showed that dual treatment blocks both PI3K 
and MAPK signaling.  Buparlisib and selumetinib were synergistic in TRP astrocytes at 
2-50 and 3.3-83 µM (≥0.6 fraction affected) (C).  Buparlisib and trametinib were 
synergistic in TRP astrocytes at 0.75-50 and 0.08-5 µM (≥0.5 fraction affected) (D).  A 
representative immunoblot quantification is shown (N=1-4 biologic replicates, 
Mean=2.5).
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Figure 3.5.  PI3Ki and MEKi treatment inhibited growth of subcutaneous TRP 
tumors.  Buparlisib plus either selumetinib (A-C) or the more potent MEKi trametinib 
(D-F) delayed tumor growth more than either drug alone and improved survival 
compared to controls (*, P≤0.01).  The more potent PI3Ki dactolisib plus either 
selumetinib (G,H) or the more potent MEKi trametinib (J,K) delayed tumor growth 
compared to controls (*, P<0.0001).  Dactolisib/trametinib delayed growth more than 
either treatment alone (*, P<0.0001).  Dactolisib/selumetinib did not improve survival 
compared to controls (I), but dactolisib/trametinib did (L) (*, P=0.01).  Doubling times 
(days) are indicated (B,E,H,K).  
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Figure 3.6.  Response of orthotopic TRP allografts and PDX to PI3Ki and MEKi.  In 
TRP allografts (A-F), selumetinib ± buparlisib delayed growth (*, P≤0.03) (A,B). 
Doubling times (days) are indicated (B).  Selumetinib alone improved survival (*, 
P=0.03) (C).  Representative immunoblot (D) and quantification showed no change in 
PI3K (E), but selumetinib trended towards decreased MAPK signaling (P=0.06) (N=3 
biologic replicates) (F).  In GBM PDX, dactolisib modestly improved GBM46 (*, 
P=0.003), but not GBM12 and GBM6 survival (G).  
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Figure S3.1.  Increased PI3Ki or MEKi potency potentiates growth inhibition in 
vitro.  Mutations in core GBM signaling pathways in PDX (A).28,60  Multiple PI3Ki 
reduced growth of cultured TRP astrocytes and PDX (R2≥0.96) (B).  Multiple MEKi 
reduced growth of cultured TRP astrocytes (R2≥0.97) and PDX (R2, 0.2-0.97) (C).  IC50 
calculated from these curves are graphed in Fig 3.1.  
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Figure S3.2.  In vitro efficacy of PI3Ki, MEKi, and mTORi in TRP astrocytes.  
Micromolar doses of the PI3Ki buparlisib induced G2/M cell cycle arrest within 48 h post-
treatment (*, P≤0.001) (A).  Summary of data from Figs 3.1AC, S3.1BC. N represents 
replicate biologic experiments (B).  Micromolar doses of the MEKi selumetinib induced 
G1/S cell cycle arrest within 48 h post-treatment (*, P≤0.05) (C). 
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Figure S3.3.  In vitro efficacy of PI3Ki and MEKi in PDX.  Summary of data from Figs 3.1BD, S3.1BC.  P≤0.01 for all 
PI3Ki IC50 in GBM59 vs. GBM12 or GBM6.  P<0.001 for selumetinib IC50 in GBM59 vs. GBM12.  P≤0.02 for trametinib 
IC50 in GBM46 vs. GBM12 or GBM6.  P≤0.0002 for all MEKi IC50 in GBM12 vs. GBM6.  Some IC50/GI50 could not be 
calculated (NA, not applicable) or were ambiguous (~).
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Figure S3.4.  Buparlisib induces dynamic kinome reprogramming in TRP 
astrocytes.  Buparlisib induced dynamic changes in numerous kinase families over 4-
48 h (A,B).  A kinome tree view of relative MIB-binding showed detected, but 
unchanged kinases (black) and those ≥1.5x (red) or ≤0.6x (blue) 48 h after buparlisib 
(A). 
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Figure S3.5.  Human GBM have diverse kinome profiles.  Tree views of all subtype 
K1 (A) and K2 (B) human GBM tumors from Fig 3.3B-F highlighted relative kinome 
hyper-activation of K1 vs. K2 tumors.  Tree views of subcutaneous PDX models from 
Fig 3.3GH (C).  Kinases with ≥2x (red) greater or ≤0.4x (blue) less MIB-binding relative 
to a pooled, standard reference consisting of established GBM cell lines are indicated.  
Other kinases detected by MIB-MS are indicated in black (A,B,C). 
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Figure S3.6.  PDX cultures have diverse kinome profiles.  Hierarchical clustering 
demonstrates heterogeneous kinome activity in cultured human GBM PDX (A).  Tree 
views of the cultured PDX models, GSC20, GSC23, and GSC6-27 (B).  The top (red) or 
bottom (blue) 25 kinases detected by MIB-binding in each model are indicated.  Other 
kinases detected by MIB-MS are indicated in black.
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Figure S3.7.  Subcutaneous PDX have diverse genetic profiles.  Circos plots 
summarizing somatic events in GBM59 (A), GBM46 (B), and GBM12 (C).  A summary 
of all identified somatic genomic alterations is shown.  Translocations are marked by 
yellow (interchromosomal) and black (intrachromosomal translocations) lines; for 
intrachromosomal translocations, the gray connecting line may appear as a single line if 
the joined regions lie within 2000 kb.  CNVs are shown along the thick black ring 
encircling the translocations (green, regions of loss; red, regions of gain; black, no 
change); on the ring encircling CNVs, somatic indels (insertion/deletions) are marked by 
light blue tick marks and on the ring encircling the indels, somatic point mutations are 
marked by dark blue tick marks.  Gene labels associated with point mutations are 
shown along the outermost area of the plot.  
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Figure S3.8.  Dual PI3Ki and MEKi treatment inhibits proliferation and induces 
apoptosis in TRP astrocytes in vitro.  Representative images of EdU incorporation 
(red) in TRP astrocytes treated with vehicle (DMSO), selumetinib (2.5 μM), buparlisib 
(1.5 μM), or both (A).  DAPI is shown in blue.  Scale bars = 50 μm.  Original 
magnifications 20X.  Proliferation (EdU incorporation) was decreased by single agent 
selumetinib (*, P=0.02), but not buparlisib treatment (B).  Combination treatment 
decreased proliferation compared to DMSO (*. P=0.003) or buparlisib alone (ǂ. P=0.02).  
Apoptosis was increased by single agent buparlisib (*, P=0.02), but not selumetinib (C).  
Combination treatment increased apoptosis compared to DMSO (*. P=0.05) or 
selumetinib alone (#. P=0.05). 
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Figure S3.9.  Single agent PI3Ki or MEKi delayed growth of subcutaneous TRP 
allografts.  The PI3Ki buparlisib or dactolisib alone delayed tumor growth (*, P<0.0001) 
(A,B).  Neither buparlisib nor dactolisib significantly improved median survival (C).  The 
MEKi selumetinib or trametinib alone delayed tumor growth (*, P<0.0001) (D,E), but 
trametinib was more effective (P=0.0008).  Trametinib improved median survival (*, 
P=0.01), but the less potent MEKi selumetinib did not (F).  Doubling times (days) are 
indicated in white (B,E). 
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Figure S3.10.  PI3Ki and MEKi inhibit their targeted pathways in subcutaneous 
TRP allografts.  Representative immunoblots of acutely isolated bulk subcutaneous 
TRP tumors (A) and quantification showed a trend (~50%) towards PI3K inhibition in 
PI3Ki treated samples (P=0.10 - 0.13) (B) and a significant decrease (64-91%) in MAPK 
signaling in MEKi treated samples (*, P≤0.04) (C).  While alternate pathway activation 
was not apparent in these bulk tumor samples (B,C), this may be due to either the 
kinetics of pathway inhibition and alternate activation in vivo and/or changes in cellular 
composition of the bulk tumor tested.  Mean ± SEM of 3 biologic replicates are graphed.  
Representative immunoblots of acutely isolated bulk subcutaneous TRP tumors (D) and 
quantification (E) showed increased cleaved caspase-3 in most single agents and all 
combination treatments.  Mean ± SEM of 2 biologic replicates are graphed. 
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Figure S3.11.  Selumetinib influences malignant progression of orthotopic TRP 
allografts.  Histology of representative control (A) or selumetinib-treated (B) mice 
showed GBM and anaplastic astrocytoma (grade III, A3), respectively.  Arrows indicate 
mitoses (black) and necrosis (white).  No significant difference in tumor area was 
evident (C).  Controls developed GBM more frequently than selumetinib-treated mice 
(P<0.05) (D).  Original magnifications 40x (HI, left panels) or 10x (HI, right panels).  
Scale bars = 100 µm.  
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Table S3.1.  Drug names and purchasing information 
  
Class Drug Alternate name Vendor(s) Reference 
PI3Ki 
LY LY294002 Cayman Chemicals 12 
Buparlisib BKM120 MedChem Express Chemietek 13 
Dactolisib BEZ235 MedChem Express 14 
MEKi 
Selumetinib AZD6244 MedChem Express Chemietek 15 
PD01 PD0125901 Cayman Chemicals 16 
Trametinib GSK1120212 MedChem Express Selleckchem 17 
mTORi 
Temsirolimus CCI-779 Selleckchem 18 
Everolimus RAD001 Selleckchem 19 
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Table S3.2.  Drug doses and schedules 
  
Treatment  Orthotopic   Subcutaneous
PI3Ki MEKi    Dose (mg/kg) 
Buparlisib       30   30 
Dactolisib       NA   50 
  
Selumetinib    37   37 
Trametinib    NA   1 
Buparlisib 
Selumetinib    25 + 18   25 + 18 
Trametinib    NA   25 + 0.5 
Dactolisib 
Selumetinib    NA   25 + 18 
Trametinib    NA   25 + 0.5 
Schedule  5 d on/2 d off continuous   qd x5 (d 14-18)
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Table S3.3.  Summary of buparlisib-induced kinome changes 
Kinase 4h 24h 48h 
AURKA 1.000 0.511 0.161 
PLK4 0.911 0.988 0.311 
CDK8 0.460 0.528 0.379 
ADCK1 0.821 0.458 0.422 
CDK18 0.882 0.805 0.431 
PLK1 1.162 0.342 0.442 
WEE1 0.968 0.721 0.475 
MET 0.881 0.782 0.487 
AKT1 0.433 0.394 0.506 
EPHA2 0.848 0.598 0.539 
AXL 0.884 1.009 0.540 
SIK1 0.991 0.863 0.550 
TTK 1.043 0.800 0.555 
ACVR1 0.894 0.862 0.591 
CDK1 1.009 1.151 0.599 
SIK2 1.028 0.801 0.612 
MARK3 0.998 0.544 0.613 
HCK 0.959 1.024 0.616 
RPS6KA4 0.934 0.844 0.622 
IGF1R 0.939 1.308 0.640 
CDK4 1.085 0.973 0.645 
DMPK 0.864 0.869 0.660 
TTN 0.946 0.685 0.661 
CDK17 0.964 0.743 0.666 
FRK 0.907 0.886 0.676 
BMPR1A 1.042 0.960 0.681 
BRAF 1.016 0.924 0.686 
EPHA4 0.882 1.010 0.699 
MELK 0.947 0.809 0.705 
MAK 0.955 0.773 0.711 
MARK2 0.770 0.746 0.718 
STK10 0.883 1.000 0.726 
CHEK1 1.022 0.967 0.732 
LATS1 0.966 0.849 0.733 
SIK3 0.828 0.719 0.754 
FLT4 1.006 1.117 0.763 
RIPK2 0.972 0.982 0.780 
IPMK 1.048 1.114 0.795 
MERTK 0.835 1.034 0.806 
STK35 0.879 0.827 0.808 
CDK6 0.855 0.729 0.813 
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DCK 1.151 1.052 0.815 
TNK2 0.966 0.791 0.816 
PKN2 0.794 0.847 0.817 
STK4 0.954 1.014 0.820 
PRKCA 0.772 0.759 0.823 
GSK3B 0.868 1.072 0.824 
ABL2 1.115 0.896 0.833 
NEK2 0.954 0.946 0.835 
FGFR2 1.048 1.033 0.838 
CSK 0.978 1.113 0.841 
NUAK1 1.064 0.889 0.846 
PRKAA2 0.934 0.824 0.847 
PTK2B 1.010 0.907 0.858 
EPHB4 0.899 0.866 0.858 
CSNK1G2 1.079 1.016 0.864 
CLK3 1.240 1.010 0.865 
CDK10 1.264 1.028 0.865 
GSK3A 0.928 1.104 0.870 
SRPK1 1.058 1.402 0.874 
GAK 1.017 0.823 0.875 
CDC42BPB 1.094 0.969 0.876 
PRKD3 1.466 1.283 0.876 
MAP3K11 0.769 0.946 0.876 
PIP4K2A 0.883 0.968 0.879 
CSNK1D 1.207 1.041 0.879 
MAP2K6 1.676 1.046 0.884 
PKN1 0.937 0.896 0.892 
IRAK1 0.912 0.965 0.894 
SRC 0.991 0.876 0.894 
CDK2 1.073 1.036 0.896 
MAPK10 1.052 0.840 0.897 
EPHA5 0.983 1.011 0.899 
ACVR1B 1.153 1.404 0.903 
STK38L 0.806 0.861 0.904 
EIF2AK2 0.966 1.029 0.904 
PRKACA 0.929 1.117 0.905 
TAOK2 0.801 0.751 0.907 
TAOK1 0.870 0.882 0.908 
ABL1 1.035 0.958 0.910 
PASK 0.973 1.148 0.912 
PAK4 1.040 1.119 0.913 
BMPR2 1.048 0.947 0.914 
LIMK1 0.958 1.130 0.917 
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MAP2K5 0.977 0.891 0.927 
MAP3K4 1.225 0.982 0.929 
ILK 1.232 0.989 0.933 
STK24 1.153 1.096 0.936 
MAPK11 1.057 1.421 0.936 
CLK2 1.206 0.989 0.938 
PIP4K2B 0.833 0.931 0.939 
MAP3K3 1.050 1.036 0.941 
BMP2K 1.089 0.947 0.943 
RIOK2 1.035 0.853 0.945 
CSNK1A1 1.330 0.916 0.948 
MLTK 0.986 0.949 0.948 
NUAK2 0.953 0.898 0.949 
ROCK2 0.964 0.991 0.955 
CSNK1E 1.271 1.015 0.957 
DDR1 1.105 1.086 0.959 
FGFR1 1.067 0.959 0.963 
RPS6KA6 1.009 0.817 0.964 
PKM 0.847 1.086 0.973 
MAP4K5 0.871 0.780 0.973 
RPS6KA5 1.018 0.911 0.974 
CDK7 1.379 1.065 0.977 
PSKH1 0.895 1.000 0.982 
MINK1 0.975 0.900 0.984 
CSNK1G3 1.054 0.964 0.985 
PTK2 1.045 0.844 0.986 
TLK2 0.894 1.028 0.988 
AURKB 1.104 0.948 0.991 
MAP4K4 0.965 0.931 0.997 
PRKD2 1.086 0.992 1.001 
PHKG2 1.069 1.127 1.004 
CDK9 1.056 1.033 1.005 
TBK1 1.005 0.900 1.009 
RPS6KB1 0.920 0.905 1.010 
STK38 1.029 0.963 1.012 
PRKD1 0.999 0.875 1.014 
MAPK8 1.030 0.892 1.015 
TGFBR2 0.919 1.261 1.018 
PRKAA1 1.014 0.853 1.022 
MAP2K4 0.853 1.015 1.023 
MAPK14 1.080 1.209 1.026 
CDK14 0.997 0.830 1.026 
CDK12 1.007 1.157 1.032 
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MAP2K1 0.984 1.120 1.033 
MAP2K2 0.831 1.004 1.037 
TYRO3 0.933 1.099 1.043 
NEK1 1.115 0.977 1.045 
EGFR 1.260 1.017 1.054 
YES1 1.029 1.089 1.058 
SRPK2 1.166 1.167 1.059 
KSR1 1.167 0.997 1.068 
MAP3K2 1.116 0.997 1.078 
ULK3 1.120 0.958 1.079 
AAK1 1.088 1.031 1.079 
PIK3C3 0.873 0.950 1.082 
ADK 0.884 1.035 1.082 
STK16 0.959 1.113 1.085 
DYRK1A 0.921 1.014 1.103 
STRADA 1.111 1.101 1.103 
MAP2K3 1.213 1.349 1.106 
TNIK 0.871 0.938 1.107 
CDK16 1.073 1.099 1.121 
EPHB2 1.050 0.878 1.124 
TGFBR1 1.388 1.242 1.127 
DAPK3 0.912 0.938 1.135 
JAK1 0.981 0.936 1.140 
CAMK2A 1.001 0.977 1.148 
FER 1.027 0.957 1.155 
CSNK1G1 1.074 1.197 1.175 
CDK19 0.723 0.801 1.175 
TLK1 1.047 1.138 1.180 
LYN 1.057 1.068 1.184 
RPS6KA1 1.066 1.036 1.191 
MAPK6 0.929 1.117 1.191 
EPHB3 1.129 1.217 1.197 
IRAK4 1.051 1.220 1.200 
STK11 1.017 0.968 1.206 
SYK 1.247 1.086 1.213 
SLK 0.935 1.367 1.231 
CHUK 1.210 1.392 1.234 
PDPK1 1.081 1.078 1.288 
PRKACB 1.053 1.179 1.290 
FN3KRP 1.009 1.242 1.294 
CLK4 1.801 1.172 1.298 
CDK20 1.009 1.306 1.318 
TK2 0.737 1.013 1.366 
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MTOR 0.895 0.773 1.368 
STK3 1.158 1.344 1.374 
MAPK9 1.061 1.231 1.388 
CSNK2A1 1.177 1.489 1.398 
CAMK1 0.787 1.459 1.406 
CAMKK2 0.013 2.128 1.459 
RPS6KA3 1.060 0.945 1.546 
MAPK1 1.138 1.241 1.593 
NME4 0.857 1.198 1.615 
DDR2 1.296 1.588 1.656 
CHKB 1.144 1.079 1.674 
CAMK2G 0.996 1.453 1.690 
TAOK3 1.419 1.191 1.722 
INSR 1.202 1.733 1.782 
MAPK3 1.162 1.603 1.883 
CAMK2D 1.036 1.225 1.906 
CDK5 1.324 1.720 1.985 
IKBKB 1.080 1.365 2.069 
CAMK2B 1.295 1.767 2.109 
CSNK2A2 1.396 1.333 2.135 
PRKG1 0.839 1.000 2.228 
PDXK 1.111 1.667 2.355 
NEK9 1.479 1.493 2.461 
PIP4K2C 1.259 0.871 2.655 
TP53RK 1.534 1.460 2.903 
CHKA 1.253 0.867 4.186 
FYN 1.696 2.785 4.446 
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Table S3.4.  Summary of PDX kinome profiles 
GBM59  GBM46 
≥2 2-0.4 ≤0.4    ≥2 2-0.4 ≤0.4 
JNK3 NEK9 MSK1    FMS EphA4 CDK7 
PKCt LRRK2 RSK1    IRAK3 GCK MET 
EGFR PKG1 AurA    PKCb ICK PKCd 
ADCK4 CaMK2a MST3    LCK CDK6 DLK 
CaMK2d CK1g2 SRC    SYK PFTAIRE1 CDK4 
IRAK3 STLK6 INSR    BTK STLK6 NuaK2 
NEK7 PFTAIRE1 IGF1R    JNK3 PIK3R4 AurA 
EphA1 PKCb YANK2    ADCK4 Erk2   
FMS BCKDK    PKG1 ADCK1 
FYN CLIK1      FGR CLK2   
TIE2 CLK2    CaMK2a PDGFRa 
PIK3R4 PHKg1      HCK Erk1   
BTK MAP2K6    NEK7 PKD1 
ADCK1 RSK3      CLIK1 BCKDK   
FES IRAK1    BLK NEK11 
GCK YES      CaMK2d TAO3   
SYK CK1g1    FES IRAK4 
LIMK1 CK2a1      FRK PEK   
DRAK1 NEK11    DMPK1 QSK 
PKD1 DRAK2      FYN LIMK1   
 MARK1    skMLCK LKB1 
  STK33      PKCa FGFR2   
 PKR    PHKg1 CK1g2 
  HCK      FLT4 CaMK1a   
 KHS1    LYN TYRO3 
  CHK2      CaMK1d p38b   
 EphB4    TRKB RSK2 
  CaMK2g      EGFR CaMK2b    
 Erk1    NDR2 NEK9 
  IRAK4      DDR1 MARK1   
 NuaK1    TAO1 
  FLT4        MAP2K6   
 CASK    Erk5 
  FGR        STK33   
 LKB1    BMPR2 
  MAP3K4        DRAK1   
 STLK5    LRRK2 
  PDK1        MAP3K1   
 TAO3    Wee1 
  PEK        PKCt   
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 p38b    TEC 
  ICK        STLK5   
 IRE1    DAPK2 
  AKT1        PDGFRb   
 CaMK1d    ATM 
  Erk2        MAP2K2   
 BMPR2    MER 
  Wee1        KHS2   
 JAK1    CASK 
  ATM        KHS1   
 PKN1    TIE2 
  GCN2        FAK   
 QSK    PKCe 
  PHKg2        BIKE   
 SRPK2    RET 
  MAP2K3        PRPK   
 TAO2    IRE1 
  MAP3K5        TESK1   
 EphA4    EphB3 
  DDR1        PASK   
 RIPK1    SRPK2 
  PRPK        CK2a1   
 CK2a2    MAP2K4 
  NDR2        ILK   
 BLK    BMPR1B 
  TEC        YES   
 EphA3    AKT2 
  MAP2K5        MARK4   
 DAPK2    HRI 
  ILK        CHK1   
 TAO1    PDK1 
  PASK        FER   
 CDK5    TAO2 
  PKCe        IRAK1   
 MARK3    NDR1 
  DMPK1        p38a   
 MAP3K7    RIPK1 
  PKD2        BRAF   
 CaMK2b     AKT1 
  TRKB        RSK3   
 TESK1    MLK2 
  FRK        MAPKAPK2   
 BRAF    TIF1b 
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  p38a        DYRK1A   
 CLIK1L    PCTAIRE2 
  FER        ABL   
 RIPK2    MAP2K5 
  MER        PKACa   
 HRI    QIK 
  PKACa        PKR   
 PKN2    PKN1 
  PDGFRa        CHK2   
 MRCKb    CK2a2 
  CDK6        MAP3K5   
 TYRO3    FGFR1 
  CaMKK2        PHKg2   
 PKACb    MAP3K7 
  ZC2/TNIK        CDK5   
 TBK1    ROCK1 
  GSK3A        RSK1   
 MARK4    CDKL5 
  MAP3K6        CK1e   
 PCTAIRE3    PKN2 
  TIF1b        YSK1   
 TYK2    MAP2K3 
  CDK2        PYK2   
 AMPKa2    KDR 
  BIKE        GSK3B   
 MET    MRCKb 
  Erk5        MAP3K6   
 MYT1    IKKb 
  MST1        NEK3   
 AKT2    PKACb 
  YSK1        MST1   
 AAK1    TGFbR1 
  skMLCK        CDK11   
 PKD3    CDK2 
  MAP2K4        NuaK1   
 CK1a    MST2 
  TLK1        MAP2K1   
 RSK2    CaMK2g 
  CK1e        p70S6K   
 MLK2    PKD2 
  SgK496        CaMKK2   
 RET    EphB4 
  DYRK1A        CK1a   
121 
 GSK3B    HIPK2 
  PKCa        CHED   
 MAP2K1    GSK3A 
  HIPK2        TGFbR2   
 CaMK1a    CK1g1 
  NDR1        JAK1   
 JNK2    DNAPK 
  ROCK1        CSK   
 MAP2K2    ZC1/HGK 
  QIK        NEK1   
 MAP3K1    DDR2 
  LYN        PKD3   
 FGFR2    ZC2/TNIK 
  PCTAIRE2        EphA1   
 ABL    CK1g3 
  MARK2        AKT3   
 KHS2    MAP3K4 
  PLK1        LATS1   
 SLK    MAP3K2 
  AMPKa1        MPSK1   
 MAP3K2    MARK2 
  NEK3        JNK2   
 NEK1    MARK3 
  MPSK1        CaMK4   
 NEK2    CRK7 
  CDC2        SgK496   
 BMPR1A    CLK1 
  AKT3        ACK   
 TLK2    TYK2 
  CDKL5        FRAP   
 MST2    TLK2 
  CLK1        ROCK2   
 CHK1    PAK4 
  CLK3        ULK3   
 IKKb    CLIK1L 
  ROCK2        TLK1   
 DDR2    LIMK2 
  PCTAIRE1        ZC3/MINK   
 CHED    TBK1 
  p70S6K        GAK   
 CDK8    AMPKa2 
  KDR        SRC   
 CK1g3    AMPKa1 
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  IKKa        BMPR1A   
 TTK    TTK 
  FRAP        TTN   
 ZC3/MINK    PLK1 
  DNAPK        MYT1   
 FGFR1    CDK8 
  TGFbR2        GCN2   
 LATS1    CDK9 
  MELK        RIPK2   
 IKKe    MAP3K3 
  PAK4        DRAK2   
 FAK    ARG 
  ACK        AAK1   
 CRK7    EphA5 
  CDK10        AurB   
 PKCd    CDC2 
  LCK        CDK10   
 EphA5    PCTAIRE1 
  ZC1/HGK        IKKe   
 ARG    EphB2 
  BUB1        PCTAIRE3   
 GAK    PLK4 
  CDK9        CLK3   
 MSK2    MLK3 
  MAPKAPK2        EphA3   
 JNK1    NEK2 
  AurB        LOK   
 PLK4    ZAK 
  PKN3        PKN3   
 RIOK2    JNK1 
  BMPR1B        SLK   
 TGFbR1    IGF1R 
  ZAK        DAPK3   
 CK1d    INSR 
  CaMK4        ALK2   
 EphB3    IKKa 
  PDGFRb        AXL   
 MAP3K3    SRPK1 
  TTN        BUB1   
 DAPK3    MSK1 
  EphB2        MELK   
 PYK2    CK1d 
  SRPK1        RIOK2   
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 LIMK2    smMLCK 
  smMLCK        MST3   
 ULK3    YANK2 
  CSK        MSK2   
 CDK11          
  DLK            
 ALK2          
  LOK            
 AXL          
  CDK4            
 NuaK2          
  MLK3            
  CDK7            
 
GBM15  GBM6 
≥2 2-0.4 ≤0.4    ≥2 2-0.4 ≤0.4 
skMLCK FGFR1 smMLCK    RET CLIK1 CDK4 
PDGFRa PRPK NuaK2    skMLCK TIE2 MSK1 
IRAK3 ATM AMPKa2    CaMK2b  IRAK4 smMLCK 
CaMK2a TYRO3 RIOK2    JNK3 DRAK2 PKCd 
MER QSK RSK1    IRAK3 CaMK1d AurA 
SYK PKD1 DDR2    PKG1 PRPK ALK2 
CaMK2b  LRRK2 PKCd    FLT4 QSK CDK7 
BTK DNAPK LIMK2    PHKg1 EphA4 RSK1 
TTN GCK AXL    PKCa LKB1 NuaK2 
PKCb YES MET    FYN NDR2 RIOK2 
MARK1 PKACb CaMKK2    ADCK4 ATM EphB2 
FMS CK1e      BTK CK1g2 AXL 
RSK2 PIK3R4    FES STK33 MET 
PKG1 CDC2      FMS YES   
FYN CLK2    CaMK2a CDK6 
HCK NDR2      SYK BMPR2   
PKCa ABL    EGFR Wee1 
FLT4 CaMK2d      CaMK2d MAP3K5   
FGFR2 MAP3K4    PKD1 FGR 
PEK CK1g2      LRRK2 HCK   
PHKg1 BMPR2    NEK11 CHK2 
FES KHS2      FGFR2 IKKb   
CASK PFTAIRE1    Erk2 STLK5 
STK33 ADCK4      AKT2 MAP2K6   
CLIK1 BLK    PKCb p38b 
BMPR1A PKACa      DDR1 ADCK1   
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Wee1 LKB1    NEK7 JAK1 
DDR1 MLK2      PEK LYN   
 TAO3    PIK3R4 RSK2 
  KHS1      MARK1 PKR   
 NEK3    TAO3 
  SLK        PFTAIRE1   
 IRE1    NEK9 
  MST1        MAP2K2   
 NuaK1    CK2a1 
  QIK        GCK   
 AKT1    FAK 
  MAP2K6        DNAPK   
 TAO1    MAP3K6 
  DYRK1A        CASK   
 STLK5    FER 
  TRKB        PDGFRa   
 PKCt    CLK2 
  AKT2        STLK6   
 ZC2/TNIK    BIKE 
  Erk2        CDK2   
 LATS1    MER 
  TIE2        PKN1   
 CK1g1    TAO1 
  MARK4        GSK3A   
 DAPK2    SRPK2 
  TIF1b        TLK1   
 YANK2    NEK3 
  CSK        GSK3B   
 CDK2    ABL 
  BIKE        BLK   
 PKCe    PKD2 
  CHK1        ICK   
 SRPK2    LCK 
  TAO2        RIPK1   
 MAP3K1    PKD3 
  ILK        BRAF   
 GSK3B    MLK2 
  SgK496        PKCt   
 FAK    EphB3 
  FGR        BCKDK   
 HRI    BMPR1B 
  BCKDK        LIMK1   
 MAP2K4    MAP2K5 
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  JNK3        TRKB   
 PDGFRb    MAP3K1 
  MAP2K5        Erk1   
 MARK2    DAPK2 
  p38b        CK2a2   
 CDK10    PCTAIRE2 
  MAP2K2        RSK3   
 LYN    TAO2 
  ROCK1        FGFR1   
 TYK2    IRAK1 
  ZC1/HGK        DYRK1A   
 CDK11    PASK 
  CHK2        MAP3K4   
 MST2    CK1e 
  CDK6        ILK   
 RIPK1    TIF1b 
  CLK1        YANK2   
 Erk5    FRK 
  TESK1        ULK3   
 CRK7    PKCe 
  TEC        Erk5   
 NEK7    FRAP 
  IRAK1        ZC1/HGK   
 TLK1    KHS2 
  YSK1        YSK1   
 GSK3A    HRI 
  IGF1R        ROCK1   
 JAK1    TYK2 
  NEK9        ROCK2   
 AurB    TEC 
  ADCK1        CDK5   
 CaMK1d    TYRO3 
  PKD3        TESK1   
 CK2a1    AKT1 
  EGFR        LATS1   
 NDR1    MAP2K1 
  PASK        NDR1   
 STLK6    PDK1 
  ULK3        MARK4   
 CLIK1L    p70S6K 
  IKKb        MAP2K4   
 FRAP    QIK 
  PCTAIRE2        CDK11   
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 DRAK1    CaMKK2 
  CK1a        DMPK1   
 PKD2    CK1a 
  ARG        ZC2/TNIK   
 p38a    PKACa 
  LCK        BUB1   
 FRK    SgK496 
  MARK3        CDC2   
 TGFbR1    CK1g3 
  BUB1        PHKg2   
 Erk1    PKN2 
  MAPKAPK2        CHK1   
 CaMK2g    AMPKa1 
  EphA5        PCTAIRE3   
 CaMK4    MARK3 
  PKN2        IRE1   
 MAP2K3    EphA1 
  EphB2        CK1g1   
 PDK1    RIPK2 
  HIPK2        p38a   
 MRCKb    MRCKb 
  RSK3        PKACb   
 PKN3    CaMK2g 
  EphB4        DRAK1   
 CaMK1a    EphB4 
  JNK1        PKN3   
 IRAK4    CSK 
  PKN1        TBK1   
 TLK2    JNK2 
  PAK4        MST2   
 CK1g3    NEK1 
  RET        GAK   
 PLK1    PAK4 
  FER        PDGFRb   
 PHKg2    MST1 
  MAP3K3        KHS1   
 MAP3K7    HIPK2 
  LIMK1        AKT3   
 BRAF    CHED 
  MAP3K6        TTK   
 TTK    PYK2 
  MELK        MARK2   
 MAP2K1    MAP2K3 
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  AurA        MAP3K2   
 NEK11    EphA5 
  CHED        ZC3/MINK   
 PYK2    TTN 
  EphB3        AMPKa2   
 MAP3K2    ARG 
  ACK        MPSK1   
 CK2a2    NEK2 
  PKR        NuaK1   
 TGFbR2    AurB 
  JNK2        PCTAIRE1   
 RIPK2    BMPR1A 
  ROCK2        CLK3   
 NEK2    KDR 
  ZAK        IGF1R   
 ZC3/MINK    ZAK 
  p70S6K        CaMK1a   
 CDKL5    MAPKAPK2 
  MLK3        AAK1   
 TBK1    CDK9 
  AKT3        TLK2   
 CLK3    TGFbR2 
  GCN2        CaMK4   
 ICK    MAP3K7 
  DRAK2        CDK10   
 CK1d    PLK1 
  CDK5        MLK3   
 AMPKa1    DDR2 
  MYT1        CLIK1L   
 CDK9    MYT1 
  PLK4        CLK1   
 EphA1    CDK8 
  DMPK1        MELK   
 BMPR1B    LIMK2 
  NEK1        SRPK1   
 AAK1    PLK4 
  MAP3K5        CRK7   
 EphA4    DLK 
  IKKa        TGFbR1   
 LOK    MAP3K3 
  PCTAIRE1        GCN2   
 SRPK1    CK1d 
  DAPK3        IKKe   
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 MPSK1    IKKa 
  GAK        JNK1   
 CDK7    SLK 
  MSK2        ACK   
 DLK    DAPK3 
  IKKe        CDKL5   
 EphA3    INSR 
  SRC        LOK   
 CDK8    EphA3 
  KDR        MSK2   
 MST3    SRC 
  PCTAIRE3        MST3   
 MSK1          
  ALK2            
 CDK4          
  INSR            
129 
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CHAPTER IV: PI3K AND MAPK PATHWAY MUTATIONS IN GLIOBLASTOMA 
INFLUENCE RESPONSE TO KINASE INHIBITORS TARGETING THESE 
PATHWAYS 
 
Introduction 
Diffuse gliomas are a histologically and genetically diverse group of malignant 
primary brain tumors.1-3  Gliomas have traditionally been classified based on their 
histologic resemblance to normal brain cells, specifically astrocytomas resemble 
astrocytes, while oligodendrogliomas resemble oligodendrocytes.4  Molecular 
characterization of these diseases have improved diagnostics via the inclusion of both 
histological and genomic criteria in the new WHO 2016 classification.1  Glioblastoma 
(GBM) is the most common and aggressive diffuse glioma in adults.  The majority of 
GBM arise de novo without a clinically detectable lower grade antecedent (primary 
GBM).5  Standard-of-care consists of surgical resection followed by radiation with 
concurrent and adjuvant temozolomide.6  Median survival is only 12-15 months, due to 
the inevitable recurrence of this devastating disease. 
Efforts such as TCGA have characterized the molecular heterogeneity of primary 
GBM (hereafter just GBM) using genomics.3,7  GBM has been stratified into four 
molecular subtypes based on transcriptome profiles: classical, neural, proneural, and 
mesenchymal.  GBM is also characterized by co-occurring mutations in the RB, TP53, 
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and receptor tyrosine kinase (RTK)/phosphoinositide 3-kinase (PI3K)/mitogen activated 
protein kinase (MAPK) pathways.3,7 
PI3K signaling is most frequently activated via inactivating mutations in its 
negative regulator, PTEN.3,8  MAPK signaling is activated in the majority of GBM, most 
frequently due to deletions/inactivating mutations in its negative regulator NF1 or 
amplifications/activating mutations of RTK or KRAS.3,9,10  Kinase inhibitors targeting the 
PI3K and MAPK pathways are in clinical development or approved for non-glioma 
tumors.11,12  Moreover, the RTK/PI3K/MAPK pathways are appealing therapeutic targets 
in GBM because they are mutated in 90% of patients and have well-established roles in 
disease pathogenesis.3,8,13,14  Nevertheless, clinical investigations of single agent kinase 
inhibitors have had disappointing results in GBM.15-18  Defining how individual mutations 
influence efficacy and resistance to targeted inhibitors may aid in the identification of 
predictive biomarkers and the design rational combination therapies. 
Preclinical studies can aid in clinical drug development by prospectively 
identifying potential resistance mechanisms and predictive biomarkers.  Genetically 
engineered mouse (GEM) models are valuable tools for these efforts because they 
enable direct genotype to phenotype comparisons.16  Activating PI3K and MAPK 
pathway mutations cooperate to promote tumorigenesis in preclinical glioma models.19-
23  For instance, we developed a series of non-germline GEM (nGEM) models in which 
astrocytes were immortalized by ablation of the Rb family of pocket proteins via 
expression of an N-terminal SV40 large T mutant (T121, T).23  PI3K and MAPK signaling 
were activated alone and in combination in T astrocytes via knock-in of a constitutively 
active Kras mutant (KrasG12D, R) and homozygous Pten deletion (P), respectively.  We 
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previously used T, TP, TR, and TRP astrocytes (hereafter the T(RP) series) to show 
that Pten deletion and mutant Kras cooperated to activate PI3K/MAPK signaling, 
promote proliferation and de-differentiation in vitro, and potentiate formation of GBM in 
vivo.19,23  In Chapter III we showed that while triple mutant TRP astrocytes were 
sensitive to single agent pan-PI3K, mTOR, and MEK1/2 inhibitors (PI3Ki, mTORi, and 
MEKi), dual treatment with PI3Ki/MEKi were most effective in vitro and in vivo.24  
However, it remained unclear whether Pten/Kras mutations influenced efficacy of single 
agent and combination treatments.  We therefore used the T(RP) nGEM series to define 
how PI3K/MAPK mutation status and drug potency interact to influence response single 
agent and combination treatments with PI3Ki, mTORi, and/or MEKi in vitro.19,23 
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Materials and Methods 
Murine astrocyte cultures.  Cortical astrocytes were harvested from GEM and 
maintained as previously described.19,23,25  Briefly, mice containing conditional alleles 
(TgGZT121, KrasG12D knock-in, and/or Pten knock-out) were crossed to generate 
compound T(RP) mice.23,26-28  Astrocytes harboring floxed, heterozygous T ± R and/or 
floxed, homozygous P alleles were harvested from neonatal mice, and recombination 
was induced in vitro with an adenoviral vector encoding Cre recombinase (Ad5CMVCre, 
University of Iowa Gene Transfer Vector Core).  Astrocytes were maintained at 37 °C 
and 5% CO2 as adherent cells in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin.  The UNC 
Institutional Animal Care and Use Committee approved all animal studies. 
Drugs.  LY294002 (LY) and PD0125901 (PD01) were purchased from Cayman 
Chemicals (Ann Arbor, MI).  Temsirolimus (CCI-779) was purchased from Selleckchem 
(Houston, TX).  Dactolisib (BEZ235) was purchased from MedChem Express 
(Monmouth Junction, NJ).  Buparlisib (BKM120) and selumetinib (AZD6244) were 
purchased from MedChem Express and Chemietek (Indianapolis, IN).  Trametinib was 
purchased from MedChem Express and Selleckchem.  Dactolisib was dissolved in N,N-
Dimethylformamide (DMF).  All other drugs were dissolved in dimethyl sulfoxide 
(DMSO). 
Immunoblots.  The T(RP) astrocyte series were plated on tissue culture treated plates, 
and at ~60 confluence they were treated with buparlisib, selumetinib, or DMSO 
(control).  Cells were mechanically harvested 4 or 24 h after treatment, lysed, and then 
protein concentration was quantified using Pierce BCA Protein Assay Kit (Thermo 
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Scientific, Waltham, MA).  Immunoblots were performed as previously described.19  
Briefly, 20 µg of proteins were resolved by SDS-PAGE (gradient 8-16%) gel 
electrophoresis (Bio-Rad, Hercules, CA), transferred to PVDF membranes (EMD 
Millipore), then probed overnight at 4 °C using primary antibodies against Gapdh 
(#AB2302, EMD Millipore) and p-Erk1/2 (Thr202/Tyr204, #9101), Erk1/2 (#4696), Akt 
(#2967), p-Akt (Ser473, #9271), and p-S6 (Ser240/244, #2215) all from Cell Signaling 
Technology (Danvers, MA).  Species specific Alexa 488, 568, and 633 conjugated 
secondary antibodies were incubated with the membranes at room temperature for 30 
min.  Immunoblots were imaged on a GE Typhoon Trio (GE Healthcare, Marlborough, 
MA), band intensities were quantified using ImageJ (NIH, Bethesda, MD), and 
intensities of phosphoproteins (p) were normalized to the corresponding total protein or 
Gapdh then set relative to control cells. 
Dose response.  The T(RP) astrocyte series were plated in 96-well tissue culture 
plates with 3-6 technical replicates per condition.  The following day, cells were treated 
with solvent or drug(s).  Effects of drugs on growth was assessed 5 days after treatment 
with the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS, Promega, 
Madison, WI) according to manufacturer’s instructions.  Absorbance at 490nm was 
measured with an Emax plate reader (Molecular Devices, Chicago, IL) equipped with 
SoftMax Pro 5 software.  Absorbance in each well was subtracted by baseline 
absorbance (MTS reagent plus culture media) and then set relative to cells treated with 
solvent. 
Data from 1-6 independent experiments were pooled, fit to a non-linear, log 
[inhibitor] versus response curves with variable slope, and Hill slopes, GI50, IC50, and 
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Imax were calculated as previously described.19,24,29,30  Effects of PI3Ki and MEKi 
potency and genotype on IC50 and GI50 were calculated by two-way ANOVA.  Effects of 
genotype on temsirolimus IC50 and GI50 were calculated by one-way ANOVA.  The 
pairwise effects of genotype (T vs. TP, TR, and TRP; TP vs. TRP; and TR vs. TRP) and 
drugs on IC50, GI50 and Hill slopes were compared using the extra-sum-of-squares F 
test.  Log10 (Log) IC50 and GI50 were graphed unless otherwise stated. 
Drug synergism.  PI3Ki/MEKi synergism was determined using the Chou-Talalay 
method.31  Briefly, relative absorbance was determined for single agents and the 
corresponding combinations at a constant molar ratio using MTS (Promega) as 
described above.  Fraction affected (1 – relative growth, FA) was calculated, and the 
combination index (CI) was determined using CompuSyn (ComboSyn, Inc., Paramus, 
NJ).  Data were pooled from 2–4 independent experiments.  Combination index (CI) 
values <0.86, 1–0.86, and >1 were considered synergistic, additive, and antagonistic, 
respectively. 
Statistics.  Statistical analyses were conducted in GraphPad Prism (La Jolla, CA).  
Error bars are SEM.  P≤0.05 were considered statistically significant. 
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Results 
The PI3K and MAPK pathways are frequently activated in GBM, and drive 
gliomagenesis in preclinical models.3,7,9,10,32,33  Using our T(RP) series of nGEM models, 
we showed that Pten deletion and mutant Kras cooperate to promote 
gliomagenesis.19,23  We recently found that TRP astrocytes were sensitive to 
pharmacological inhibition of PI3K and MAPK signaling.24  Whether mutations that 
activated PI3K/MAPK signaling influenced response to their inhibition remained unclear.  
To address this issue, we used a combinatorial experimental approach to determine 
how Pten/Kras mutation status and drug potency interact to influence efficacy, 
synergism, and alternate pathway activation in vitro. 
PI3Ki-induced alternate MAPK activation is independent of Pten and Kras 
mutation status 
The PI3K pathway is a potential therapeutic target in GBM.18  We previously 
found that the PI3Ki buparlisib inhibited PI3K signaling and induced dynamic kinome 
reprogramming of TRP astrocytes, including alternate activation of MAPK signaling.24  
Here, we determined whether buparlisib-induced changes in PI3K and MAPK signaling 
were influenced by Pten and/or Kras mutation status.  Immunoblots showed that 
proximal (p-Akt) and distal (p-S6) PI3K signaling was inhibited within 4 h (Fig S4.1AB) 
and sustained for 24 h (Fig 4.1AB) in all four genotypes of T(RP) astrocytes.  Although 
buparlisib caused minimal changes in MAPK signaling at four h (Fig S4.1AC), it 
increased MAPK signaling by 24 h post-treatment regardless of Pten/Kras mutation 
status (Fig 4.1AC).  Thus, buparlisib-induced PI3K inhibition and alternate MAPK 
activation was independent of mutational activation of either PI3K or MAPK signaling. 
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PI3Ki efficacy is potentiated by Pten and/or Kras mutations 
Pten/Kras mutation status did not affect PI3Ki-induced changes in signaling (Figs 
4.1, S4.1), but these mutations may modulate drug efficacy.  We previously found a 
direct association between PI3Ki potency (dactolisib > buparlisib > LY) and efficacy in 
TRP astrocytes.24  We therefore determined the effects of these three PI3Ki on T(RP) 
astrocyte growth in vitro.  Dactolisib, buparlisib, and LY all caused dose-dependent 
decreases in growth, and a direct association between PI3Ki potency and efficacy (IC50 
and GI50) was evident in all four genotypes (Fig 4.2, S4.2).  Furthermore, Pten and/or 
Kras mutations increased PI3Ki efficacy, especially for the most potent inhibitor 
dactolisib. 
Dactolisib is a dual PI3Ki/mTORi, and it was the most effective inhibitor in all four 
T(RP) genotypes.  Moreover, dactolisib was the only PI3Ki in which efficacy was 
increased in T astrocytes with both Pten deletion and mutant Kras compared to those 
with either mutation alone (TRP vs. TP or TR) (Fig 4.2BC).  These data suggested that 
mTORi efficacy might also be influenced by Pten/Kras mutation status.  The mTORi 
temsirolimus caused dose-dependent decreases in growth of all four T(RP) astrocyte 
genotypes (Fig S4.3A).  Compared to dactolisib, temsirolimus was less effective in all 
genotypes (P≤0.01), and caused more gradual decreases in growth of TP, TR, and TRP 
astrocytes (Hill slope, P≤0.001) (Fig S4.2, S4.3).  Temsirolimus IC50 were similar among 
T, TP, and TR astrocytes (Fig S4.3B).  In contrast, temsirolimus IC50 was lower in TRP 
than T astrocytes (Fig S4.3B), and its GI50 was lower in TRP than TP and TR astrocytes 
(Fig S4.3C).  Thus, Pten deletion and mutant Kras sensitized T astrocytes to mTORi 
more than either mutation alone. 
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Mutant Kras modulates MEKi-induced alternate activation of PI3K signaling 
Consistent with other preclinical models, we previously found that multiple MEKi 
reduced TRP astrocyte growth, inhibited MAPK signaling, and induced proximal PI3K 
signaling.24,34-37  Data from Fig 4.1 demonstrated that PI3Ki ablated PI3K signaling and 
potentiated MAPK activation regardless of genotype.  However, the effects of Pten/Kras 
mutation status on MEKi-induced signaling changes remained unclear.  We therefore 
assessed MAPK/PI3K signaling in the T(RP) astrocyte series 4 h (Fig 4.S4) and 24 h 
(Fig 4.3) after treatment with the MEKi selumetinib.  Immunoblots showed that MAPK 
signaling was reduced at 4 h, and inhibition was sustained for 24 h in all four genotypes.  
Ablation of MAPK signaling was more pronounced at 24 h in T astrocytes with Pten 
deletion (TP, TRP) than those without (T, TR) (Fig 4.3AB).  Selumetinib increased 
proximal PI3K signaling in T, TR, and TRP astrocytes at 4 h (Fig S4.4AC), and this 
potentiation progressively increased over 24 h, particularly in astrocytes with mutant 
Kras (TR, TRP) (Fig 4.3AC).  However, distal PI3K signaling was generally not 
activated in any genotype at either time.  Taken together, these results indicate that 
Pten deletion influences MEKi-induced MAPK inhibition, while mutant Kras modulates 
MEKi-induced alternate PI3K activation. 
MEKi efficacy is increased by Pten deletion 
Because Pten/Kras mutation status influenced MEKi-induced changes in 
signaling (Fig 4.3), we hypothesized that these mutations would also influence MEKi 
efficacy.  We therefore determined how increasingly potent MEKi (trametinib > PD01 > 
selumetinib) influenced T(RP) astrocyte growth in vitro.38-40  All three MEKi caused 
dose-dependent decreases in growth, and potency was directly associated with efficacy 
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in all four genotypes (Figs 4.4A, S4.2).  Moreover, MEKi sensitivity was influenced by 
Pten/Kras mutation status.  TR astrocytes tended to have lower IC50 (P≥0.11) (Fig 4.4B) 
and had significantly lower GI50 (Fig 4.4C) than T astrocytes for the more potent MEKi 
(PD01 and trametinib).  Pten-deleted astrocytes (TP and TRP) had significantly lower 
IC50 and GI50 than T astrocytes for all MEKi (Fig 4.4BC).  Furthermore, TRP astrocytes 
also had decreased IC50 and GI50 compared to TR astrocytes.  Thus, Pten deletion 
sensitizes T astrocytes to MEKi regardless of Kras status. 
PI3Ki/MEKi synergism is influenced by drug potency and Pten/Kras mutation 
status 
We previously found that dual PI3Ki/MEKi treatment was synergistic in TRP 
astrocytes.24  However, Pten/Kras mutation status influenced MEKi-induced signaling 
changes, and efficacy of single agent PI3Ki and MEKi (Figs 4.2, 4.4).  We therefore 
determined whether Pten/Kras mutation status also influenced synergism of dual 
PI3Ki/MEKi treatment in vitro.  Buparlisib/selumetinib treatment inhibited growth and 
was synergistic in all four T(RP) genotypes (Fig 4.5A).  However, the 
buparlisib/selumetinib concentrations required for synergism were lower in TP, TR, and 
TRP than in T astrocytes.  Because MEKi potency influenced the effects of mutant Kras 
on efficacy (Fig 4.4C), MEKi potency may also alter the effects of Pten/Kras mutations 
PI3Ki/MEKi synergism.  To address this issue, we assessed drug synergism in cultured 
T(RP) astrocytes treated with buparlisib/trametinib.  This inhibitor combination also 
reduced growth in all four genotypes, and the buparlisib/trametinib concentrations 
required for synergism were dramatically reduced compared to buparlisib/selumetinib 
treatment (Fig 4.5AB).  Interestingly, the effects of Pten/Kras mutation status on 
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PI3Ki/MEKi synergism was blunted with dual buparlisib/trametinib treatment (Fig 4.5B).  
Thus, increased MEKi potency lowered the PI3Ki/MEKi concentrations required for 
synergism and abrogated the effects of Pten deletion and mutant Kras.  
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Discussion 
PI3K and MAPK mutations influence efficacy of single agent targeted inhibitors 
GBM are genetically heterogeneous, but recurrent mutations commonly 
converge on three “core” pathways: RB, TP53, and RTK/PI3K/MAPK.3,41  Moreover, the 
vast majority of GBM harbor activated PI3K and MAPK signaling.3,9  Preclinical models 
may aid in the clinical development of targeted inhibitors by defining how frequent 
mutations influence drug efficacy and resistance.  To this end, the influence of “core” 
pathway mutations on sensitivity to single agent kinase inhibitors has been investigated 
using GBM established cell lines (ECL) and patient derived xenografts (PDX).7,34,42,43  
Nevertheless, ECL models poorly correlate with clinical outcomes.16  Additionally, these 
preclinical studies were generally designed to correlate specific mutations with drug 
efficacy.  In contrast, nGEM models enable direct genotype/phenotype comparisons 
and thus may be more predictive.44,45 
Because PTEN deletion activates PI3K signaling, it may promote sensitivity to 
inhibitors of this pathway.  However, the utility of PTEN status as a predictive biomarker 
remains unclear, and preclinical studies which sought to answer this question in a 
variety of cancer types, including GBM, have had variable results.42,43,46-51  We 
previously showed that TRP astrocytes were sensitive to PI3Ki.24  Here we found that 
Pten deletion and/or mutant Kras resulted in biologically marginal, but statistically 
significant increases in efficacy of the less potent PI3Ki LY and buparlisib (Fig 4.2).  
This finding is consistent with the lack of correlation between PTEN status and 
buparlisib efficacy in GBM ECL.42  The influence of Pten/Kras mutation status on 
inhibitor efficacy was much more pronounced with the most potent, dual PI3Ki/mTORi 
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dactolisib (Fig 4.2).  Pten/Kras mutations resulted in 5-15 fold decreases in IC50 and 10-
34 fold decreases in GI50 compared to T astrocytes.  Furthermore, T astrocytes with 
both Pten deletion and mutant Kras (TRP) were more sensitive to dactolisib than those 
with either mutation alone (TP, TR).  These data suggest that Pten/Kras mutation status 
has a greater impact on PI3Ki efficacy when a more potent PI3Ki and/or a dual 
mTOR/PI3Ki is used.  Similar to the finding that PTEN loss does not predict efficacy of 
mTORi in GBM PDX, we found that Pten deletion alone did not alter sensitivity to the 
mTORi temsirolimus (Figs S4.2, S4.3).43  However, mTORi efficacy was greatest in 
TRP astrocytes, suggesting that Pten deletion and mutant Kras cooperate to promote 
sensitivity to mTORi. 
We previously found that mutant Kras activated MAPK signaling, and promoted 
tumorigenesis.23  We therefore hypothesized that Kras status would increase MEKi 
efficacy.  Nevertheless, the effects of mutant Kras were relatively minor, and only 
decreased GI50 for the more potent MEKi (PD01 and trametinib) (Fig 4.4).  This 
indicates that MEKi potency influences the impact of MAPK mutations on efficacy.  See 
et al. found that only a subset of NF1-null GBM ECL were sensitive to MEKi.34  Taken 
together, these results suggest that MAPK mutations alone may not accurately predict 
MEKi efficacy in GBM. 
We found that Pten deletion had a far more dramatic effect on MEKi sensitivity 
than mutant Kras (Fig 4.4).  While surprising, there is a precedent for this result in the 
literature.  Similar to our previous finding that Pten deletion and mutant Kras cooperate 
to potentiate MAPK signaling and gliomagenesis, Ebbesen et al. showed that Pten 
knock-down increased PI3K and MAPK signaling and promoted malignant progression 
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of HER2/neu driven breast carcinomas.23,52  Interestingly, MEKi treatment phenocopied 
Pten restoration in this model, and was more effective than either PI3K or AKT inhibitors 
at inhibiting tumor growth.  Taken together, these results demonstrate that PTEN loss 
increases sensitivity to MEKi, suggesting that GBM patients with PTEN-null tumors may 
be uniquely sensitive to MEKi. 
Activation of bypass pathways promote resistance to single agent kinase 
inhibitors 
There is extensive cross talk between the PI3K and MAPK pathways.53  We and 
others have found that pharmacologic inhibition of either PI3K or MAPK signaling 
induces compensatory activation of the alternate arm of RTK signaling (Figs 4.1, 
4.3).34,37,54  We expanded these findings here by demonstrating that Pten deletion 
potentiated MEKi-induced MAPK inhibition, while mutant Kras enhanced MEKi-induced 
PI3K activation (Fig 4.3).  In contrast, we found that Pten/Kras mutation status did not 
influence PI3Ki-induced signaling changes, suggesting that they are intrinsic to 
astrocyte biology (Fig 4.1).  However, the specific PI3K/MAPK mutations and cellular 
origin may influence the signaling changes characterized here.  Future work will be 
required to investigate how cellular origin and additional PI3K/MAPK pathway mutations 
interact to impact the dynamic kinome response to PI3Ki/MEKi. 
We and others have shown that cooperativity between PI3K and MAPK signaling 
is important for glioma stem cell biology and tumorigenicity.19,23,37  Moreover, PI3K and 
MAPK are reciprocal bypass pathways that promote resistance to inhibition of either 
pathway alone.34,37,54  We expanded these results here by determining how Pten/Kras 
mutations affect PI3Ki/MEKi synergism in vitro.  Pten deletion and/or mutant Kras 
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increased the concentration range in which buparlisib/selumetinib were synergistic (Fig 
4.5A).  We also found that increased MEKi potency (trametinib vs. selumetinib) 
expanded the range of synergistic concentrations for both PI3Ki and MEKi in all four 
genotypes.  Moreover, the effects of Pten/Kras mutation status on synergism were 
blunted with dual trametinib/buparlisib treatment (Fig 4.5B).  Taken together, these 
results suggest that both MEKi potency and Pten/Kras mutation status interact to 
influence PI3Ki/MEKi synergism. 
Conclusion 
Defining mechanisms of drug resistance and characterizing predictive 
biomarkers in preclinical studies may aid in the design and use of rational drug 
combinations in GBM patients likely to respond.  Here we used a series of nGEM 
models to determine the influence of Pten deletion and mutant Kras on response to 
single agent and combination treatments with PI3Ki and MEKi in vitro.  These results 
indicate that PI3Ki/MEKi single agent efficacy and synergism are influenced by drug 
potency and PI3K/MAPK mutations.  Moreover, our results demonstrate how mutations 
in cooperating pathways interact to enhance efficacy of single agent PI3Ki/mTORi, 
suggesting that prospective screening for multiple mutations may be necessary to 
accurately predict drug efficacy.  
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Figures and Tables 
 
Figure 4.1.  Buparlisib inhibits PI3K signaling and induces MAPK signaling 
regardless of Pten/Kras mutation status.  Immunoblots (A) of the T(RP) astrocyte 
series 24 h after buparlisib treatment showed that buparlisib caused dose-dependent 
decreases in proximal (p-AKT) and distal (p-S6) PI3K (B), and increases in MAPK (p-
Erk1/2) (C) signaling regardless of Pten/Kras mutation status. 
.  
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Figure 4.2.  PI3Ki efficacy is influenced by Pten/Kras mutation status.  Multiple 
PI3Ki reduced growth of the T(RP) astrocyte series (R2≥0.99) (A), and both drug 
potency and Pten/Kras mutation status influenced IC50 (B) and GI50 (C) (ANOVA, 
P<0.0001).  P≤0.003 for all PI3Ki IC50/GI50 in T vs. TP, TR, or TRP.  P≤0.001 for LY 
IC50/GI50 in TR vs. TRP.  P≤0.001 for dactolisib IC50/GI50 in TP/TR vs. TRP.  IC50/GI50 
fold decreases for T(RP) relative to T astrocytes are shown as heatmaps.  
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Figure 4.3.  MEKi-induced MAPK inhibition and PI3K activation is influenced by 
Pten/Kras mutation status.  Immunoblots (A) of the T(RP) astrocyte series 24 h after 
selumetinib treatment showed that selumetinib inhibited MAPK signaling at lower 
concentrations in Pten-null (TP, TRP) astrocytes (B).  They also showed that 
selumetinib-induced alternate activation of proximal, but not distal, PI3K signaling was 
most pronounced in Kras mutant (TR and TRP) astrocytes (C).  
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Figure 4.4.  MEKi efficacy is increased by Pten deletion.  Multiple MEKi reduced 
growth of the T(RP) astrocyte series (R2≥0.93) (A), and both drug potency and 
Pten/Kras mutation status influenced IC50 (B) and GI50 (C) (ANOVA, P<0.0001).  P≤0.03 
for all MEKi IC50/GI50 in T vs. TP and TRP, and TR vs. TRP.  P≤0.002 for 
PD01/trametinib GI50 in T vs. TR.  P≤0.04 for PD01 IC50/GI50 and selumetinib GI50 in TP 
vs. TRP.  IC50/GI50 fold decreases for T(RP) relative to T astrocytes are shown as 
heatmaps.
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Figure 4.5.  PI3Ki/MEKi synergism is influenced by Pten/Kras mutation status and drug potency.  
Buparlisib/selumetinib treatment reduced growth of the T(RP) astrocyte series (R2≥0.97) and were synergistic at ≥7.5x 
lower concentrations in TP, TR, and TRP compared to T astrocytes (A).  Buparlisib/trametinib treatment reduced growth of 
T(RP) astrocytes (R2≥0.99) (B).  The concentration ranges in which PI3Ki and MEKi were synergistic was increased when 
the more potent MEKi trametinib was used, but the effects of Pten/Kras mutation status on PI3Ki/MEKi synergism were 
blunted.  Combination index (CI) and corresponding fraction affected (FA) for synergistic PI3Ki/MEKi concentrations in the 
T(RP) astrocyte series are shown as heatmaps. 
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Figure S4.1.  The PI3Ki buparlisib ablates PI3K signaling within 4 h post-
treatment.  Immunoblots performed on the T(RP) astrocyte series 4 h after buparlisib 
(A) showed dose-dependent decreases in proximal (p-Akt) and distal (p-S6) PI3K 
signaling (B) and little to no increases in MAPK signaling (p-Erk1/2) (C).  These results, 
in combination with those in Fig 4.1, demonstrated that the dynamic changes in PI3K 
inhibition and alternate activation of MAPK signaling was independent of Pten/Kras 
mutation status.
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Figure S4.2.  In vitro efficacy of PI3Ki, MEKi, and mTORi in T(RP) astrocytes.  Summary of data from Figures 4.2, 
4.4, and S4.3. N represents replicate biologic experiments. 
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Figure S4.3.  mTORi sensitivity is increased in triple mutant TRP astrocytes.  
Temsirolimus reduced growth of the T(RP) astrocyte series (R2≥0.74) (A).  Only triple 
mutant TRP astrocytes had a significantly lower IC50 compared to T astrocytes (*, 
P=0.02) (B). TRP also had a significantly lower GI50 compared to TP and TR astrocytes 
(*, P≤0.0003) (C).  GI50 of temsirolimus could not be calculated in T astrocytes (NA, not 
applicable).  IC50 fold decreases for the T(RP) astrocyte series relative to T astrocytes 
and GI50 fold decreases for T(RP) relative to TR astrocytes are shown as heatmaps. 
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Figure S4.4.  MEKi ablates MAPK signaling and induces alternate activation of 
proximal PI3K signaling.  Immunoblots (A) performed on the T(RP) astrocyte series 4 
h after selumetinib treatment showed dose-dependent decreases in MAPK signaling in 
all four T(RP) genotypes (B) and modest alternate activation of proximal, but not distal 
PI3K signaling in T, TR, and TRP astrocytes (C).  These results, in combination with 
those in Fig 4.3, demonstrated that alternate activation of PI3K begins shortly after 
treatment (within 4 h) and increases over time (24 h). 
  
158 
REFERENCES 
1. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization 
classification of tumors of the central nervous system: a summary. Acta 
Neuropathol. 2016;131(6):803-820. 
2. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, et al. 
Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N 
Engl J Med. 2015;372(26):2481-2498. 
3. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of 
glioblastoma. Cell. 2013;155(2):462-477. 
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO classification of 
tumours of the central nervous system. 4th ed. Lyon: IARC; 2007. WHO 
Classification of Tumours. 
5. Miller CR, Perry A. Glioblastoma. Arch Pathol Lab Med. 2007;131(3):397-406. 
6. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and 
adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. 
7. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis 
identifies clinically relevant subtypes of glioblastoma characterized by 
abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-
110. 
8. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, 
modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7-24. 
9. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A. Proliferation of human 
malignant astrocytomas is dependent on Ras activation. Oncogene. 
1997;15(23):2755-2765. 
10. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S, Wesseling P. 
RAS/RAF pathway activation in gliomas: the result of copy number gains rather 
than activating mutations. Acta Neuropathol. 2007;114(2):121-133. 
11. Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the point of inhibition: a 
comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther. 
2014;13(5):1021-1031. 
12. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein 
kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291-3310. 
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 
2011;144(5):646-674. 
159 
14. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates 
regulate diverse cellular functions. Growth Factors. 2006;24(1):21-44. 
15. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular 
pathology to targeted treatment. Annu Rev Pathol. 2014;9:1-25. 
16. McNeill RS, Vitucci M, Wu J, Miller CR. Contemporary murine models in 
preclinical astrocytoma drug development. Neuro Oncol. 2015;17(1):12-28. 
17. Prados MD, Byron SA, Tran NL, et al. Toward precision medicine in 
glioblastoma: the promise and the challenges. Neuro Oncol. 2015;17(8):1051-
1063. 
18. Akhavan D, Cloughesy TF, Mischel PS. mTOR signaling in glioblastoma: lessons 
learned from bench to bedside. Neuro Oncol. 2010;12(8):882-889. 
19. Schmid RS, Simon JM, Vitucci M, et al. Core pathway mutations induce de-
differentiation of murine astrocytes into glioblastoma stem cells that are sensitive 
to radiation but resistant to temozolomide. Neuro Oncol. 2016;18(7):962-973. 
20. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC. Ink4a-
Arf loss cooperates with KRas activation in astrocytes and neural progenitors to 
generate glioblastomas of various morphologies depending on activated Akt. 
Cancer Res. 2002;62(19):5551-5558. 
21. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway 
activation converts anaplastic astrocytoma to glioblastoma multiforme in a human 
astrocyte model of glioma. Cancer Res. 2001;61(18):6674-6678. 
22. Chow LM, Endersby R, Zhu X, et al. Cooperativity within and among Pten, p53, 
and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 
2011;19(3):305-316. 
23. Vitucci M, Karpinich NO, Bash RE, et al. Cooperativity between MAPK and PI3K 
signaling activation is required for glioblastoma pathogenesis. Neuro Oncol. 
2013;15(10):1317-1329. 
24. McNeill RS, Canoutas DA, Stuhlmiller TJ, et al. Combination therapy with potent 
PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single 
agents in preclinical models of glioblastoma. Neuro Oncol. 2017. 
doi:10.1093/neuonc/nox044. 
25. McNeill RS, Schmid RS, Bash RE, et al. Modeling astrocytoma pathogenesis in 
vitro and in vivo using cortical astrocytes or neural stem cells from conditional, 
genetically engineered mice. J Vis Exp. 2014(90):e51763. 
160 
26. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and 
progression using conditional expression of oncogenic K-ras. Genes Dev. 
2001;15(24):3243-3248. 
27. Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T. Astrocyte inactivation of the 
pRb pathway predisposes mice to malignant astrocytoma development that is 
accelerated by PTEN mutation. Cancer Cell. 2002;1(2):157-168. 
28. Xiao A, Yin C, Yang C, Di Cristofano A, Pandolfi PP, Van Dyke T. Somatic 
induction of Pten loss in a preclinical astrocytoma model reveals major roles in 
disease progression and avenues for target discovery and validation. Cancer 
Res. 2005;65(12):5172-5180. 
29. Reinhold WC, Sunshine M, Liu H, et al. CellMiner: a web-based suite of genomic 
and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell 
line set. Cancer Res. 2012;72(14):3499-3511. 
30. Pawaskar DK, Straubinger RM, Fetterly GJ, Ma WW, Jusko WJ. Interactions of 
everolimus and sorafenib in pancreatic cancer cells. AAPS J. 2013;15(1):78-84. 
31. Chou TC. Drug combination studies and their synergy quantification using the 
Chou-Talalay method. Cancer Res. 2010;70(2):440-446. 
32. Huszthy PC, Daphu I, Niclou SP, et al. In vivo models of primary brain tumors: 
pitfalls and perspectives. Neuro Oncol. 2012;14(8):979-993. 
33. Schmid RS, Vitucci M, Miller CR. Genetically engineered mouse models of 
diffuse gliomas. Brain Res Bull. 2012;88(1):72-79. 
34. See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO. Sensitivity of 
glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 
deficiency. Cancer Res. 2012;72(13):3350-3359. 
35. Turke AB, Song Y, Costa C, et al. MEK inhibition leads to PI3K/AKT activation by 
relieving a negative feedback on ERBB receptors. Cancer Res. 
2012;72(13):3228-3237. 
36. Hoeflich KP, O'Brien C, Boyd Z, et al. In vivo antitumor activity of MEK and 
phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin 
Cancer Res. 2009;15(14):4649-4664. 
37. Sunayama J, Matsuda K, Sato A, et al. Crosstalk between the PI3K/mTOR and 
MEK/ERK pathways involved in the maintenance of self-renewal and 
tumorigenicity of glioblastoma stem-like cells. Stem Cells. 2010;28(11):1930-
1939. 
161 
38. Yoshida T, Kakegawa J, Yamaguchi T, et al. Identification and characterization of 
a novel chemotype MEK inhibitor able to alter the phosphorylation state of 
MEK1/2. Oncotarget. 2012;3(12):1533-1545. 
39. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 
(AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 
inhibitor. Clin Cancer Res. 2007;13(5):1576-1583. 
40. Sebolt-Leopold JS, Merriman R, Omer C, et al. The biological profile of PD 
0325901: A second generation analog of CI-1040 with improved pharmaceutical 
potential [abstract]. Cancer Research. 2004;64(7 Supplement):925. 
41. Cancer Genome Atlas Research Network. Comprehensive genomic 
characterization defines human glioblastoma genes and core pathways. Nature. 
2008;455(7216):1061-1068. 
42. Koul D, Fu J, Shen R, et al. Antitumor activity of NVP-BKM120--a selective pan 
class I PI3 kinase inhibitor showed differential forms of cell death based on p53 
status of glioma cells. Clin Cancer Res. 2012;18(1):184-195. 
43. Yang L, Clarke MJ, Carlson BL, et al. PTEN loss does not predict for response to 
RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin 
Cancer Res. 2008;14(12):3993-4001. 
44. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse 
models in cancer drug development. Nat Rev Drug Discov. 2006;5(9):741-754. 
45. Herter-Sprie GS, Kung AL, Wong KK. New cast for a new era: preclinical cancer 
drug development revisited. J Clin Invest. 2013;123(9):3639-3645. 
46. Meric-Bernstam F, Akcakanat A, Chen H, et al. PIK3CA/PTEN mutations and Akt 
activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer 
Res. 2012;18(6):1777-1789. 
47. Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of 
function, determines the sensitivity of breast cancer cells to mTOR inhibitory 
drugs. Oncogene. 2011;30(29):3222-3233. 
48. Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O. PTEN deficiency 
is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer 
through the unhampered feedback loop driving PI3K/Akt activation. Br J Cancer. 
2013;109(6):1586-1592. 
49. Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S. 
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro 
and in vivo and synergizes with temozolomide to increase orthotopic xenograft 
survival. Clin Cancer Res. 2014;20(22):5756-5767. 
162 
50. Spoerke JM, O'Brien C, Huw L, et al. Phosphoinositide 3-kinase (PI3K) pathway 
alterations are associated with histologic subtypes and are predictive of 
sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res. 
2012;18(24):6771-6783. 
51. Sangai T, Akcakanat A, Chen H, et al. Biomarkers of response to Akt inhibitor 
MK-2206 in breast cancer. Clin Cancer Res. 2012;18(20):5816-5828. 
52. Ebbesen SH, Scaltriti M, Bialucha CU, et al. Pten loss promotes MAPK pathway 
dependency in HER2/neu breast carcinomas. Proc Natl Acad Sci U S A. 
2016;113(11):3030-3035. 
53. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-
talk and compensation. Trends Biochem Sci. 2011;36(6):320-328. 
54. El Meskini R, Iacovelli AJ, Kulaga A, et al. A preclinical orthotopic model for 
glioblastoma recapitulates key features of human tumors and demonstrates 
sensitivity to a combination of MEK and PI3K pathway inhibitors. Dis Model 
Mech. 2015;8(1):45-56. 
  
163 
 
CHAPTER V: PIK3CA MISSENSE MUTATIONS PROMOTE GLIOBLASTOMA 
PATHOGENESIS, BUT DO NOT ENHANCE PI3K INHIBITOR EFFICACY 
 
Introduction 
Glioblastoma (GBM) is the most common malignant primary brain tumor in 
adults.  It is also the most aggressive, with a median survival of only 12-15 months.1-3  
The molecular heterogeneity of GBM has been extensively characterized in order to 
better understand the biology of this devastating disease.4-6  The vast majority of GBM 
arise de novo and harbor frequent mutations in three “core” signaling pathways: RB, 
TP53, and receptor tyrosine kinase (RTK)/mitogen activated protein kinase 
(MAPK)/phosphoinositide 3-kinase (PI3K).  GBM can be stratified into four molecular 
subtypes based on gene expression.  However, this knowledge has yet to impact GBM 
standard-of-care.  First line therapy consists of surgical resection followed by radiation 
with concurrent and adjuvant temozolomide, a DNA damaging chemotherapeutic.3  
Clinical investigations of inhibitors targeting the pathways frequently mutated in GBM 
have had disappointing results for a variety of reasons, including drug resistance and 
inclusion of genetically heterogeneous patients.7,8  Preclinical modeling can aid in the 
development of novel therapies by defining whether mutations associated with GBM 
drive disease pathogenesis and are predictive of drug response. 
 The PI3K pathway promotes many cancer hallmarks, including survival, 
proliferation, and migration.9-11  PI3K is a heterodimeric lipid kinase composed of a 
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catalytic and regulatory subunit encoded by genes such as PIK3CA and PIK3R1 
respectively.12  Pathway activation is mediated by the conversion of PIP2 to PIP3 by the 
catalytic subunit of PI3K, resulting in recruitment and activation of effector proteins, 
including AKT.  PI3K signaling is antagonized by the tumor suppressor PTEN.12  PI3K 
signaling is an attractive therapeutic target in GBM because mutually exclusive 
mutations in PIK3CA, PIK3R1, and PTEN occur in 46% of pateints.13-15 
Activation of PI3K signaling via Pten deletion, PIK3R1 mutations, or constitutively 
active AKT promotes tumorigenesis in multiple preclinical GBM models.16-21  For 
example, we found that Pten deletion cooperates with mutant Kras in immortalized 
mouse astrocytes to activate PI3K signaling and potentiate malignant progression.17,22  
Similarly, in cultured normal human astrocytes that were immortalized by expression of 
the HPV oncogenes E6 and E7 to inhibit the TP53 and RB pathways respectively, and 
by expression of hTERT to maintain telomere length (NHA), constitutively active AKT 
cooperated with mutant RAS (NHARAS) to promote gliomagenesis.20,23  However, the 
role of PIK3CA mutations in gliomagenesis has not been experimentally investigated. 
 PIK3CA is altered in 10% of GBM, mostly via missense mutations.4,13,14  These 
missense mutations are generally restricted to three of its functional protein domains 
(adaptor binding (ABD), helical, and kinase) and are predicted to activate PI3K signaling 
via distinct mechanisms.24  Some PIK3CA missense mutations that occur in GBM 
promote tumorigenesis in non-brain tissues, particularly the most prevalent E542K and 
E545K helical mutations, and H1047R kinase mutation.25-27  However, their role in 
gliomagenesis has yet to be determined.  Here we used NHA with and without mutant 
RAS to define the role of PIK3CA missense mutations in GBM pathogenesis.  
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Furthermore, we determined if PIK3CA missense mutations influenced response to 
single agent and combination treatments with PI3K/MEK inhibitors in order to elucidate 
the utility of PIK3CA mutation status as a predictive biomarker. 
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Materials and Methods 
PIK3CA mutagenesis.  Third generation lentiviral gateway destination vector (pLenti-
PGK-Hygro-DEST, #19066), pENTR4 vector (pENTR4-no-ccDB, #17424), 
hemagglutinin (HA)-tagged wild-type (WT) PIK3CA (PIK3CAWT, pBabe-puro-
HAPIK3CA, #12522), and HA-tagged GFP (GFP, pDEST-Flag-HA-GFP, #22612) 
plasmids were purchased from Addgene (Cambridge, MA).  PIK3CAWT was excised 
from the pBabe backbone by sequential restriction digests with SalI and BamHI (New 
England BioLabs, Ipswich, MA).  The pENTR4 vector was digested with BamHI and 
EcoRV, then PIK3CAWT was inserted into this vector by ligation.  Alternatively, both 
pDEST-Flag-HA-GFP and pENTR4 vectors were digested with NcoI and EcoRI (New 
England BioLabs) followed by insertion of GFP into the pENTR4 vector by ligation.  Six 
PIK3CA missense mutations (PIK3CAmut: R88Q, C90Y, E542K, E545K, M1043V, or 
H1047R) were generated by point mutagenesis of PIK3CAWT within the pENTR4 vector 
using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs) according to 
manufacturer’s instructions.  GFP, PIK3CAWT, and the PIK3CAmut genes were 
transferred from their pENTR4 vectors to pLenti-PGK-Hygro-DEST vectors by 
recombination as previously described.28  Subsequent point mutagenesis of PIK3CAWT- 
and PIK3CAmut-pLenti-PGK-Hygro-DEST vectors were performed using the Q5 Site-
Directed Mutagenesis Kit to substitute an adenine to a guanine within an upstream ATG 
start codon in the NcoI restriction site from the pENTR4 vector.  All point mutations were 
confirmed by Sanger sequencing (Genewiz, South Plainfield, NJ). 
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Lentivirus production.  Lentiviral particles encoding GFP, PIK3CAWT, or individual 
PIK3CAmut were generated using 293FT cells (Invitrogen, Grand Island, NY) according 
to manufacturer’s instructions.  Briefly, 5 x 105 cells were plated on 10 cm tissue culture 
plates in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS, 
1% Penn/Strep, 2 mM GlutaMAX (Invitrogen), 0.1 mM MEM Non-Essential Amino Acids 
(Invitrogen), and 1 mM sodium pyruvate (Invitrogen) (293FT media).  The next day 
medium was replaced with fresh 293FT medium without penicillin/streptomycin, and 9 
μg GFP-, PIK3CAwt-, or PIK3CAmut-pDEST, plus 9 μg pMDL/pRRE (Addgene, #12251), 
3.6 μg pRSV-Rev (Addgene, #12253), and 1.89 μg pMD2.G (Addgene, #12259) 
plasmids were transfected into these cells using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s instructions.  Medium was exchanged for new 293FT 
medium supplemented with 1 M HEPES (Invitrogen) after 24 hours.  Supernatants 
containing lentiviruses were collected and fresh 293FT medium supplemented with 1M 
HEPES was added to cells 48 h and 72 h post-transfection.  Viral supernatants from 
each time point were filtered through a 45 μm PES filter, and stored at 4 ºC until all time 
points could be pooled, aliquoted, and stored at -80 ºC. 
Cell culture.  NHA and NHARAS lines were a kind gift from Dr. Russell O. Pieper.9  All 
cells were maintained as adherent cultures at 37 ºC and 5% CO2 in DMEM 
supplemented with 5% FBS and 1% penicillin/streptomycin (complete DMEM).  All in 
vitro experiments were performed in DMEM supplemented with 2.5% FBS and 1% 
penicillin/streptomycin (low serum medium) unless otherwise stated.  To create NHA 
and NHARAS lines expressing GFP, PIK3CAWT, or PIK3CAmut, 135,000 and 120,000 
cells respectively were plated on 60 cm2 tissue culture plates.  Lentiviral vectors were 
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added two days after plating, and then incubated with the cells overnight in complete 
DMEM containing 8 μg/ml polybrene (Sigma-Aldrich, St. Louis, MO) at 37ºC and 5% 
CO2.  Two days post-infection, transduced cells were selected by culture in complete 
DMEM supplemented with 300 μg/ml hygromycin B (Gold Biotechnology, St. Louis, MO) 
for 14 days.  Stable gene expression was confirmed by immunoblot for the HA tag on 
PIK3CAwt and PIK3CAmut. 
Drugs.  The PI3K inhibitor (PI3Ki) buparlisib (BKM120) and the MEK inhibitor (MEKi) 
selumetinib (AZD6244) were purchased from MedChem Express and Chemietek 
(Indianapolis, IN) and dissolved in dimethyl sulfoxide (DMSO). 
Immunoblots.  Control (parental, GFP, and PIK3CAWT) and PIK3CAmut NHA and 
NHARAS were plated on 60 or 100 cm2 tissue culture plates.  At ~60% confluence, cells 
were washed with Hank’s Balance Salt Solution (HBSS), then serum-starved in DMEM 
supplemented with 0.5% FBS and 1% penicillin/streptomycin.  Alternatively, cells were 
washed with HBSS, low serum medium was added, and then cells were treated with 
vehicle control (DMSO), buparlisib, or selumetinib.  Twenty-four h after serum starvation 
or drug treatment, cells were mechanically harvested and snap frozen.  Cell pellets 
were lysed, and protein concentration was quantified using Pierce BCA Protein Assay 
Kit (Thermo Scientific, Waltham, MA) according to manufacturer’s instructions.  
Immunoblots were performed as previously described.22  Briefly, protein samples (20 
μg) were separated by gradient (4-15% or 8-16%) gel electrophoresis (SDS-PAGE, Bio-
Rad, Hercules, CA) and transferred to PDVF membranes (EMD Millipore Corp, Billerica, 
MA).  Membranes were probed with primary antibodies against GAPDH (EMD Millipore 
Corp, Billerica, MA, MAB374), AKT (#2920S), phospho (p)AKT (Ser473, #4060), pS6 
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(Ser240/244, #2215), ERK1/2 (#4696), or pERK1/2 (Thr202/Tyr204, #4370) all from 
Cell Signaling Technology (Danvers, MA).  Blots were then probed with species specific 
Alexa 488, 555, or 647 conjugated secondary antibodies (Life Technologies, Grand 
Island, NY) and imaged on a Typhoon Trio (GE Healthcare, Pittsburgh, PA).  
Alternatively, membranes were probed with an anti-HA-peroxidase antibody (Roche 
Applied Science, Penzberg, Germany, #12013819001) and imaged using enhanced 
chemiluminescence (Clarity Western ECL Substrate, Bio-Rad) on an Image Quant LAS 
4000 (GE Healthcare).  Band intensities were quantified using ImageJ (NIH, Bethesda, 
MD).  Phospho-proteins were normalized to their respective total protein or GAPDH.  
Normalized band intensities from serum-starved immunoblots were set relative to an 
external standard and then normalized to parental and PIK3CAWT cells.  Normalized 
band intensities from drug-treated samples were set relative to vehicle control cells.  
Differences between groups were determined by one-way ANOVA.  Pairwise 
comparisons were performed by unpaired t-tests. 
Cell growth.  NHA and NHARAS lines were plated in triplicate or quadruplicate in 96-well 
tissue culture plates at 1000 cells/well and 675 cells/well respectively.  Changes in 
absorbance (cell growth) was assessed using CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay (MTS, Promega, Madison, WI) according to manufacturer’s 
instructions.  Briefly, absorbance at 490 nm was measured daily for 4-5 days using an 
Emax 96-well plate reader (Molecular Devices, Chicago, IL) equipped with SoftMax Pro 
5 software.  Absorbance of experimental samples were subtracted by baseline 
absorbance (low serum media + MTS), then set relative to day 0.  Data (mean ± SEM) 
from 2-4 independent experiments (mean=3) were fit to an exponential growth equation 
170 
and the rate constant k and doubling time [ln(2)/k] were calculated.  Differences in 
growth rates (k) were compared using the extra-sum-of-squares F test. 
Cell migration.  Migration rate across a cell-free gap was determined using culture 
inserts (Ibidi, Munich, Germany) according to manufacturer’s instructions.  Briefly, 
inserts were attached to individual wells of a 6-well tissue culture plate.  Twenty-six 
thousand cells were seeded into each well of the insert and allowed to adhere 
overnight.  The following morning inserts were lifted to create a cell free gap that was 
imaged at 3 non-overlapping locations every 2 hours for 12 hours using a VistaVision 
inverted microscope (Model #82026-630, VWR, Radnor, PA) equipped with a DV-300 
digital camera.  The area of the gap between the cell fronts was analyzed using ImageJ 
(NIH).  Gap area was normalized to time 0 at each image location, and data from hours 
2-12 were fit to a linear regression equation to calculate and compare rates of gap 
closure. 
Colony formation in soft agar.  Colony formation was determined in 6-well tissue 
cultured treated plates as previously described with minor modifications.23,29  Briefly, a 
base layer of a low serum DMEM/0.5% low melting temperature agarose (Denville 
Scientific INC., Holliston, MA) mixture was added to each well and allowed to solidify.  
Cells were harvested by trypsinization, placed in a mixture of low serum DMEM/0.35% 
low melting temperature agarose, and plated (14,000 per well) in duplicate or triplicate.  
Cells were maintained at 37 ºC and 5% CO2 for 4 weeks, then fixed and stained with 
0.005% crystal violet in 70% ethanol for ≥1 hr.  Wells were washed with PBS, and 
colonies were imaged on a Typhoon Trio (GE Healthcare).  Colonies ≥ 30 μm2 were 
automatically counted using ImageJ (NIH).  Mean (± SEM) colonies per well was 
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calculated from 2 independent experiments and data were compared using unpaired t-
tests. 
Orthotopic xenografts.  Control and PIK3CAmut NHARAS lines were harvested by 
trypsinization, counted, and suspended in serum free DMEM with 5% methyl cellulose.  
Adult athymic nude mice (mean ~3 months) were anesthetized with Avertin (250 mg/kg) 
and 2 x 105 GFP, PIK3CAWT, PIK3CAR88Q, PIK3CAE542K, or PIK3CAH1047R NHARAS cells 
were injected the right basal ganglia of mice (N=5-10 per group, mean=9) using the 
coordinates 1, -2, and -4 mm (A, L, D) from bregma as previously described.22  Animals 
were monitored for the onset of neurological symptoms and were then sacrificed.  
Survival was determined by Kaplan-Meier analyses and was compared by log-rank 
tests.  The UNC Institutional Animal Care and Use Committee approved all animal 
studies (protocol # 16-112). 
Drug response.  Dose response assays were performed as previously described.22  
Briefly, cells were plated in triplicate in 96-well plates and maintained at 37˚C and 5% 
CO2.  The following day they were treated with vehicle control (DMSO) or increasing 
concentrations of buparlisib and/or selumetinib.  Effects of drugs on cell growth was 
determined with CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS, 
Promega) according to manufacturer’s instructions.  Briefly, absorbance at 490 nm was 
measured 5 days post-treatment as described above.  Absorbance of experimental 
wells was subtracted by baseline absorbance and then set relative to vehicle control.  
Data (mean ± SEM) were pooled from 2-4 (mean=3) independent experiments and fit to 
a non-linear, log [inhibitor] versus response curves with variable slopes, and IC50 were 
calculated.  Differences in IC50 were compared using the extra-sum-of-squares F test. 
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Synergism between MEKi and PI3Ki was determined by the BLISS method in 
Combenefit v1.31.30 
Cell cycle.  Control and PIK3CAmut NHARAS were plated in 12-well tissue culture plates, 
and were treated with buparlisib or vehicle control the following day.  Cell cycle analysis 
was performed 2 days post-treatment on a Guava EasyCyte Plus using Guava Cell 
Cycle Reagent according to the manufacturer’s instructions (EMD Millipore, Billerica, 
MA).  Cell cycle distribution was determined using ModFit LT v3.2 (Verity, Topsham, 
ME).  Percent cells in G0/G1, S, and G2/M were calculated from one experiment. 
Statistics.  Statistical analyses were performed in GraphPad Prism (La Jolla, CA) 
unless otherwise stated.  P≤0.05 were considered significant.  Error bars are SEM 
unless otherwise stated. 
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Results 
 PIK3CA missense mutations frequently occur in GBM and are heterogeneously 
distributed across multiple of the encoded protein domains, particularly the ABD, helical, 
and kinase domains (Fig S5.1A).13,14  PTEN deletion or activating AKT mutations, 
cooperate with activated MAPK signaling to promote tumorigenesis in preclinical glioma 
models.17,20  However, the role of PIK3CA mutations in gliomagenesis has not been 
experimentally determined.  To this end, we selected the missense mutations that most 
frequently occur in the helical (E542K and E545K) and kinase (M1043V and H1047R) 
domains of PIK3CA in GBM, as well as other cancer types (Fig S5.1A-C).  Individual 
missense mutations in the ABD of PIK3CA are less prevalent in most cancers than the 
hotspot helical (E542K and E545K) and kinase (H1047R) domain mutations.  R88Q is 
generally the most common ABD mutation in PIK3CA-mutated cancers, and it is the 
only recurrent ABD mutation in GBM.  We therefore selected R88Q as well as one other 
ABD (C90Y) mutation to evaluate here.  We transduced NHA and NHARAS with lentiviral 
vectors encoding each individual PIK3CAmut.  Parental lines and those transduced with 
either GFP or PIK3CAWT were used as controls.  We then used these cells to define the 
role of PIK3CA missense mutations in both tumorigenesis and response to kinase 
inhibitors. 
PIK3CAmut increase PI3K signaling in vitro 
 Immunoblots showed that PIK3CAWT and all PIK3CAmut were expressed at 
similar levels in NHA and NHARAS (Fig S5.2), suggesting that any phenotypic 
differences are a consequence of the PIK3CA missense mutation.  Next, we performed 
immunoblots to determine whether these mutations activate PI3K signaling in serum-
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starved NHA.  Neither PIK3CAWT nor ABD PIK3CAmut significantly increased activation 
of proximal (pAKT) or distal (pS6) PI3K signaling (Fig 5.1A-C).  In contrast, helical and 
kinase PIK3CAmut induced proximal and distal PI3K signaling compared to parental and 
PIK3CAWT NHA respectively.  Moreover, E542K and H1047R PIK3CAmut increased 
proximal PI3K signaling more than PIK3CAWT. 
We previously found that mutant Kras cooperated with Pten deletion to activate 
PI3K signaling in immortalized mouse astrocytes.17  We therefore determined the 
effects of PIK3CAmut on PI3K signaling in NHARAS via immunoblots.  PIK3CAWT and all 
PIK3CAmut increased proximal PI3K signaling compared to parental NHARAS (Fig 
5.1DE).  Furthermore, helical and kinase PIK3CAmut potentiated proximal PI3K signaling 
more than PIK3CAWT.  However, distal PI3K signaling was only increased by the 
M1043V PIK3CAmut in NHARAS (Fig 5.1DF).  Taken together, these results suggest that 
mutant RAS cooperated with ectopic expression of both PIK3CAWT and PIK3CAmut to 
increase proximal PI3K signaling. 
 There is extensive cross-talk between the PI3K and MAPK pathways.31  We 
therefore determined the effects of the PIK3CAmut on MAPK signaling.  Neither 
PIK3CAWT nor any of the PIK3CAmut significantly altered MAPK (pERK1/2) signaling in 
NHA and NHARAS (Fig S5.3).  Thus, PIK3CA missense mutations activated PI3K 
signaling, without affecting the MAPK pathway. 
PIK3CAmut increase NHA proliferation in vitro 
 PIK3CAmut, particularly those in the helical and kinase domains, activated PI3K 
signaling, suggesting that they may also promote cell growth (Fig 5.1).  MTS assays at 
high-serum concentrations (10% FBS) showed that PIK3CAWT and a subset of 
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PIK3CAmut increased proliferation of NHA (Fig S5.4).  However, these changes were 
relatively minor (≤15%), and all lines were rapidly proliferating with doubling times ≤1 
day.  We therefore hypothesized that the growth factor concentration within the high-
serum media was masking the effects of the PIK3CAmut on NHA growth.  We therefore 
performed MTS assays in low-serum medium (2.5% FBS) in order to reduce the 
concentration of mitogenic growth factors.  Proliferation was increased in both GFP and 
PIK3CAWT NHA compared to parental cells (Figs 5.2A, S5.5A), indicating that lentiviral 
transduction and antibiotic selection caused enrichment for a more proliferative subset 
of cells.  Moreover, all PIK3CAmut, except C90Y, increased proliferation compared to 
parental and PIK3CAWT NHA.  In contrast, proliferation rates were similar in NHARAS 
lines, regardless of PIK3CAmut status (Figs 5.2B, S5.5B).  Taken together, these data 
suggest that PIK3CA missense mutations promote astrocyte growth in the absence of 
mutant RAS. 
PIK3CA mutations increase migration in vitro 
 Complete surgical resection of GBM is precluded by its diffuse infiltration of the 
brain.32  The PI3K pathway has an established role in migration.33  Indeed, we 
previously showed that Pten deletion increased migration of immortalized mouse 
astrocytes.17  We therefore determined the effects of PIK3CAmut on migration using a 
gap closure assay in vitro.  GFP, PIK3CAWT and all PIK3CAmut increased migration 
compared to parental NHA (Figs 5.2C, S5.5C).  These increases were greater in 
PIK3CAWT and all PIK3CAmut, except C90Y, than GFP NHA (P≤0.04).  Similarly, all 
PIK3CAmut, except C90Y, increased migration compared to GFP and parental NHARAS 
176 
(P≤0.006, Figs 5.2D, S5.5D).  Moreover, E542K and H1047R PIK3CAmut increased 
migration compared to PIK3CAWT in NHA and NHARAS (Fig 5.2CD). 
PIK3CA mutations potentiate tumorigenesis 
 Anchorage-independent growth is an established marker of cellular 
transformation.23,29  Mutant RAS promotes colony formation and tumorigenicity of 
NHA.23  To determine whether PIK3CAmut also promote anchorage independent growth 
of NHA, we selected the most potent PIK3CAmut per domain based on induction of 
proximal PI3K signaling, proliferation, and migration (Figs 5.1, 5.2).  We then assessed 
colony formation in soft agar.  PIK3CAWT, and both R88Q and E542K PIK3CAmut did not 
increase colony formation compared to GFP and parental NHA (Fig 5.3A).  In contrast, 
H1047R PIK3CAmut increased colony formation of NHA to an extent similar to mutant 
RAS.  Because H1047R was the only PIK3CAmut to potentiate colony formation of NHA, 
we also tested whether it potentiated colony formation of NHARAS.  However, no 
significant differences in colony formation between H1047R PIK3CAmut and parental 
NHARAS was evident (Fig 5.3A). 
 We next performed orthotopic xenografts of GFP, PIK3CAWT, and PIK3CAmut 
NHARAS lines to determine whether PIK3CAmut potentiate tumorigenesis in vivo.  All 
xenograft mice eventually succumbed to disease, but PIK3CAWT tended to decrease 
survival (P=0.08), while the R88Q PIK3CAmut significantly decreased survival compared 
to GFP controls (Fig 5.3BC).  E542K and H1047R PIK3CAmut were more potent and 
resulted in decreased survival compared to GFP, PIK3CAWT, and R88Q PIK3CAmut 
NHARAS (P≤0.0002).  Taken together, these results indicate that both the domain 
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mutated, and the presence of mutant RAS influence the role of PIK3CAmut in 
gliomagenesis in vitro and in vivo. 
PI3Ki efficacy is similar regardless of PIK3CAmut status 
 Cancer treatments are transitioning away from broadly cytotoxic chemotherapies 
towards precision medicine, in which the mutation profiles of patients are utilized to 
tailor treatment with targeted inhibitors.8,34  However, successful implementation of 
precision medicine requires knowing which oncogenic drivers influence response 
targeted inhibitors.  To this end, we determined to effects of PIK3CAmut on PI3Ki efficacy 
in vitro.  The PI3Ki buparlisib caused dose-dependent decreases in growth of control 
and PIK3CAmut NHA (Fig S5.6A), with high nanomolar IC50 regardless of PIK3CAmut 
status (Fig 5.4A).  Similar results were obtained with control and PIK3CAmut NHARAS, 
except that buparlisib IC50 tended to be slightly higher (Figs 5.4B, S5.6BC).  Moreover, 
buparlisib induced G2/M cell cycle arrest in NHARAS lines, regardless of PIK3CAmut 
status (Fig. S5.7). 
PI3Ki treatment ablates PI3K signaling and potentiates MAPK signaling 
 PIK3CAmut in NHA and NHARAS did not alter efficacy of PI3Ki in vitro (Fig 5.4AB).  
However, they differentially activated PI3K signaling (Fig 5.1).  We therefore 
investigated whether PIK3CAmut influence PI3Ki-induced changes in PI3K signaling by 
immunoblots.  Buparlisib caused dose-dependent decreases in proximal (Fig 5.4CD) 
and distal (Fig S5.8) PI3K signaling in control and PIK3CAmut NHA.  We and others 
have shown that PI3K inhibition induces alternate activation of MAPK signaling in 
preclinical GBM models.31,35  Immunoblots of NHA lines showed that buparlisib induced 
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dose-dependent increases in MAPK signaling, regardless of PIK3CAmut status (Fig 
5.4CE). 
 Mutant RAS cooperated with PIK3CAWT and PIK3CAmut to potentiate activation of 
proximal PI3K signaling (Fig 5.1).  We therefore performed immunoblots of buparlisib-
treated control and PIK3CAmut NHARAS to determine whether RAS status influences 
PI3Ki-induced changes in PI3K and MAPK signaling.  Buparlisib caused PI3K inhibition 
and dose-dependent increases in MAPK activation in control and PIK3CAmut NHARAS 
(Figs 5.4F-H, S5.8CD, S5.9).  Furthermore, inhibition of proximal PI3K signaling was 
least pronounced in the helical and kinase PIK3CAmut lines at the lowest buparlisib 
concentration.  These results demonstrate that a higher PI3Ki concentration is required 
to ablate PI3K signaling in the presence of activating PIK3CAmut in NHARAS.  
Furthermore, they indicate that PIK3CAmut status does not influence alternate activation 
of MAPK signaling. 
MEKi efficacy is similar in NHA regardless of PIK3CAmut 
 Because we found that PI3Ki promoted MAPK signaling regardless of 
PIK3CA/RAS mutation status, we determined efficacy of the MEKi selumetinib in control 
and PIK3CAmut NHA and NHARAS lines in vitro.  Selumetinib caused gradual, dose-
dependent decreases in growth (Fig S5.10AB).  PIK3CAmut status did not influence 
selumetinib IC50 in NHA (Fig 5.5A).  Selumetinib IC50 were also similar between 
parental NHA and NHARAS.  However, PIK3CAWT and all PIK3CAmut NHARAS, except 
C90Y and H1047R, had slightly higher selumetinib IC50 than parental cells (Figs 5.5B, 
S5.10C).  Thus, PIK3CA missense mutations and mutant RAS had little to no effect on 
MEKi sensitivity. 
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PIK3CAWT and PIK3CAmut influence MEKi-induced activation of PI3K signaling in 
NHARAS 
 We next performed immunoblots to confirm MAPK inhibition in control and 
PIK3CAmut NHA treated with selumetinib (Fig 5.5C).  Selumetinib induced dose-
dependent decreases in pERK, regardless of PIK3CAmut status (Fig 5.5CD).  We and 
others have shown that MEKi induced alternate activation of PI3K signaling in 
preclinical GBM models.31,36,37  We extended these findings here by demonstrating that 
selumetinib potentiated proximal PI3K signaling by 1.4-5 fold in control and PIK3CAmut 
NHA (Fig 5.5CE).  Interestingly, this induction was least pronounced in E542K and 
H1047R PIK3CAmut NHA. 
 Mutant RAS cooperated with PIK3CAWT and PIK3CAmut to promote activation of 
proximal PI3K signaling (Fig 5.1).  We therefore investigated whether PIK3CAmut 
influence MEKi-induced changes in MAPK and PI3K signaling in NHARAS.  PIK3CAmut 
status did not affect MAPK inhibition in selumetinib treated NHARAS lines (Fig 5.5FG, 
S5.11AB).  Similar to NHA, selumetinib caused alternate activation of proximal PI3K 
signaling in GFP and parental NHARAS (Fig 5.5FH, S5.11AC).  However, induction of 
proximal PI3K signaling was ablated in PI3KCAWT and all PIK3CAmut NHARAS.  Taken 
together, these results indicate that ectopic expression of PIK3CA in combination with 
mutant RAS prevents MEKi-induced alternate activation of the PI3K pathway. 
Dual PI3Ki/MEKi treatment is synergistic in control and PIK3CAmut NHA and 
NHARAS 
We and others have shown that efficacy of PI3Ki/MEKi is increased by dual 
treatment.31,35-37  However, the effects of GBM-associated mutations on PI3Ki/MEKi 
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synergism remain unclear.  To this end, we determined whether PIK3CAmut influence 
the effects of dual PI3Ki/MEKi treatment on growth of NHA in vitro.  Treatment with 
buparlisib/selumetinib inhibited growth and functioned synergistically in control and 
PIK3CAmut NHA (Fig 5.6A).  Moreover, synergy was greatest in R88Q and E542K 
PIK3CAmut NHA compared to PIK3CAWT and H1047R PIK3CAmut lines. 
 PIK3CAWT and PIK3CAmut in NHARAS marginally decreased efficacy of MEKi 
(Figs 5.5B, S5.10BC).  They also cooperated with mutant RAS to prevent MEKi-
induced potentiation of proximal PI3K signaling (Figs 5.5F-H, S5.11).  Therefore, 
PIK3CAWT and PIK3CAmut in combination with mutant RAS may alter PI3Ki/MEKi 
synergism.  Dual buparlisib/selumetinib treatment inhibited growth of all NHARAS lines 
and functioned synergistically (Figs 5.6B).  However, synergism between buparlisib and 
selumetinib was most pronounced at higher concentrations of both drugs in NHARAS 
lines compared to NHA.  Furthermore, buparlisib/selumetinib synergy was greatest in 
R88Q and E542K PIK3CAmut NHARAS.  Taken together, these data suggest that mutant 
RAS and PIK3CAmut alter synergism between PI3Ki/MEKi. 
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Discussion 
PIK3CAmut differentially activate PI3K signaling and promote gliomagenesis 
 The vast majority of GBM harbor mutations in core PI3K pathway genes and/or 
upstream RTK.4  Activation of PI3K signaling via Pten deletion, PIK3R1 mutations, or 
constitutively active AKT mutants, promotes tumorigenesis in glioma models.17-20  Here, 
we determined the effects of ABD, helical, and kinase PIK3CA missense mutations on 
gliomagenesis.  Both helical and kinase PIK3CAmut potentiated PI3K signaling, 
proliferation, and migration of NHA compared to parental and PIK3CAWT lines (Figs 5.1, 
5.2).  In contrast, only the H1047R kinase PIK3CAmut potentiated colony formation of 
NHA (Fig 5.3A).  Similarly, H1047R PIK3CAmut induced tumors with a shorter latency 
than the E545K helical mutation in a mammary carcinoma model.38 
 We and others have shown that Pten deletion and constitutively active AKT 
cooperates with activated MAPK signaling to potentiate PI3K signaling and 
gliomagenesis.17,20-22  We extended these finding here by demonstrating that mutant 
RAS promoted PIK3CAWT- and PIK3CAmut-induced proximal PI3K signaling (Fig 5.1).  
Unlike in NHA, PIK3CAmut did not increase proliferation of NHARAS, likely due to the 
rapid proliferation rate of parental cells (Fig 5.2AB).  H1047R PIK3CAmut also did not 
potentiate colony formation of NHARAS (Fig 5.3A).  However, compared to GFP 
andPIK3CAWT, the E542K and H1047R PIK3CAmut potentiated malignancy of NHARAS in 
vivo (Fig 5.3BC).  These results are consistent with the previous findings that 
constitutively active AKT does not enhance proliferation or colony formation of NHARAS 
in vitro, but promoted tumorigenesis in vivo.20  Taken together, these data suggest that 
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the E542K and H1047R PIK3CAmut equally promote gliomagenesis in the presence of 
mutant RAS, but not in its absence. 
 In contrast to helical and kinase PIK3CA mutations, ABD PIK3CAmut did not 
increase PI3K signaling, migration, or colony formation of NHA more than PIK3CAWT 
(Figs 5.1-3).  Similar results were obtained with ABD PIK3CAmut in NHARAS.  Moreover, 
R88Q PIK3CAmut did not promote malignancy of NHARAS more than PIK3CAWT in vivo 
(Fig 5.3BC).  Taken together, these results demonstrate that the phenotypic 
consequences of ABD PIK3CAmut are similar to ectopic over-expression of PIK3CAWT.  
Furthermore, they suggest that mutations in the ABD of PIK3CA are passenger 
mutations in GBM.  However, ectopic expression of PIK3CAWT and PIK3CAmut may not 
fully recapitulate the effects of PIK3CA missense mutations when expressed under its 
endogenous promoter.  Furthermore, other cooperating mutations and/or cellular origin 
may influence the role of PIK3CA missense mutations in gliomagenesis.  Future work 
will be required to investigate the role of PIK3CAmut in other cellular/genetic contexts. 
PIK3CAmut do not influence PI3Ki efficacy 
The precision medicine initiative seeks to direct treatment with targeted inhibitors 
based on the mutation profiles of patients.8,34  However, this requires an understanding 
of how oncogenic mutations influence drug response.  Mutational activation of kinases 
can cause oncogene addiction, in which tumor cells become reliant upon the activated 
signaling pathway(s), and are thus highly sensitive to their inhibition.39  Additionally, 
kinase mutations can alter drug affinity, thereby altering efficacy.40  Buparlisib inhibits 
purified PIK3CAWT and the most common PIK3CAmut, E542K, E545K, and H1047R, with 
similar IC50.41,42  Because these helical and kinase domain PIK3CAmut activated PI3K 
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signaling and promoted gliomagenesis, we hypothesized that they would also increase 
PI3Ki efficacy.  Activating PIK3CAmut, particularly those in the helical and kinase 
domains, increased the buparlisib concentration required to ablate PI3K signaling (Fig 
5.4).  However, they did not influence efficacy of PI3Ki treatment in vitro.  These results 
suggest that PIK3CA missense mutations do not induce oncogene addiction and do not 
enhance sensitivity to PI3Ki.  Whether they influence efficacy of isoform specific PI3Ki 
or inhibitors of downstream kinases, such as mTOR, remains to be determined. 
PIK3CAmut influence MEKi-induced activation of PI3K signaling and PI3Ki/MEKi 
synergism 
 We previously found that buparlisib induced widespread kinome changes, 
including MAPK activation, in immortalized murine astrocytes with Pten deletion and 
mutant Kras.37  We expanded these findings here by demonstrating that buparlisib 
potentiated MAPK signaling regardless of RAS/PIK3CA mutation status (Fig 5.4C-H).  
PIK3CAmut also had minimal to no effect on sensitivity of NHA and NHARAS to MEKi in 
vitro (Figs 5.5AB). 
We and others have also shown that MEKi promote PI3K signaling in preclinical 
GBM models.31,36,37  We found that selumetinib increased proximal PI3K signaling in 
control and PIK3CAmut NHA, and in GFP and parental NHARAS (Fig 5.5C-H).  
Interestingly, this increase was not apparent in PIK3CAWT and PIK3CAmut NHARAS (Figs 
5.5FH, S5.11AC).  The mechanism by which ectopic PIK3CA expression in combination 
with mutant RAS alters MEKi response is unclear.  A mutually inhibitory crosstalk 
between PI3K and MAPK signaling is mediated by p70S6K in glioma stem cells.31  
MAPK inhibition induces PI3K signaling in non-GBM cell lines via removal of a negative 
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feedback loop on RTK.43  Similarly, selumetinib induces widespread kinome changes in 
breast cancer models, including increased expression and activity of multiple RTK.44  
Taken together, these results suggest that PIK3CAWT and PIK3CAmut may cooperate 
with mutant RAS to alter MEKi-induced dynamic kinome changes, particularly as it 
pertains to PI3K activation. 
Dual PI3Ki/MEKi treatment is effective in multiple preclinical GBM models.31,35-37  
It remained unclear whether the underlying genetics of these models influenced drug 
synergism.  We therefore determined if PIK3CAmut  affected PI3Ki/MEKi synergism in 
the presence and absence of mutant RAS.  Consistent with other GBM models, we 
found that dual buparlisib/selumetinib treatment was synergistic in NHA and NHARAS 
lines (Fig 5.6).  However, RAS/PIK3CAmut status influenced drug response.  A higher 
concentration of buparlisib and selumetinib was required to maximize synergism in 
NHARAS lines compared to NHA.  Furthermore, synergy was generally greater in R88Q 
and E542K PIK3CAmut NHA and NHARAS compared to those with either PIK3CAWT or 
H1047R PIK3CAmut.  Taken together, these results suggest that GBM patients with ABD 
or helical PIK3CA missense mutations may be most sensitive to dual PI3Ki/MEKi 
treatment. 
Conclusion 
Defining the role of frequently occurring mutations on GBM pathogenesis and 
drug response can aid in the identification of predictive biomarkers.  Our results 
demonstrate that PIK3CA missense mutations differentially promote gliomagenesis.  
Furthermore, they suggest that PIK3CA mutations do not predict PI3Ki sensitivity, but 
they do  impact PI3Ki/MEKi synergism.  
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Figure 5.1.  Helical and kinase PIK3CAmut activate proximal PI3K signaling.  
Representative immunoblots (A) and quantification showed that compared to parental 
NHA, proximal PI3K signaling (pAKT) was increased by helical and kinase PIK3CAmut 
(B), while distal PI3K signaling (pS6) was only increased by H1047R (C) (*, P≤0.02).  
Compared to PIK3CAWT NHA, E542K and H1047R PIK3CAmut increased proximal PI3K 
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signaling and all helical and kinase PIK3CAmut increased distal PI3K signaling (ǂ, 
P≤0.04).  Representative immunoblots (D) and quantification showed that proximal PI3K 
signaling was increased by PIK3CAWT and all PIK3CAmut compared to parental NHARAS 
(E).  Helical and kinase PIK3CAmut also increased proximal PI3K signaling compared to 
PIK3CAWT NHARAS (ǂ, P≤0.007).  Only M1043V PIK3CAmut increased distal PI3K 
signaling compared to parental (*, P=0.03) and PIK3CAWT (ǂ, P=0.03) NHARAS (F).  Bar 
graph data are set relative to parental lines (N=4 biologic replicates). Fold changes in 
pAKT and pS6 relative to PIK3CAWT lines are shown as heatmaps.  
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Figure 5.2.  PIK3CAmut potentiate proliferation and migration in vitro.  MTS assays 
showed that PIK3CAWT and all PIK3CAmut decreased doubling times of parental NHA 
(A), but not parental NHARAS (B) (*, P≤0.02. See Fig. S5.5AB).  All PIK3CAmut, except 
C90Y, decreased doubling times compared to PIK3CAWT NHA (ǂ, P≤0.03).  Statistical 
analyses of growth rates were performed by comparing k values.  Error bars are 95% 
confidence intervals.  PIK3CAWT and all PIK3CAmut, except C90Y, increased migration 
of both NHA (C) and NHARAS (D) (*, P≤0.04. See Fig. S5.5CD).  E542K and H1047R 
PIK3CAmut also potentiated migration compared to PIK3CAWT NHA and NHARAS (ǂ, 
P≤0.005).  Fold changes in doubling times and migration rates relative to parental and 
PIK3CAWT lines are shown as heatmaps.  
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Figure 5.3.  Helical and kinase PIK3CAmut potentiate tumorigenesis.  Only H1047R 
PIK3CAmut increased colony formation compared to parental (*, P=0.03) and PIKCAWT 
(ǂ, P=0.04) NHA (A).  H1047R PIK3CAmut did not affect colony formation of NHARAS 
(P=0.5).  Representative images of parental and H1047R PIK3CAmut NHA and NHARAS 
are shown.  Orthotopic xenografts of GFP, PIK3CAWT, and PIK3CAmut NHARAS (B,C).  
Median survival of mice injected with R88Q, E542K, or H1047R PIK3CAmut NHARAS was 
decreased compared to GFP controls (*, P≤0.003).  E542K and H1047R PIK3CAmut 
also decreased survival compared to PIK3CAWT (ǂ, P≤0.002) and R88Q PIK3CAmut 
(P<0.0001). Fold changes in median survival relative to GFP and PIK3CAWT NHARAS 
are shown as heatmaps.  
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Figure 5.4.  PI3Ki inhibits growth and ablates PI3K signaling regardless of 
PIK3CAmut status.  Buparlisib IC50 were similar regardless of PIK3CAmut status in NHA 
(A) and NHARAS (B) (See Fig S5.6). Fold changes in IC50 relative to parental and 
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PIK3CAWT lines are shown as heatmaps.  Representative immunoblots of control and 
PIK3CAmut NHA (C) and NHARAS (F) treated with buparlisib for 24 h.  Immunoblot 
quantification (D,E,G,H) demonstrated dose-dependent decreases in proximal PI3K 
signaling (D,G), with corresponding increases in MAPK signaling (E,H) in all NHA (D,E) 
and NHARAS (G,H) lines (See Fig S5.9).  Immunoblot data were pooled from 1-3 biologic 
replicates (Mean=2.3).  
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Figure 5.5.  MEKi inhibits growth and ablates MAPK signaling regardless of 
PIK3CAmut status.  Selumetinib IC50 were similar regardless of PIK3CAmut status in 
NHA (A).  Selumetinib IC50 were slightly higher in most PIK3CAmut NHARAS, compared 
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to parental cells (*, P≤0.03) (B) (See Fig S5.10). Fold changes in IC50 relative to 
parental and PIK3CAWT lines are shown as heatmaps.  Representative immunoblots of 
control and PIK3CAmut NHA (C) and NHARAS (F) treated with selumetinib for 24 h.  
Immunoblot quantification (D,E,G,H) demonstrated dose-dependent decreases in 
MAPK signaling in all NHA (D) and NHARAS (G) lines.  Although proximal PI3K signaling 
was induced in all control and PIK3CAmut NHA (E), it was only potentiated in GFP and 
parental NHARAS (H) (See Fig S5.11).  Immunoblot data were pooled from 1-2 biologic 
replicates (Mean=1.8)
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Figure 5.6.  PI3Ki/MEKi synergism in vitro is influenced by PIK3CAmut and mutant RAS.  Buparlisib and selumetinib 
inhibited growth and were synergistic in control and PIK3CAmut NHA (A) and NHARAS (B).  BLISS analyses showed that 
synergy was most pronounced at high nanomolar concentrations of buparlisib when used with low micromolar- high 
nanomolar concentrations of selumetinib in NHA lines.  In contrast, synergistic concentrations in NHARAS lines were 
generally most pronounced at low micromolar concentrations of both buparlisib and selumetinib. 
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Figure S5.1.  Distribution of PIK3CA missense mutations across the protein.  Lollipop diagram showing the 
frequency and distribution of PIK3CA missense mutations (green), in-frame deletions (brown), and truncating mutations 
(black) in GBM (A) and all published TCGA datasets (B).  The PIK3CA missense mutations investigated here are 
indicated.  Data were downloaded from cBioPortal (http://www.cbioportal.org/) on March 10th, 2017.  Ribbon diagram of 
PIK3CA with the mutations investigated highlighted (C) (R88Q = light green; C90Y = dark green; E542K = pink; E545K = 
red; M1043V = purple; H1047R = blue).  Model was generated in PyMOL. (Schrödinger, New York City, NY) using a script 
downloaded from cBioPortal.13,14 
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Figure S5.2.  PIK3CAWT and PIK3CAmut are expressed at similar levels. 
Representative immunoblots (A,C) and quantification (B,D) of HA-tagged PIK3CA 
showed that PIK3CAWT and all PIK3CAmut are expressed at similar levels in NHA (B,C) 
and NHARAS (C,D) (ANOVA, P≥0.3).  Bar graph data are set relative to PIK3CAWT lines 
(N=3-4 biologic replicates, Mean=3.5).  
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Figure S5.3.  PIK3CAmut do not alter MAPK signaling.  Representative immunoblots 
(A,C) and quantification (B,D) showed that PIK3CAmut did not alter MAPK signaling 
(phosphorylation of ERK1/2, pERK) in either NHA (A,B) or NHARAS (C,D) (P≥0.93).  Bar 
graph data are set relative to parental lines (N=3-4 biologic replicates, Mean=3.5).  Fold 
changes in pERK relative to PIK3CAWT lines are shown as heatmaps.  
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Figure S5.4.  PIK3CA mutations have minor effects of on growth in high-serum 
culture.  MTS assays (A) showed that, when grown in media containing high (10% 
FBS) serum concentrations, PIK3CAWT and a subset of PIK3CAmut slightly reduced 
doubling times compared to parental NHA (*, P≤0.03) (B).  Growth of R88Q PIK3CAmut 
was slightly less than PIK3CAWT NHA (ǂ, P=0.01).  Statistical analyses of growth rates 
were performed by comparing k values. Fold changes in doubling times relative to 
parental and PIK3CAWT lines are shown as heatmaps.  Error bars in B are 95% 
confidence intervals. 
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Figure S5.5.  Mutant RAS affects the impact of PIK3CAmut on proliferation, but not 
migration in vitro.  Growth of control and PIK3CAmut NHA (A) and NHARAS (B) (See 
Fig 5.2AB).  Growth was determined by assessing changes in relative absorbance daily 
by MTS.  Migration of control and PIK3CA mutant NHA (C) and NHARAS (D) across a 
gap (See Fig 5.2CD).  
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Figure S5.6.  PI3Ki inhibits in vitro growth independent of PIK3CAmut status.  MTS 
assays showed that buparlisib caused dose-dependent decreases in growth of control 
and PIK3CAmut NHA (A) and NHARAS (B).  Buparlisib IC50 were similar between control 
and all 6 PIK3CAmut NHARAS (C). 
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Figure S5.7.  PI3Ki induces G2/M cell cycle arrest in NHARAS cells regardless of 
PIK3CAmut status.  Micromolar doses of buparlisib induced G2/M cell cycle arrest within 
48 h post-treatment in control and PIK3CAmut NHARAS. 
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Figure S5.8.  PI3Ki inhibits distal PI3K signaling regardless of PIK3CAmut status.  
Representative immunoblots of control and PIK3CAmut NHA (A) and NHARAS (C) 24 h 
after buparlisib treatment.  Immunoblot quantification demonstrated dose-dependent 
decreases in distal PI3K signaling in all NHA (B) and NHARAS (D) lines (N=1-3 biologic 
replicates, Mean=1.7). 
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Figure S5.9.  PI3Ki inhibits proximal PI3K signaling and induces MAPK signaling in all control and PIK3CAmut 
NHARAS.  Representative immunoblots (A) and quantification of proximal PI3K (B) and MAPK (C) signaling showed that 
within 24 h, buparlisib induced dose-dependent decreases in PI3K signaling, with concurrent increases in MAPK signaling 
in parental, GFP, PIK3CAWT, and all 6 PIK3CAmut NHARAS lines (N=2-3 biologic replicates, Mean=2.7). 
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Figure S5.10.  MEKi inhibits in vitro growth in all PIK3CAmut lines.  MTS assays 
showed that selumetinib caused dose-dependent decreases in growth of control and 
PIK3CAmut NHA (A) and NHARAS (B).  Selumetinib IC50 were slightly increased by 
PIK3CAWT and all PIK3CAmut, except C90Y and H1047R, compared to parental NHARAS 
(*, P≤0.03) (C).
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Figure S5.11.  MEKi-induced potentiation of proximal PI3K signaling is abrogated in PIK3CAWT and PIK3CAmut 
NHARAS.  Representative immunoblots (A) and quantification of MAPK (B) and proximal PI3K (C) signaling showed that 
selumetinib caused dose-dependent decreases in MAPK signaling regardless of PIKCAWT or PIK3CAmut status, but 
concurrent increases in proximal PI3K signaling only occurred in parental and GFP NHARAS (N=2-3 biologic replicates, 
Mean=2.7). 
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CHAPTER VI: DISCUSSION 
 
 The results described in the previous chapters provide significant insight that 
should inform future preclinical drug development.  They determined how drug potency 
influences efficacy of single agent and combination treatments with targeted inhibitors of 
PI3K and MAPK signaling.  Furthermore, they helped define how PI3K and MAPK 
pathway mutations influence response to their inhibition. 
 In Chapter III, we used a non-germline genetically engineered mouse (nGEM) 
model of GBM in which PI3K and MAPK signaling are activated in immortalized (T) 
astrocytes via Pten deletion (R) and a constitutively active mutant Kras (R, KrasG12D) 
(TRP) and a panel of EGFR-amplified patient derived xenografts (PDX).  We found that 
cultured TRP astrocytes and PDX were sensitive to single agent PI3K and MEK 
inhibitors (PI3Ki and MEKi), and drug potency directly associated with efficacy in these 
models.  However, the extent of sensitivity to MEKi was variable between GBM PDX.  
We showed that the kinomes of GBM established cell lines (ECL), PDX, and patient 
samples were highly variable.  A subset of GBM patient samples was characterized by 
widespread of hyper-activation of numerous kinase families, and extensive activation of 
MAPK signaling.  The PI3Ki buparlisib induced dynamic kinome reprogramming of 
cultured TRP astrocytes, including alternate activation of MAPK signaling.  Similarly, 
multiple MEKi inhibited MAPK and induced PI3K signaling in vitro, indicating that PI3K 
and MAPK signaling are alternative bypass pathways that promote resistance to 
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inhibition of either pathway alone.  Indeed, we found that dual PI3Ki/MEKi treatment 
was synergistic in vitro and effective in subcutaneous TRP allografts, especially when 
the most potent PI3Ki/MEKi combination (buparlisib/trametinib) was used.  However, 
drug-induced toxicity necessitated a reduction in dose for combination treatments 
compared to the corresponding single agents, and toxicity was still apparent with the 
more potent PI3Ki dactolisib.  Furthermore, efficacy of the brain penetrant PI3Ki and 
MEKi, buparlisib and selumetinib alone and in combination was limited in orthotopic 
TRP allografts, likely due to inefficient target inhibition within the brain.  Taken together, 
these results suggest that increased PI3Ki/MEKi potency enhances efficacy and 
synergy in vitro and in vivo, but limited brain penetrance and systemic toxicity reduces 
the effectiveness of kinase inhibitors when used alone and in combination. 
 In Chapter IV, we extended the findings described in Chapter III by defining how 
activation of PI3K and MAPK signaling via deletion of Pten and mutant Kras influence 
response to PI3Ki and MEKi in vitro.  We found that buparlisib induced PI3K inhibition 
and alternate activation of MAPK signaling regardless of Pten/Kras mutation status.  
However, Pten deletion and/or mutant Kras marginally (<5 fold) increased sensitivity to 
the PI3Ki LY or buparlisib, but dramatically (5-34 fold) increased sensitivity to the more 
potent dual PI3Ki/mTORi dactolisib.  Furthermore, sensitivity to dactolisib and the 
mTORi temsirolimus was enhanced in T astrocytes with both Pten and Kras mutations 
compared to either alone.  Pten/Kras mutation status also influenced response to MEKi.  
Mutant Kras potentiated MEKi-induced alternate activation of PI3K signaling, and 
decreased GI50, but not IC50, of the more potent MEKi, PD01 and trametinib.  In contrast, 
Pten deletion enhanced MEKi-induced MAPK inhibition, and dramatically increased 
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MEKi sensitivity independent of Kras status.  Pten deletion and/or mutant Kras also 
enhanced synergy between PI3Ki and MEKi when a less potent MEKi (selumetinib) was 
used.  These results demonstrate that drug potency and activating mutations in PI3K 
and MAPK signaling interact to influence response to inhibitors of these pathways. 
 In Chapter V, we used immortalized human astrocytes with (NHARAS) and without 
(NHA) mutant RAS to define whether PIK3CA missense mutations promote 
gliomagenesis and influence PI3Ki/MEKi response.  PIK3CA missense mutations, 
particularly those in the helical and kinase domains, potentiated proximal PI3K signaling 
and migration of NHA in vitro.  Furthermore, they cooperated with mutant RAS to further 
promote proximal PI3K signaling in vitro and tumorigenesis in vivo.  PIK3CAmut had little 
to no effect on PI3Ki or MEKi efficacy in NHA and NHARAS.  We confirmed the findings 
in the previous chapters by showing that single agent PI3Ki or MEKi caused inhibition of 
their targeted pathway, activation of the alternate arm of RTK signaling, and functioned 
synergistically in vitro.  Interestingly, MEKi-induced PI3K activation was not apparent in 
PIK3CAWT and PIK3CAmut NHARAS, suggesting that the combination of ectopic PIK3CA 
expression and mutant RAS may alter the dynamic kinome response to MEKi.  Taken 
together, these results demonstrate that mutations in the helical and kinase domains of 
PIK3CA promote gliomagenesis, but do not enhance sensitivity to single agent PI3Ki. 
Multiple PI3K pathway mutations promote gliomagenesis 
Large scale sequencing projects, such as TCGA, predict oncogenic drivers 
based on the frequency of alterations in a given gene.1-3  These studies are invaluable 
in identifying the most frequently altered genes and pathways in a disease, and in 
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characterizing inter-tumor heterogeneity.  However, they are correlative by nature and 
experimental validation of putative driver mutations in animal models is necessary. 
The RTK/MAPK/PI3K pathways are mutated in 90% of GBM, and their activation 
promotes gliomagenesis in mouse models.2,4-6  RTK activate PI3K and MAPK signaling 
in normal and tumor cells.7  The most frequent RTK mutation in GBM, EGFRvIII, 
preferentially activates PI3K signaling, and EGFR activation cooperates with other 
“core” pathway mutations to promote gliomagenesis.8-12  Mutations in canonical PI3K 
signaling genes, particularly PIK3R1, AKT, and PTEN, have also been validated as 
oncogenic drivers in gliomas.  PIK3R1 mutations were shown to activate PI3K signaling 
and promote tumorigenesis in orthotopic xenografts.13  Although mutations in AKT are 
infrequent in GBM, constitutively active AKT mutants are commonly used to model PI3K 
activation in preclinical glioma models.14-19  For instance, Sonoda et al. determined that 
constitutively active AKT alone was insufficient to transform NHA, but it cooperated with 
mutant RAS to promote malignant progression.16,17  PTEN is the most frequently 
mutated canonical PI3K signaling gene, and we and others have extensively 
characterized its role in gliomagenesis using GEM and nGEM models.2,4,12,20-23  Pten 
deletion alone does not induce gliomas in adult mice, but cooperates with other “core” 
pathway mutations, such as mutant Kras and ablation of the Rb family members, or 
deletion of Rb1 and TP53, to promote tumorigenesis.21,24,25 
Missense mutations in PIK3CA frequently occur in GBM.  These mutations are 
heterogeneously distributed across multiple of its protein domains.2,26,27  Mutations in 
the helical (E542K and E545K) and kinase (H1047R) domains of PIK3CA are the most 
prevalent in PIK3CA-mutated cancers, and they drive tumorigenesis in non-brain 
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tissues.26-31  However, the role of PIK3CA missense mutations in gliomagenesis had not 
been experimentally investigated until now.  In Chapter V, we found that helical and 
kinase domain PIK3CA missense mutations activate PI3K signaling in vitro and 
cooperate with mutant RAS to promote gliomagenesis in orthotopic xenografts.  
Interestingly, while both helical and kinase domain PIK3CA mutations promoted 
malignancy of NHARAS in vivo, only kinase mutations induced colony formation of NHA 
in vitro.  These results suggest that helical mutations require MAPK activation to 
promote gliomagenesis.  Moreover, they are consistent with the observation that helical 
PIK3CA (p110α) mutants must interact with RAS to activate PI3K signaling and 
transform chicken embryonic fibroblasts.32 
We also found that the infrequent R88Q and C90Y mutations in the adaptor-
binding domain (ABD) of PIK3CA did not activate PI3K signaling or promote 
gliomagenesis more than ectopic expression of wild-type PIK3CA (PIK3CAWT) 
alone.26,27  However, introduction of the PIK3CA mutants into NHA and NHARAS via 
lentiviral vectors likely does not fully recapitulate the phenotypic consequences of 
expression of PIK3CA missense mutants under the control of its endogenous promoter.  
Thus, future studies utilizing CRISPR/Cas9 and GEM with PIK3CA missense mutations 
knocked into its endogenous promoter will be important in further defining the role of 
individual PIK3CA missense mutations in gliomagenesis.  Moreover, cellular origin and 
associating mutations may influence the effects of PIK3CA mutations on gliomagenesis, 
and future work will be focused on answering these questions. 
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Drug delivery, resistance, and toxicity hinder the development of targeted 
therapies in GBM 
The advent of targeted therapies has led to the rapid expansion of FDA approved 
cancer treatments.33  Some of these targeted agents have revolutionized the standard-
of-care for certain cancers and greatly improved prognoses, such as imatinib in 
Philadelphia chromosome-positive chronic myelogenous leukemia (CML).34,35  
However, no targeted therapies have effectively improved survival of GBM patients.  
One unique challenge in the development of beneficial drugs for brain tumors, including 
GBM, is the blood-brain barrier (BBB).36,37  The BBB precludes many anti-cancer agents 
from accumulating within the brain, leading to poor pharmacodynamics, particularly in 
diffusely infiltrating GBM cells, and limiting their efficacy.33,36-38 
In Chapter III, we found that TRP astrocytes and PDX were sensitive to single 
agent PI3Ki and MEKi in vitro.39  We also found that 5 consecutive days of treatment 
with PI3Ki or MEKi dramatically reduced growth of subcutaneous TRP tumors for at 
least 2 weeks.  Nevertheless, even the brain penetrant PI3Ki and MEKi, buparlisib and 
selumetinib respectively, had minor effects on growth of orthotopic TRP allografts.39-42  
Buparlisib and selumetinib poorly inhibited their respective targets within the brain 
tumors, indicating that there was an insufficient accumulation of these drugs.  Thus, 
even though PI3K/MAPK signaling are effective therapeutic targets in TRP astrocytes, 
the benefits of PI3Ki and MEKi in the intracranial allografts were likely masked by their 
limited brain penetrance.  Taken together, these results highlight that a major obstacle 
in preclinical and clinical development of novel therapies for GBM is determining 
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whether targeted agents have limited efficacy due to ineffective targets or poor 
pharmacokinetics in the brain. 
Intrinsic drug resistance is also a barrier in the development of novel treatments.  
Preclinical studies demonstrate that single agent kinase inhibitors induce adaptive 
kinome changes that promote drug resistance.43-46  Moreover, GBM harbor extensive 
genetic and phenotypic intratumor heterogeneity, suggesting that divergent 
subpopulations of cells within a tumor may have different drug sensitivies.2,38,47-50  Thus, 
combination therapies will likely be required to effectively treat GBM.38,51 
In Chapters III-V, we determined that single agent PI3Ki and MEKi treatment 
inhibited PI3K and MAPK signaling respectively, and potentiated activation of the 
alternate arm of RTK signaling.39  We also found that PI3Ki/MEKi were synergistic in 
vitro, and that dual treatment was most effective at inhibiting growth of subcutaneous 
TRP tumors.  However, a frequent challenge in the clinical development of targeted 
inhibitors, particularly when used in combination, is systemic toxicity.52,53  In order to 
avoid toxicity of dual treatments in mice, we reduced the doses of individual PI3Ki/MEKi 
by up to 50%.39  Even with this precaution, the PI3Ki/mTORi dactolisib was toxic alone 
and in combination with the MEKi selumetinib.  Furthermore, dual buparlisib/selumetinib 
treatment was less effective than selumetinib alone in intracranial TRP allografts, likely 
due to the requisite dose reductions.  Toxicity induced by dual PI3Ki/MEKi treatment is 
also a problem in patients.  Clinical investigations showed that the long-term tolerability 
of dual PI3Ki/MEKi treatment was limited by toxicity in patients with RAS or BRAF 
mutant cancers.52  Taken together, these results suggest that the clinical 
implementation of targeted drugs in GBM will likely require the development of highly-
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brain penetrant drug combinations that do not cause dose-limiting toxicity.  Going 
forward, the achievability of this requirement could be enhanced by using alternate drug 
delivery methods, such as nanoparticles, or drugs that disrupt the BBB to improve the 
pharmacokinetics of targeted agents within the brain, while limiting adverse advents.38,54 
Using mutation status to guide treatment with targeted inhibitors 
 Predictive biomarkers such as HER2, Philadelphia-chromosome, and BRAF 
status in breast cancer, CML, and melanoma respectively, guide the use of many of the 
most beneficial targeted therapies.34,35  However, clinical investigations of targeted 
inhibitors in GBM were largely done in genetically diverse patients.33,38,55  Even clinical 
trials evaluating kinase inhibitors in rationally selected GBM patients, such as the 
mTORi temsirolimus in PTEN-null GBM, have had disappointing results.56 
Preclinical studies may aid in the identification of predictive biomarkers by 
defining how mutations associated with GBM influence response to targeted kinase 
inhibitors.33  We therefore used our previously developed series of nGEM astrocyte 
cultures in Chapter IV, to determine whether PI3K and MAPK activation via Pten 
deletion and mutant Kras influence response to PI3Ki and MEKi.25  Similar to the 
observation that PTEN status did not correlate with buparlisib efficacy in GBM ECL, we 
found that Pten deletion modestly increased efficacy of the PI3Ki LY and buparlisib.  
Mutant Kras also had minor effects on sensitivity to these drugs.  However, Pten 
deletion cooperated with mutant Kras to increase efficacy of the dual PI3Ki/mTORi 
dactolisib and the mTORi temsirolimus.  Additionally, Pten deletion, but not mutant 
Kras, dramatically increased MEKi efficacy, and the influence of Pten/Kras mutation 
status on sensitivity to MEKi was potentiated by increased drug potency.  Taken 
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together, these results demonstrate that drug potency and cooperativity between 
multiple mutations can influence the impact of oncogenic mutations on drug sensitivity.  
They also suggest that accounting for both drug potency and cooperating mutations 
may be advantageous in the design of studies seeking to identify predictive biomarkers. 
Our findings in Chapter IV represent a valuable addition to the GBM field by 
defining how Pten deletion and mutant Kras influence PI3Ki/MEKi efficacy, but 
questions remain.  Only TRP astrocytes form tumors with high penetrance, short 
latencies, and uniform growth kinetics when injected into mice.25  The poor 
tumorigenicity of T, TP, and TR astrocytes precluded us from determining whether Pten 
deletion increased sensitivity PI3Ki/MEKi in vivo.  Furthermore, our series of nGEM 
models are all derived from astrocytes.25  However, human GBM likely arise from 
multiple cellular origins.  The transcriptomes of the four molecular subtypes defined by 
TCGA resemble different purified brain cell types.47  Multiple brain cell types, particularly 
neural stem cells (NSC), oligodendrocyte precursor cells (OPC), and astrocytes, can be 
transformed by GBM-associated mutations, and give rise gliomas in GEM.11,25,57-61  
Moreover, cellular origin can affect the impact of oncogenic mutations on tumorigenesis, 
and thus may influence the role of Pten deletion and mutant Kras on PI3Ki/MEKi 
sensitivity.  An ongoing project in the Miller lab is the establishment of a large panel of 
nGEM models in which combinations of frequently occurring GBM mutations, including 
deletion of Pten, Nf1, Cdkn2a, and Trp53, and/or expression of constitutively active 
Kras, Pik3ca, Pdgfra, and Egfr mutants are induced in nGEM astrocytes, OPC, and 
NSC.2  Once established, this panel can be used to determine how diverse oncogenic 
mutations and cellular origins influence PI3Ki/MEKi response. 
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Using kinome activity to guide treatment with targeted inhibitors 
Novel clinical trials designs, such as adaptive and basket trials, utilize the 
mutation status of one or more genes to guide treatment with targeted inhibitors.62  One 
goal of these designs is to increase the efficiency of clinical drug development by 
prospectively enriching for likely responders.33,62  However, comparative analyses 
between genetic mutations and pathway activation in GBM have demonstrated a non-
linear relationship between mutation status and protein signaling.2  This highlights the 
complex and dynamic signaling in GBM.  Moreover, it suggests that analyses of kinome 
activity will aid in guiding treatment with targeted inhibitors, and could potentially prove 
more predictive than genomics based assays.  Our collaborators in the Johnson lab are 
testing these hypotheses in a window trial of triple-negative breast cancer patients.63  
They are using multiplexed inhibitor beads-mass spectrometry (MIB-MS) and 
comparative genomics in the hopes of identifying kinome based biomarkers that predict 
response to therapy. 
In Chapter III, we used MIB-MS based profiling to demonstrate that human GBM 
samples as well as PDX and ECL models have heterogeneous kinomes.  Moreover, we 
showed that GBM tissue samples can be stratified based on kinome activity, with a 
subset of patients having hyper-activation of their kinomes, including an enrichment in 
MAPK signaling.  This suggests that these patients will be uniquely sensitive inhibitors 
of MAPK signaling.  Furthermore, we will be evaluating the utility of MIB-MS analyses in 
predicting drug response by kinome profiling of an integrated panel of nGEM and PDX 
models with diverse mutations.  We will then use the kinome activity of these preclinical 
models to direct treatment of single agent and combination therapies in specific disease 
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subsets.  Taken together, the results of this project will help validate the utility of kinome 
activation status to predict drug response, and aid in the development of rationally 
designed treatments. 
Predicting PI3Ki/MEKi efficacy based on the specific PI3K pathway mutation 
 As discussed above, in Chapter IV, we utilized our T(RP) series of nGEM 
astrocyte cultures to determine how Pten deletion and mutant Kras influence response 
to PI3Ki/MEKi.  We expanded these finding in Chapter V by defining whether PIK3CA 
missense mutations influence response of NHA and NHARAS to PI3Ki/MEKi in vitro.  
Pten deletion minimally increased buparlisib efficacy in the T(RP) astrocyte series, while 
PIK3CA missense mutations in NHA and NHARAS did not.  Wild-type TP53, but not loss 
of PTEN, has been shown to correlate with a slight increase in sensitivity to buparlisib in 
GBM ECL.64  TP53 is inhibited in NHA and NHARAS lines, but not in the T(RP) 
series.17,25  Therefore, differences in TP53 status may be affecting PI3Ki response in 
these model systems, and thus causing the differential effects between Pten deletion 
and PIK3CA mutations on buparlisib efficacy that we observed.  Moreover, we found 
that Pten deletion and mutant Kras cooperated to increase efficacy of the dual 
PI3Ki/mTORi dactolisib and the mTORi temsirolimus.  Whether PIK3CA missense 
mutations increase sensitivity to dactolisib or temsirolimus is unknown and is currently 
under investigation within the Miller lab. 
 In Chapters IV and V, we also showed that mutant RAS did not affect efficacy of 
the MEKi selumetinib in T astrocytes and NHA.  In contrast, Pten deletion dramatically 
increased sensitivity to MEKi in the T(RP) astrocyte series, while PIK3CA missense 
mutations in NHA and NHARAS (NHA±RAS) did not.  There are a few potential reasons for 
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this disparity between Pten deletion and PIK3CA missense mutations in the T(RP) and 
NHA±RAS models, respectively.  One reason may be species-specific differences in the 
effects of PI3K activation on MEKi efficacy. 
Another reason may be that activating PIK3CA mutations and deletion of Pten 
have divergent impacts on PI3K signaling.  The p110α and p110β isoforms of the 
catalytic subunit of PI3K (encoded by PIK3CA and PIK3CB respectively), differentially 
respond to upstream proteins, particularly RTK, GPCR, and RAS.7  In preclinical models 
of multiple cancer types, including GBM, Pten deletion activates PI3K signaling and 
promotes tumorigenesis via p110β, not p110α.7,65-67  However, the reliance on p110β in 
Pten-null cells is influenced by cellular origin and cooperating mutations.68,69  PIK3CA 
mutations and deletion of Pten can also have divergent effects on downstream 
signaling.  Vasudevan et al. showed that AKT is highly activated in PTEN-null cells from 
multiple cancer types and breast tumors.70  They also demonstrated that Pten-null cells 
rely on AKT activation for tumorigenicity.  In contrast, AKT activation was generally less 
robust in PIK3CA-mutant cells and tumors, and PIK3CA mutant cells were less 
dependent on AKT.70  Moreover, PIK3CA-mutant cells highly expressed PDK1 and were 
reliant upon PDK1-dependent singling for tumorigenicity.  Taken together, these data 
suggest that PTEN deletion and mutant PIK3CA may have divergent effects on PI3K 
signaling, and thus may differentially affect sensitivity to targeted inhibitors. 
PTEN deletion and PIK3CA mutations could also have divergent impacts on 
response to targeted inhibitors due to the PI3K-independent nuclear functions of PTEN.  
Besides PTEN’s well characterized cytoplasmic role in antagonizing PI3K signaling, it 
also has important nuclear functions in chromosome stability, DNA repair, and cell cycle 
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arrest.71  At this time, it is unclear whether the PI3K-dependent or independent functions 
of Pten contribute to the increased efficacy of MEKi in the T(RP) astrocyte series. 
Future work will seek to answer the important mechanistic questions discussed 
above.  To this end, we will knockout-PTEN using shRNA in NHA and NHARAS, and 
introduce constitutively active PIK3CA missense mutations into T and TR astrocytes.  
Comparisons between the effects of Pten deletion and PIK3CA mutations in both of 
these model systems will enable us to determine whether our disparate findings on 
MEKi efficacy were due to species-specific differences or divergent consequences of 
these PI3K pathway mutations.  Furthermore, if PTEN-loss uniquely sensitives the 
T(RP) astrocyte series and NHA±RAS to MEKi, we will then assess MEKi efficacy in 
PTEN-null cells reconstituted with PTEN mutants lacking either phosphatase or nuclear 
activity.71  Comparisons of MEKi efficacy in these cells will enable us to determine 
whether PTEN-loss influences response to MAPK inhibition via PTEN’s PI3K-dependent 
or independent functions. 
Conclusions 
 In the work above, we use PDX, genetically modified normal human astrocytes, 
and nGEM to evaluate efficacy to single agent and combination treatments with 
PI3Ki/MEKi.  Furthermore, we defined how PI3K and MAPK pathway mutations 
influence response to these drugs.  These studies provide a valuable platform to 
functionally validate whether cellular origin and other PI3K/MAPK mutations influence 
response to targeted inhibitors.  Additionally, the knowledge gained here will facilitate 
future preclinical testing of combination therapies and predictive biomarkers. 
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